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ABSTRACT OF DISSERTATION

Self-Reported Exercise and Risk of Osteoporosis in Prostate Cancer
Patients Receiving Androgen Deprivation Therapy
By
Lori Mennen-Winchell
Doctor of Public Health Candidate in Preventive Care
Loma Linda University, 2011
Serena Tonstad, Chair

Prostate cancer is stimulated to grow in response to testosterone. Androgen
deprivation therapy (ADT) leads to chemical castration and suppression of prostate cancer
cell production. Testosterone levels less then 300ng/ml decreases bone mineral density and
could result in osteoporosis. Studies have shown that during the first year of ADT, fracture
risk, mainly in hips and spine increases about 50%. In men, 40% of hip fractures result in
death. Exercise may reduce the risk of osteoporosis and thus contribute to the prevention of
hip and other fractures. There is limited data regarding whether exercise is associated with
a reduced risk of osteoporosis in men treated with ADT.
Purpose of this study was to evaluate the relationship between self-reported
exercise and bone mineral density measured by dual-energy x-ray absorptiometry (DEXA)
and 25 hydroxy vitamin D levels in prostate cancer patients receiving ADT.
A convenience sample of 96 men with prostate cancer treated with ADT for a
minimum of nine months or longer and up to the time of inclusion in the study completed
m

the Canadian Fitness Survey questionnaire to assess the amount and types of exercise
performed. In addition, questions from a section of the NHANES survey about cigarette
and alcohol use, history of non traumatic fracture, diseases causing fracture, and use of
medication including calcium supplementation were asked. A serum vitamin D level and
DEXA scan were completed within a specified time period based on length of time
receiving ADT. Subjects were recruited from eight urology practices and one cancer center
in Clark County, Nevada.
The relationships between total duration of exercise, intensity, frequency, bone
density T-scores, and serum vitamin D were examined using correlation analysis, as was
the relationship between specific types of exercise, measured the same way and bone
density T-scores. Furthermore, regression analysis was used to examine for potential
confounders. Confounders identified for this study include age, body mass index, cigarette
smoking, alcohol use, history of non-traumatic fracture or disease causing fracture, and use
of medication, including calcium supplementation. Regression analysis was conducted to
determine if there was an independent association between exercise and bone mineral
density and serum vitamin D. This study provides evidence associating exercise with
reduced risk of osteoporosis in patients receiving ADT.
The second study looked at determinants of 25 OH vitamin D. We found that the
only independent modifiable determinant was vitamin D supplementation of >800 HJ/day.
Avoiding osteoporosis by increasing exercise in this group of patients is a practical
measure that preventive care specialists could institute.
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CHAPTER 1
INTRODUCTION

A. Statement of the Problem
Prostate cancer is the second leading cause of cancer death in men (Strief, 2007;
American Cancer Society [ACS] 2006). Prostate cancer is stimulated to grow in response
to testosterone. Testosterone levels below 50ng/ml suppress prostate cancer cell
production (Ellsworth & Caldamone, 2007). Androgen deprivation therapy (ADT) also
known as chemical castration is widely used as a treatment for all tumor and disease stages
(Ellsworth et al. 2007). One of the major risks of ADT is osteoporosis.
Risk of osteoporosis increases as testosterone levels fall below 300ng/ml (Waxman, 2007).
Lowering testosterone levels suppresses prostate cancer growth and decreases bone
mineral density (BMD) increasing risk of osteoporosis and bone fractures (Fredrich, 2003;
Smith, 2002; Strief, 2007). The first year of ADT, fracture risk is increased 1.5 times,
occurring mainly in hips and spine (Holzbeierlein, 2006; Matthews, 2007). After a hip
fracture, the risk of mortality for men is two times greater than for women (Waxman,
2007). Hip fracture is the most serious fracture in terms of mortality.
Among men, 40% of hip fractures result in death (Berarducci, 2004). Factors other
than androgen levels also determine risk of osteoporosis and may interact with ADT in
determining risk of osteoporosis These include: age, ethnicity, height and weight, current
medications both prescription and non prescription, calcium intake and vitamin D levels,
parathyroid or other disease increasing risk of fracture, previous history of fracture, use of
tobacco, alcohol, and physical activity. Exercise is recognized in the prevention and
1

treatment of osteoporosis. Identification of patients at increased risk for osteoporosis from
secondary causes is important so effective treatment can be introduced to reduce
potentially life-threatening complications (Ebling, 2008; Fitzpatrick, 2002).
B. Prostate Cancer
1. Epidemiology
One in six men will be diagnosed with prostate cancer in the course of a
lifetime and 1 in 35 will die from this disease (Strief, 2007; ACS, 2006). The National
Cancer Institute (NCI, 2008) estimated approximately 218,890 new cases of prostate
cancer and 27,050 deaths in the United States for 2007. Weiss, Kaplan, and Fair (2004)
note that 70% of all prostate cancers diagnosed are in men 65 years or older. Prostate
cancer is two times higher in African American men as compared to Caucasians. Weiss et
al. (2004) identify other risk factors that may contribute to risk of prostate cancer such as
increased intake of dietary fat and genetics. They note that 5-10% of prostate cancers
suggest a genetic familial predisposition. Prostate cancer in a first degree relative increases
risk factor by two times. Prostate cancer in first degree and second degree relatives
increases risk by 8 times (Steinberg, Carter, Beaty, Childs, & Walsh, 1990). A genetic
factor associated with increases risk for prostate cancer is chromosome mutation BRCA2.
(Strueing, Hartge, & Watcholder, 1997; Sigurdsson, Thorlacus, & Tomasson, 1997). Other
risk factors include: increased levels of circulating testosterone (Pienta & Esper, 1993;
Gann, Hennekens, Ma, Longcope, & Stampfer, 1996); vitamin A from animal sources
(Duyff, 1996); exposure to environmental toxins or metals (Weiss et al. 2004); and
possible viral infection acting as an initiator (Weiss et al. 2004).
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Over 2 million men who have had prostate cancer at some point are still alive today.
Weiss et al. (2004) note that earlier diagnosis by blood test for prostate specific antigen
(PSA) levels in asymptomatic men has lead to early diagnosis of 85% of all prostate cancer
in the local and regional stages. According to Weiss et al. (2004) a 100% survival rate after
5 years occurs when diagnosis is made during the local and regional stages. The death rate
for prostate cancer is declining due to early recognition and intervention. Over the past 20
years, survival rate has increased from 67% to 97% for all stages of prostate cancer (Weiss
et al. 2004). Survival rates have increased, but morbidity and mortality is a concern due to
the adverse treatment effects. An example is the use of ADT with the side effect of
decreased bone mineral density and increased risk of osteoporosis. Osteoporosis in men
leads to hip fractures and this has a high mortality rate.
2.

Physiology of the Prostate Gland
Weiss et al. (2004) provide a summary of the physiology of the prostate

gland. The gland circles the urethra at the bladder neck. It is a walnut size fibromuscular
gland that weighs about 20-30grams. The prostate size remains stable until men reach their
forties then a growth spurt occurs during the fourth or fifth decade. The prostate has a thin
outer fibrous capsule; a dense layer of muscular tissue, a dense layer of circular fibers
around the urethra, and excretory and prostatic ducts. The excretory ducts are lined by
columnar epithelium.
Cormack (1993) provides a histological overview of the prostate. He describes
tubuloaveolar prostatic glands that are arranged in three regions around the prostatic
urethra. These glands have a branching duct system with secretory units. Cormack (1993)
states that low testosterone levels change the shape and function of the epithelial secretory
3

cells.
Guyton (1991) describes the seminal vesicles as located on each side of the
prostate. The seminal fluid empties into the ampulla at the body of the prostate gland. He
notes that the fluids from the seminal vesicle and ampulla pass through the ejaculatory duct
within the prostate gland and empty in to the internal urethra at the base of the bladder.
Guyton (1991) summarizes the physiology of the prostate gland secretions. He describes
the secretion as a thin, milky, alkaline fluid that contains citrate ion, calcium, acid
phosphate, a clotting enzyme, and profibrinolysin. This fluid adds bulk to the semen for
ejaculation. The epithelial cells lining the excretory ducts of the prostate produce a
glycoprotein called prostate specific antigen (PSA). This is produced only within the
prostate gland and hydrolyzes the coagulum of the ejaculate (Weiss et al. 2004). PSA
values increase as prostate volume increases.
An abnormal rise in PSA levels of a 3.5ng/ml average correlates with prostate
cancer and has become a unique marker for prostate cancer screening (Weiss et al. 2004).
According to the National Cancer Institute factsheet (2010) there are two forms of PSA
circulating in the blood, free and bound to protein. A greater percentage of PSA bound to
protein is found in men with prostate cancer (NCI 2010). A screening test for early
detection of prostate cancer is the serum PSA level. Once an elevated protein bound PSA
level is determined, further evaluation by prostate biopsy may be indicated. The biopsy
involves obtaining multiple core samples from two of the prostate lobes. Tissue analysis
provides cancer grading and staging.
3. Pathophysiology of Prostate Cancer
Prostate cancer is uncommon is men under the age of 50 years old (ACS
4

2008; Weiss et al. 2004). According to Weiss et al. (2004) about 80-90% of prostate cancer
starts in the peripheral zone, 20% in the transition zone, and only 5-10% in the central
zone. Prostate cancer has a slow progression. Weiss et al. (2004) reviewed data about
progression of prostate cancer noting two thirds of all prostate cancer takes greater than 4
years to double. The progression of prostate cancer in men 70 years or older is summarized
in Table 1.1.
Table 1.1 Progression of Prostate Cancer in Males Older Than 70 Years
5 Year Cumulative
Risk

10 Year Cumulative Risk

Locally invasive

49%

79%

Develop metastasis

8%

23%

2%

8%

Prostate Cancer
Progression

Dying of prostate cancer
Weiss et al. 2004

Matthews (2007) summarizes the role testosterones plays in prostate cancer
growth. Lutenizing hormone releasing hormone (LH-RH) and lutenizing hormone (LH)
released from the hypothalamus and anterior pituitary gland stimulate the testes to produce
of testosterone. The testes produce 90% of the body’s testosterone. Androgen receptors
convert testosterone to dihydrotestosterone. Dihydrotestosertone stimulates cancer cell
production in the prostate.
Prostate cancer begins with very small changes in the size and shape of the prostate
gland cells (ACS, 2008). These microscopic changes are known as prostatic intraepithelial
neoplasia (PIN). PIN occurs within the cells and has not spread outside the prostate gland.
These changes are described as either low-grade or high-grade. Cell changes with PIN
begin to grow out of control and crowd out normal prostate cells. As the cells continue to
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multiply, eventually they break through the prostate gland tissue and spread to other parts
of the body forming new tumors. When this happens, it is called metastasis (ACS, 2008).
4. Prostate Cancer Staging and Classification System to Determine Treatment
Once the prostate biopsy has confirmed a diagnosis of cancer, it is graded
and histopathologically staged using the Gleason Score System and the Tumor, Node,
Metastasis (TNM) classification system of the American Joint Cancer Committee (Weiss
et al. 2004; Ellsworth et al. 2007; ACS, 2008).
The Gleason Score (Weiss et al. 2004; ACS, 2008) assigns a Gleason grade, using
numbers from 1 to 5 based on comparison of cells in the cancerous tissue to normal
prostate tissue. The two most prevalent histopathologic patterns of tumor architecture are
scored and then added together. Because prostate cancers often have areas with different
grades, a grade is assigned to the two areas that make up most of the cancer. These two
grades are added together to form a Gleason score between 2 and 10 refer to Table 1.2 and
Table 1.3.
Table 1.2 Gleason Scores
Description

Gleason Score
Grade 1

Sharply circumscribed aggregates of small, closely packed uniform
glands

Grade 2

Greater variation in gland size; more stroma between glands; more
infiltrative margins

Grade 3

Further variation in gland size; glands are more widely dispersed in
stroma; distinctly infiltrative margins with loss of circumscription

Grade 4

Fused gland pattern irregular masses of neoplastic glands
coalescing and branching; infiltration of the prostate stroma

Grade 5

Diffusely infiltrating tumor cells with only occasional gland
formation; prominent nucleoli

Weiss et al. 2004
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Table 1.3 Sum of Gleason Scores
Gleason scores (sum of 2
scores)

Classification

Grade Tumor grade is the
strongest prognostic
factor)

2-4

Well differentiated

Low Grade
(Scores 4 or less is low
aggressive)

5-6

Moderately differentiated

Intermediate grade

7

Moderate to poorly
differentiated

Intermediate grade (Scores 7
or more high aggressive)

8-10

Poorly differentiated

High grade

Weiss et al. 2004; Ellsworth et al. 2007

The staging classification system tumor, node, metastasis (TNM) is defined by the
American Joint Commission on Cancer (AJCC) in the Cancer Staging Manual and
referenced by Siroky, Edelstein, & Krane (1999). Table 1.4 below provides a summary of
the tumor component with treatment recommendations. Treatment with ADT is
highlighted.
5.

Treatment Options and Use ofADT
Treatment of early disease can be curative. Treatments for later stages of

prostate cancer are palliative. A general summary of treatment recommendations for
prostate cancer based on stage of disease is summarized in Table 1.4. ADT is initiated once
non-invasive procedures such as external beam radiation, brachytherapy, or radical
prostatectomy have been ineffective or the cancer has extended through the prostate
capsule (Weiss et al. 2004). Suppression of testosterone using ADT can produce regression
of the cancer in approximately 50% of the patients and subjective improvement in 80% of
the patients (Weiss et al. 2004).
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Table 1.4 Staging Classification System for Tumor as Defined by the American Joint
Commission on Cancer (AJCC) and Treatment Recommendations

TX

Description
Primary tumor, can’t be assessed

Treatment Recommendations
No treatment

TO

No evidence primary tumor

No treatment

TI

Clinically in apparent tumor or
not, palpable or visible by
imaging

No treatment

Tla

Tumor incidental histologic
finding in less than 5% tissue
resected

No definitive treatment
(>70y/o consider radical
prostatectomy or external beam
radiation for Gleason 7+)

Tib

Tumor incidental histologic
finding in more than 5% tissue
resected

External beam radiation
Radical prostatectomy

1c

Tumor identified by needle
biopsy

External beam radiation
Radical Prostatectomy

T2

Tumor confined within prostate

External beam radiation, APT
Radical prostatectomy (no nodes)
ADT prior to surgery Brachytherpy
and ADT

T2a

Tumor involves one lobe

see T2

Tumor (TX)

Ellsworth et al. 2007; Siroky et al. 1999; Weiss et al. 2004

Treatment methods to decrease testosterone are described by Weiss et al. (2004)
and Ellsworth et al. (2007). One treatment of prostate cancer is bilateral orchiectomy since
90-95% of all testosterone is in produced in the testes. A less dramatic and effective
treatment is chemical castration. Examples of ADT are diethylstilbesterol (DES) or
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luteinizing hormone-releasing hormone (LH-RH). DES is an exogenous estrogen that is
not commonly used due to increased risk of thrombosis. LH-RH is an analogue that inhibits
the release of the pituitary gonadotropins. An analogue is structurally similar to the body’s
natural androgens but has an altered function to block enzymatic reactions (Dirck, 1997).
LH-RH agonists or LH-RH antagonists suppress the transfer of LH-RH from the
hypothalamus to the anterior pituitary gland resulting in suppression of testosterone
produced in the testes (Matthews, 2007). The outcome of LH-RH agonist or antagonist
therapy is a decrease in testosterone to below 50ng/ml resulting in chemical castration.
Anti-androgens, such as Flutamide or bicalutamide, are also used to block
androgens at target tissues. Weiss et al. (2004) notes that 5-10% of testosterone is produced
in the adrenal glands and the use of amino gluthethimide, an adrenal suppressing drug, and
ketoconazole, an antifungal, act to block, steroid biosynthetic pathways. It is not
uncommon for ADT to consist of combined androgen blockade (CAB). This is when
LH-RH or orchiectomy plus an antiandrogen are used.
The adverse effect of ADT regardless of treatment type, orchiectomy, LH-RH
agonist, or addition of estrogens is osteoporosis. In the next section, osteoporosis is
discussed.
C. Osteoporosis
1.

Epidemiology
a. General According to the Surgeon General’s Report (NIH 2004;

National Osteoporosis Foundation [NOF] 2002), the prevalence of osteoporosis and low
bone mass is expected to increase The projections noted in the report for year 2020
indicate that one in two Americans over age 50 is expected to have or to be at risk of
9

developing osteoporosis of the hip; and even more will be at risk of developing
osteoporosis at any site in the skeleton (NIH 2004; Looker et ah, 1997; Praemer, Fumer,
& Rice, 1999).
Leibson, Totson, Gabriel, Ransom, & Melton (2002) noted the National Health and
Nutrition Examination Survey (NHANES) III findings that 1% percent of men, age 65 and
older reported a diagnosis of osteoporosis. In contrast, the NHANES findings, (Looker et
al. 1998) indicate that four times as many men (4%) actually had the disease when tested
by dual energy x-ray absorptiometry (DEXA) at the hip. Table 1.5 shows male prevalence
as provided in the Surgeon General’s Report (NIH 2004; Looker et al. 1997; Praemer et al.,
1999).
Table 1.5 Prevalence (per 100 persons) of Osteoporosis and Hip Fracture in Persons 65
Years of Age and Older, by Gender and Age in the U.S. from 1988-1994 American
Academy of Orthopedic Physicians
Tested

Self-Reported
Groups

% of hip fracture

% osteoporosis

% osteoporosis

Males

2.3

1.3

3.8

65-74 year old

2.1

1.3

2.0

75-84 years old

2.4

1.3

6.4

85 years & older

4.1

1.6

13.7

Praemer etal. 1999

The Surgeon General's report, Bone Health and Osteoporosis (NIH 2004), states
that the prevalence of osteoporosis and osteoporotic-related fractures will increase
significantly unless the underlying bone health status of Americans is improved. It is
projected that the number of hip fractures could double or triple by 2040 (Schneider and
Guralnik 1990). Not surprisingly, bone disease takes a significant financial toll on society
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and individuals who suffer from it. The direct care expenditures for osteoporotic fractures
alone range from $12.2 to $17.9 billion each year. (Leibson et al.2002).
The Surgeon General’s report (NIH, 2004) identifies specific objectives outlined
by Healthy People 2010 (Appendix A). These objectives were to reduce the number of
osteoporosis cases by 8%, reduce hospitalizations for vertebral fractures from 17.5 to 14
per 10,000, reduce hip fractures, and increase physical activity. It included a national
action plan aimed at improving overall health and quality of life by enhancing the
underlying bone health of all individuals.
b. Epidemiology of Osteoporosis in Men.

Only 1 of 5 individuals with

established osteoporosis is male. However, the risk of mortality after a hip fracture for a
man is two times greater than for a woman (Waxman, 2007). Hip fracture is the most
serious fracture in terms of mortality. The risk of mortality is 2.8 to 4 times greater during
the first 3 months after the fracture (Leibson et al., 2003; Richmond, Aharonoff,
Zuckerman, & Koval, 2003). Among men, 40% of hip fractures result in death
(Berarducci, 2004). Fractures can have devastating consequences for the individual and
their family members. Osteoporosis is now recognized as a significant pathology in men
that will strain Medicare’s budget over the next 20 years (Rutecki, 2008).
The Surgeon General’s Report (NIH, 2004) discusses lack of agreement about
how osteoporosis should be defined in men. Aging is a contributing factor for loss of bone
mineral density. Loss of bone mineral density (BMD) increases the risk osteoporosis.
However, available data is limited about how to measure for osteoporosis in men. A
meta-analysis by Liu et al. (2008) assessed screening tests for osteoporosis and concluded
that only dual energy x-ray absorptiometry (DEXA) were sufficiently sensitive for
11

measurement of BMD and diagnosis of osteoporosis. The World Health Organization
(WHO) definition of osteoporosis for men uses the same criteria as for women. Central
DEXA devices measure BMD in the hip and spine at lumbar vertebrae 1 through 4.
T-scores compare BMD with that of a young adult of the same gender. A score above -1 is
considered normal. A score between -1 and -2.5 is classified as osteopenia (low bone
mass). A score below -2.5 is defined as osteoporosis (WHO 2004).
2. Bone Biology
a. General.

A review of bone biology and disease from the Surgeon

General’s Report (NIH, 2004; Bilezikian, Marcus, & Levine, 2001; Marcus, Feldman, &
Kelsey, 2001; Guyton, 1991; Favus, 2003) is summarized below. The skeleton is
described as serving two different functions: (1) structural for mobility, support, and
protection; (2) a reservoir -for storage of calcium and phosphorus (American College of
Sports Medicine [ACSM], 2006).
Bone health is difficult to maintain because the two different functions are in
competition with each other. Bone must be responsive to changes in mechanical loading or
weight bearing, and this requires strong bones with ample supplies of calcium and
phosphorus. When these minerals are in short supply in other areas of the body, the
regulating hormones take them out of the bone to serve vital functions in other body
systems. To respond to its dual roles of support and regulation of calcium and phosphorus,
as well as to repair any damage to the skeleton, bone is constantly changing. Old bone
breaks down and new bone is formed. This regulatory system requires specialized cells that
communicate with each other. These cells must respond to many different signals that are:
(1) internal and external; (2) mechanical and hormonal; and (3) systemic based on the
12

entire skeleton or localized sites which selectively affect a small region of the skeleton
(NIH, 2004, Guyton, 1991).
The minerals, calcium and phosphorous used for bone remodeling are essential for
the functioning of other body systems, and in times of need removed from bone. The
maintenance of a constant level of calcium in the blood as well as an adequate supply of
calcium and phosphorus in cells is essential for the function of body organs, particularly
the nerves and muscle. A system of regulatory hormones maintains adequate supplies of
these minerals. These hormones act not only on bone but also on other tissues.
Osteoblasts continuously deposit new bone tissue by absorbing calcium from the
blood. Osteoclasts continuously dissolve bone tissue by break down bone releasing
calcium and phosphorous into blood. This continuous process is called bone remodeling
and occurs at rates equal to each other so total bone mass remains constant (Guyton, 1991;
ASCM, 2006).
Vitamins C and D influence bone growth. Cormack (1993) summarized the clinical
implications of these vitamins. Vitamin C is needed for collagen formation by promoting
proline hydroxylation. Collagen is responsible for 90% of the bone matrix. In absence of
vitamin C there is decreased collagen and the bones become thin and fracture easily.
Vitamin D promotes absorption of calcium from the intestines. Formation of Vitamin D
requires exposure to sunlight, UV rays, to convert provitamin into vitamin D. While many
people are able to obtain enough vitamin D naturally, studies show that vitamin D
production decreases in the elderly, in people who are housebound, and for people in
general during the winter (NIH, 2007). A lack of vitamin D impairs calcification of the
matrix (Cormack 1993). Serum 25 OH vitamin D levels are obtained to determine vitamin
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D deficiency (Malone & Kessnich, 2008). Vitamin D is converted in the liver to 25
hydroxy vitamin D. It is the major circulating form of vitamin D and a serum blood test is
commonly used to determine vitamin D status deficiency (Malone et al., 2008). Deficiency
is determined by 25 OH hydroxy vitamin D measurement that represents sources of
endogenous and exogenous vitamin D (Alpert & Shikkh, 2007).
Ferrari et al. (2007) completed a meta-analysis to assess the relationship of calcium
intake to risk of hip fracture in men and women. The found that calcium intake was not
significantly associated with hip fracture risk in women or men.
b. Pathophysiology of Osteoporosis. Surgeon General's Report (NIH,
2004), Bilezikian et al. (2001), Marcus et al. (2001), and Favus (2003) summarize how
osteoporosis occurs. The skeleton deposits, stores, and removes calcium and phosphorus
in times of need. Not enough deposits or too much withdrawal of calcium weakens the
bone and can lead bone fractures. The amount of bone deposits, bone architecture, and
shape is determined by mechanical force that acts on the skeleton. Bone mass and
architecture are continuously modified as function and the mechanical force require
change.
Bones weaken if they are not subjected to adequate amounts of loading and weight
bearing for sufficient periods of time. In other words, if bone is not stressed, it is removed
and then bone becomes weakened. Conversely, the amount and architecture of the bones
can be improved by mechanical loading. Bone strength is determined by the composition
of the mineral and matrix, the structure of trabecular bone, the porosity of the cortical bone
and the presence of micro-fractures and other forms of damage in bone (NIH, 2000).
Osteoporosis occurs when there are alterations in the micro-architecture of trabecular bone
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causing decreased bone matrix and abnormal bone calcification. Guyton (1991) provides
two possible causes: (1) decreased activity by osteoblast cells so that new bone deposition
is decreased; (2) increased osteoclast activity or bone is dissolved faster than deposited.
Guyton (1991) identifies several risk factors that contribute to development of
osteoporosis. These risk factors include: inactivity causing lack of physical stress on
muscles that in turn stress the skeletal bones; malnutrition; lack of vitamin C necessary for
intercellular substances to form bone tissue by osteoblasts; decreased hormones such as
estrogen or testosterone; deficiencies of protein metabolism; lack of vitamin D to absorb
calcium from the intestines into the blood; and many other pathologies.
3. Risk Factors for Osteoporosis
NHANES (USDHHS 2006) provided a summary and brief discussion of
risk factors that contribute to osteoporosis. These primary risk factors are aging, body size,
cigarette and alcohol use, use of certain medications, or medical diseases. It is well
documented that aging is a contributing factor to bones becoming thinner and weaker. Also
a person with a small thin body size increases fracture risk. Cigarette use increases risk of
bone loss and fractures. Cigarette smokers are believed to absorb less calcium from their
diets contributing to a low BMD. Alcohol consumption of 2 to 3 ounces a day may be
damaging to the skeleton. Heavily drinkers are more prone to bone loss and fractures,
because of both poor nutrition and increased risk of falling. Long-term use of
glucocorticoids and some anticonvulsants can lead to loss of bone density and fractures.
Bone loss can also result from long-term treatment with certain anti-seizure drugs, such as
phenytoin, barbiturates, and the excessive use of aluminum-containing antacids.
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Recently, the American College of Physicians (ACP) adopted screening guidelines
for osteoporosis risk factors and appropriate screening practices for men based on
meta-analysis completed by two different reviews (Liu, Paige, & Goldzweig, 2008;
Qaseem, Snow, & Shekelle, 2008). The meta-analysis identified the following risk factors:
sedentary lifestyle; ADT; age older than 70; weight loss greater than 10%; previous
osteoporotic fractures not related to trauma; decreased body mass index; and use of
corticosteroids.
Conde et al. (2004) sought to identify risk factors for osteoporosis in men with
prostate cancer who have not yet received ADT. They were concerned about accelerated
bone loss during ADT and identification of patients at higher risk who may need bone
mineral density assessment. Their study involved 34 subjects with non-metastatic prostate
cancer, who had not started ADT. They found of the 73.5 % of the subjects had osteopenia
and 17.6% had osteoporosis.
Ryan et al. (2007) found that, “BMD loss is a function of the duration of ADT
during the first year of therapy. The body mass index, calcium, vitamin D supplementation
were associated with greater BMD even after controlling for ADT exposure.
A secondary risk factor for osteoporosis is a deficiency of vitamin D. Malone et al.
(2008) summarize a meta-analysis of 25 trials regarding post-menopausal women in which
Vitamin D supplementation helped to reduce the incidence of low bone mineral density.
Vitamin D has an indirect effect on BMD by influencing intestines to absorb
calcium into the blood stream. It also has a direct influence on prostate cancer. Current
studies have shown an association between plasma levels of 25-OH vitamin D and
mortality in men with prostate cancer (Fang et al., 2011). This association suggests that
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vitamin D may mediate prostate cancer prognosis (Choo, Mamedov, Chung, Kiss, &
Danjoux, 2011). Another study by Zheng et al. (2010) indicated that a higher vitamin D
blood level is associated with improved prognosis of prostate cancer. Lips (2006) states
that vitamin D has an antiproliferative effect and down regulates inflammatory markers.
Karlsson et al. (2010) support prior research suggesting vitamin D regulates prostate cell
biology thorough several pathways and acts as a therapeutic agent in inhibiting prostate
cancer cell proliferation through autocrine synthesis. Autocrine synthesis occurs when a
hormone or chemical is released and binds on the same cell causing that cell to change.
Vitamin D receptor cells in the prostate gland are believed to cause a biochemical process
that prevents prostate cancer cell growth (Schwartz, 2009). In contrast, two studies, the
Harvard Cohort study and the Nurses’ Health Study did not demonstrate an association
between vitamin D blood level or dietary vitamin D intake with prostate cancer in with
middle age men (Giovannucci, 2009). A meta-analysis of 67 independent studies by
Raimondi, Johansson, Maisonneuve, & Gandini (2009) found that the vitamin D receptor
cells modulate prostate cancer. Measurement for vitamin D insufficiency is by 25-OH
vitamin D blood level (Binkley, Krueger, & Lensmeyer, 2009; Caplan, 2006) According to
Caplan (2006) and Binkley, Krueger, & Cowgill (2004), different methods of testing
provide different results with the same specimen. The current recommendation for testing
is by tandem mass spectrometry assay as other tests tend to underestimate 25-OH vitamin
D levels (Caplan, 2006).
ADT is a risk factor for osteoporosis. Testosterone suppression can reduce bone
growth weakening bony structure (Marks, 2002; Smith, 2002). Lack of testosterone
impairs the cellular replication of new osteoblasts (Guyton, 1991; Guyton & Hall, 1998).
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Lowering testosterone levels through ADT slows prostate cancer growth, decreases bone
mineral density (BMD), and may result in development of osteoporosis and bone fracture
(Fredrich, 2003; Smith, 2002; Strief, 2007). Osteoporosis starts to occur when testosterone
levels are less then 300ng/ml (Waxman, 2007). The first year of ADT, fracture risk is
increased 1.5 times occurring mainly in hips and spine (Holzbeierlein, 2006; Matthews,
2007). Berarducci (2004) describes osteoporosis as micro-fractures in bone architecture
weakening it from the inside out. Weakening of the bone structure leads to fractures
resulting from minimal trauma or stress.
4. Diagnosis of Osteoporosis
There is a lack of agreement about how osteoporosis should be defined for
men. Since aging men of all races lose bone from the hip, one would expect the prevalence
of osteoporosis to increase with age in men as it does in women. According to the National
Institute of Health (NIH, 2004) data for men with osteoporosis is limited. Dual energy
x-ray absorptiometry (DEXA) scans is the recommended instrument to diagnose
osteoporosis in men with identified risk factors. Meta-analysis by Liu et al. (2008) assessed
screening tests to evaluate for osteoporosis and concluded only DEXA scans were
sufficiently sensitive for diagnosis. Liu et al (2008) considered DEXA the gold standard
for measurement of BMD to diagnose osteoporosis. Liu et al. (2008) evaluated 1) risk
factors for osteoporotic fracture in men that may be mediated through low BMD and 2) the
performance of non-DEXA tests in identifying men with low BMD. Their conclusion
indicates non-DEXA tests either are too insensitive or have insufficient data to reach valid
conclusions. Central DEXA devices measure bone density in the hip and spine at lumbar
vertebrae 1 through 4. The DEXA machine sends a thin, invisible beam of low-dose x-rays
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with two distinct energy peaks through the bones being examined. The peak is absorbed
mainly by soft tissue and the other by bone. The soft tissue amount can be subtracted from
the total and what remains is a patient's bone mineral density. The DEXA test is usually
completed within 10 to 30 minutes. Bone density tests are a quick and painless procedure
(NIH, 2004; Sieber, 2002).
Waxman (2007) considered DEXA T-scores of less than -2.5 for males as criteria
to initiate treatment for osteoporosis. Ebling (2008) stated that sex specific T-scores remain
controversial. He noted that the World Health Organization (WHO) assigned diagnostic
thresholds for osteopenia and osteoporosis for post-menopausal women using total hip
bone mineral density and these thresholds are now applied to men.
5. Prevention of Osteoporosis
a. General Prevention. Kaplan (1990) stated there are only two health
outcomes that are of importance. These are life expectancy and quality of life. He
described biological and physical events as mediators of behavioral outcomes. He used a
behavioral conceptualization of health outcomes to define future practices. Kaplan (1990)
proposed a model that includes biological, environmental, and psychological variables as
mediators of behavioral health outcomes.
Twiss, Gross, Waltman, Ott, & Lindsey (2006) examined health behavior outcomes
in breast cancer survivors experiencing bone loss. Analysis of their research supports the
model proposed by Kaplan (1990). Twiss et al. (2006) described baseline healthy lifestyle
behaviors of postmenopausal breast cancer survivors and then identified any relationship
of healthy lifestyle behaviors with bone mineral density. Their research involved 249
subjects who provided self-reported responses to demographic and health status
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questionnaires, a 3 day diet record, and 7 day physical activity questionnaire about lifestyle
behaviors. The health behaviors assessed included diet, calcium intake, vitamin D, caffeine
and alcohol intake, smoking history, and physical activity. A baseline bone mineral density
was obtained using a DEXA scan. Height, weight and body mass index (BMI) were also
measured. Conclusions note that an imbalance between calorie intake and expenditure,
inadequate calcium and vitamin D intake affected bone mass. Caffeine, alcohol and
tobacco use were already decreased in this population and demonstrated significant
negative relationships with bone mass. There was also a significant relationship between
weight, BMI and bone mass. Their recommendations for clinical practice emphasized
incorporation of biological, environmental, and psychological variables as mediators for
behavioral health outcomes. The mediators described are health teaching strategies,
intensive counseling, coaching, and support mechanisms to enable Breast Cancer
Survivors understanding of the importance of healthy lifestyle practices performed daily to
prevent of osteoporosis.
Application of Kaplan’s model to the proposed study describes a pathway for
improving health outcomes by decreasing risk of osteoporosis with physical activity in
patients receiving ADT for prostate cancer. Exercise before and during ADT will reduce
the risk of osteoporosis influencing health outcomes, quality of life, and life expectancy for
prostate cancer patients.
b. Exercise. Bones weaken if they are not subjected to adequate amounts
of loading and weight bearing for sufficient periods of time. Conversely, the amount and
architecture of the bones can be improved by mechanical loading. One of the risk factors
identified by Guyton (1991) is inactivity causing lack of physical stress on bones. Guyton
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(1991) notes that bone is deposited proportional to the compression load that the bone has
to carry. In other words, increasing muscle size results in increasing muscle weight and this
leads to increase stress one the bone resulting in increased bone size. Physical activity can
play an important role in the prevention and treatment of osteoporosis (NIH, 2005). Bone is
living tissue that responds to exercise by becoming stronger. Gutin and Kaspar (2002)
stated that young women and men who exercise regularly generally achieve greater peak
bone mass (maximum bone density and strength) than those who do not. For most people,
bone mass peaks during the third decade of life and after this peak people can begin to lose
BMD.
The Surgeon General’s Report, Physical Activity and Health (1996) and U.S.
Department of Health and Human Services, Promoting Physical Activity (ASCM 2005)
defined physical activity as any bodily movement that is produced by the contraction of
skeletal muscle and that substantially increases energy expenditure. Exercise is defined in
the Surgeon General’s Report, Physical Activity and Health (1996) and U.S. Department
of Health and Human Services, Promoting Physical Activity (ASCM 2005) as planned,
structured, and repetitive body movement done to improve or maintain one or more
components of physical fitness. Nieman (1999) defined exercise as physical exertion of
sufficient intensity, duration, and frequency to achieve and maintain fitness or other health
objectives. Several studies demonstrate that bone density can be increased with exercise
(Kanis & Gluer, 2000; Pfeifer, Sinaki, & Gesens, 2004).
The Surgeon General (1996) and USDHHS (1999) reported: (1) more than 60% of
American adults are not regularly physically active, 25-30% are not active at all; (2)
participation in leisure time physical activity decreases as age increases; women are less
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likely to engage in moderate or vigorous physical activity.
The National Health and Nutrition Examination Survey (NHANES) (Moayyeri,
2008; U.S. Department of Health Human Services [USDHHS], 1999; Neiman, 1999)
included exercise training as non-pharmacologic treatment for osteoporosis. NHANES is a
series of national examination studies conducted in the U.S. Data is obtained from national
samples of the U.S. population. The data from NHANES has been used to develop national
nutrition and health policies. The first threes surveys were initiated in the 1960s in response
to the National Health Survey Act passed in 1956. NHES I focused on selected chronic
diseases of adults 18-79. NHES II and III focused on growth and development of children
using sample sizes of 7,500. Studies after 1970 added a nutrition component thus the first
National Health and Nutrition Examination Survey (NHANES). NHANES I through III
have been part of a national epidemiologic multiphase follow-up survey by interviews with
NHANES I survey population to provide a longitudinal picture of health in the U.S. In
1999 NHANES became a continuous annual survey program. A national representative
sample of civilian non-institutionalized persons of all ages are interviewed and examined.
Data from these studies are released in two year cycles. Approximately 7000 people of all
ages in households across the U.S. are randomly surveyed. The study design includes a
representative sample of groups by age, sex, and income levels.
There are three components of health related fitness these are cardiorespiratory
endurance, body composition, and musculoskeletal fitness (Nieman 1999). The three areas
defined by Nieman (1999) are:
c. Cardiorespiratory Endurance. Cardiorespiratory endurance is the
ability of the cardiorespiratory systems to adjust to and recover from the effect of work
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involving the whole body. It is measured by oxygen consumption or V02 max. Normal
range is 55-90% maximal heart rate engaged for 20-30 minutes 3-5 days a week. Some
examples are walking, running, step-test racquetball, rowing, tennis, bicycling.
d. Body Composition. A formula to calculate percent of body fat using
fat free, bone and lean muscle, weight to body fat weight. Body mass index is calculated
from height and weight. Neiman (1999) describes optimal body fat levels at 15% body fat
or less for men He defines men who are obese as having a body fat of 25% or higher.
e. Musculoskeletal Fitness. Muscle fitness has three components:
flexibility; muscular strength; and endurance. Flexibility is the movement of each joint.
Muscular strength is maximum amount of force that one can generate in an isolated
movement of a single muscle group. An example is weight lifting maximum weights once
or twice. Muscular endurance is the ability of the muscle to apply a submaximal force
repeatedly or to sustain a submaximal contraction for a period of time. Examples of
common exercises are push-ups, sit-ups, abdominal curls, chin-ups, or weight lifting 10-15
times in succession.
Borst (2005) evaluated three strategies for preventing decreased muscle mass and
strength that accompany aging. These strategies included testosterone replacement for
men, growth hormone replacement, and resistance exercise training. They found resistance
training the most effective intervention for increasing muscle mass and strength. As noted
earlier, increased muscle mass and strength strengthens bone and indirectly decreases bone
mineral loss. Conditioning training according to ACSM (2006) indicated there are no
studies evaluating cardiovascular adaptations in patients with osteoporosis.
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f Exercise in Patients. Treated with ADT Research by Daniell et al.
(2000) attempted to quantify bone loss for men with prostate cancer receiving ADT. They
found that bone mineral density decreased 2.4-7.6% and continued to decrease with
uninterrupted ADT with each additional year of treatment. Chemical castration in men
with prostate cancer is usually followed by greatly accelerated bone loss which may be
superimposed on already depleted bone mass before hormonal therapy. Their age corrected
baseline found bone mineral density was greater in men who were obese, younger the 75
year old, or participated in regular exercise. Investigators were not able to isolate the
influence of these three characteristics. Summary of finding includes a comment that
baseline bone mass and subsequent bone loss may be influenced by obesity, age, and
exercise habits influencing the affect of ADT on osteoporosis.
Lowering testosterone levels suppresses prostate cancer growth and decreases bone
mineral density (BMD) increasing risk of osteoporosis and bone fractures (Fredrich, 2003,
Smith, 2002; Strief, 2007). Among men, 40% of hip fractures result in death (Berarducci,
2004). Exercise is recognized in the prevention and treatment of osteoporosis. This study
will provide evidence to clarify whether exercise reduces risk of secondary osteoporosis
associated with ADT. Avoiding osteoporosis by increasing exercise in this group of
high-risk patients would be a practical measure for preventive care specialists to institute.
Kelley et al. (2000) noted that exercise is available to the general public and provides an
inexpensive, non pharmacologic approach for treatment of osteoporosis. Identification of
patients at increased risk for osteoporosis from secondary causes is important so effective
treatment can be introduced to reduce potentially life-threatening complications (Ebling,
2008; Fitzpatrick, 2002).
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D. Purpose of the Study
The purpose of this study is to evaluate the relationship between self reported
exercise and risk of osteoporosis measured by DEXA scan in prostate cancer patients
receiving ADT.
E. Hypotheses
There is an inverse relationship between self-reported exercise and osteoporosis in
patients with prostate cancer who have received ADT for at least 9 months or more.
F. Research Question
•

Is there a relationship between frequency, intensity, and duration of total
resistance and endurance exercise to development of osteoporosis assessed by
bone mineral density measured by DEXA scan and serum 25 OH vitamin D
levels in prostate cancer patients receiving ADT?

•

Does the association of exercise and osteoporosis depend on type of exercise,
specifically resistance or endurance?

G. Theoretical Justification
The biochemical and physiological actions of testosterone are summarized by
information provided by Guyton (1991), Frayn (1996), and Cormack (1993). Testosterone
is secreted by the Leydig cells in the testes proportional to the amount of LH released by
the anterior pituitary gland. Testosterone enters the cells of the prostate tissue and is
converted to dihydrotestosterone where it binds to a protein receptor in the cell cytoplasm.
The protein receptor then migrates to the nucleus and binds with nuclear protein. This
initiates the DNA-RNA transcription process activating RNA to increase its concentration
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of RNA, which increases cellular protein that stimulates increased production of new
prostate cells.
ADT is a palliative treatment for prostate cancer that is initiated when
prostatectomy or radiation is unsuccessful. The drug classification, LH-RH agonists, is
commonly used for ADT. According to TAP Pharmaceutical (2006), the LH-RH agonist,
is a synthetic non-peptide analog of naturally occurring gonadotropin releasing hormone
(GnRH). LH-RH possesses a greater potency then the natural hormone, GnRH (TAP
2006). There are several different LH-RH agonists available for use. Different LH-RH
agonists are available, for example injections at 3 month or 6 month intervals or by implant
which is changed yearly.
Frayn (1996) described the metabolic regulation of GnRH and lutenizing hormones
(LH) secreted by the anterior pituitary gland. The pituitary gland is attached to the
hypothalamus by a small stalk like structure in the brain. The anterior portion of the
pituitary gland secretes several peptide and glycoprotein hormones. The hormone specific
to testosterone synthesis is LH. GnRH is a hypophysiotropic neurohormone in the
hypothalmus that controls the release or inhibits secretions of LH from the anterior
pituitary gland (Guyton et al., 1998). LH is a gonadotropin that originates in the basophil
cells of the anterior pituitary gland. It is a glycoprotein that, through regulation of GnRH,
in the hypothalamus acts on the testes in male to initiate testosterone synthesis.
According to the manufacturer, TAP Pharmaceuticals (2006), LH-RH inhibits
GnRH secretions when administered on a continuous basis. This results in the suppression
of biological synthesis of testosterone formed in the leydig cells by the testes. Testosterone
influences other tissues. Unlike the prostate gland, these tissues are not able to convert
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testosterone into dihydrotestoterone so the overall effect is reduced. Testosterone enters the
cell and has an intracellular affect to stimulate the formation of more proteins. The cellular
proteins stimulate RNA to produce new cells increasing the bone density and size by
increasing osteoblasts and muscle mass. (Guyton, 1991) Lowering testosterone levels
slows prostate cancer growth and decreases BMD (Fredrich, 2003; Smith, 2002; Strief,
2007). This may lead to osteoporosis.
Guyton et al. (1998) provides a review of how testosterone regulates bone
metabolism. Testosterone stimulates osteoblastic activity. Suppression of testosterone
decreases the activity of the osteoblasts and results in decreased deposits of new bone.
Osteoporosis occurs when the deposit of new bone is depressed. Testosterone stimulates
muscle growth and strength Muscle is attached to bone and moves the skeleton. Muscle
places greater stress on the bone and this stress increase osteoblasts to form new bone.
Skeletal muscles are composed of cylindrical cells that are able to contract, have elasticity,
irritability, and conductivity. The cytoplasm also known as karyoplasms is made of
sarcomeres. Sarcomeres are bundles of muscle fiber that are able to contract voluntarily
(Guyton, 1991, Frayn, 1996).
The effect of exercise is to increase muscle mass by increasing the size of the cell
rather than increasing the number of cells. The increase in muscle size increases muscle
weight this leads to increase in bone size. Guyton (1991) noted that bone is deposited
proportional to the compression load that the bone has to carry. He provides the example
that athletes’ bones are considerably heavier than those of non-athletes. He concludes that
continuous physical stress stimulates calcification and osteoblastic deposition of bone.
ACSM (2006) described the effect of exercise as promoting skeletal loading. The process
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of skeletal loading involves a complex process involving musculoskeletal and endocrine
systems. Multiple sources (Guyton, 1991; NIH, 2004) identified that one of the common
causes of osteoporosis is lack of physical stress on the bones from inactivity. ASCM (2006)
noted that a reversal of physiological adaptations to exercise occurs when exercise is
decreased or stopped. Inactivity reduces bone mass and adversely affects calcium
formation and bone formation process (ASCM, 2006) They recommended exercise as one
factor to prevent or improve bone mineral density but improvement is limited and does not
occur rapidly. Kelley, Kelley, & Tran (2000) completed a meta-analysis for exercise and
bone mineral density in men. Their results indicated that in men, over 31 years old,
exercise maintains and may improve BMD.
H. Significance to Preventive Care
Lack of exercise is a contributing factor to osteoporosis (McGlynn, 1987). Exercise
stimulates the production of new bone tissue. It is important to identify patients at
increased risk for osteoporosis from secondary causes and then implement effective
methods to prevent or reduce potentially life-threatening complications (Ebling, 2008;
Fitzpatrick, 2002). There is limited research about prevention or treatment of osteoporosis
m men (USDHHS, 1998; Woolf, Jonas, & Lawrence, 1996). Research to prevent
osteoporosis and development of intervention strategies is essential. Promotion of bone
health by increasing knowledge about efficient and effective ways to assess, diagnose, and
apply therapeutic tools can reduce associated risks improving quality of life and for some,
life expectancy (NIH, 2004).
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CHAPTER 2
LITERATURE REVIEW

A. Introduction
The use of ADT for prostate cancer has increased from about 4% in 1991 to about
31% in 1999 (Greenspan, 2008; Shahinian, Kuo, Freeman, Orihuela, & Goodwin, 2005).
ADT lowers the testosterone level to slow prostate cancer growth. A decreased
testosterone level may result in a decrease in bone mineral density (BMD) that may result
in osteoporosis (Fredrich, 2003; Smith, 2002; Strief, 2007). Bone mineral density begins to
decrease with testosterone levels of less than 300ng/ml (Waxman, 2007).
A study by Daniell et al. (2000) assessed bone mineral density prior to ADT and
during ADT at intervals of six months. They found that bone loss was greatly accelerated
m men after receiving chemical or surgical castration and this may be superimposed on
depleted bone mass occurring prior to treatment. The magnitude of low BMD prevalence
m men receiving ADT is unknown. An interesting finding is that use of ADT lowers BMD
but it does not have a significant effect on 25-hydroxyvitamin D or serum calcium
(Greenspan, 2008).
Studies by McLeod, Huynh, & Rashid (2008) found that men receiving ADT had
experienced an annual bone loss of 3-5% for the first 2-3 years with measurable changes
occurring the first nine months of use. Loss of BMD due to ADT is compound by the fact
that one to two million, (6%), of men have osteoporosis and 8-13 million (28%) have low
bone mass by bone mineral density test as part of the aging process (Greenspan 2008).
DEXA scan was used to diagnosis osteoporosis in men using criteria of a T-score lower
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than -2.5 standard deviations at the femoral neck and hip. Sixty percent of bone loss in men
is due to secondary causes (Greenspan, 2008). Fracture risk in the first year of ADT is
increased 1.5 times and occurs mainly in hips and spine (Holzbeierlein, 2006; Matthews,
2007).
Wilens (2005) and Greenspan (2008) reported that, men sustain 25-30% of all hip
fractures. In 1999, approximately 81,000 hip fractures were reported in men over the age of
65. The risk of mortality after a hip fracture for men is two times greater than for women
(Waxman, 2007; Wilens, 2005; Forsen, Sogaard, Myer, Edna, & Kopjar, 1999). In terms of
mortality, hip fracture is the most serious. Among men, 40% of hip fractures result in death
(Berarducci, 2004).
B. Prevention of Osteoporosis: Biological and Physical Mediators
Eastham (2007) and Kaplan (1990) noted prostate cancer patients who undergo
ADT, do not receive adequate intervention to prevent or treat osteoporosis. He quotes a
study with 184 subjects receiving ADT and only 15% received any prevention information
or therapy to maintain bone health (Tanvetyanon, 2005). The implication that ADT causes
a decrease in BMD and increases risk of osteoporosis impact a prostate cancer patient’s
quality of life and possibly life expectancy. Prostate cancer patients receiving ADT need
adequate intervention to prevent and treat osteoporosis.
Kaplan (1990) described behavioral outcomes such as prevention of osteoporosis
as a result of mediators. His model describes mediators of behavioral health outcomes as
biological, environmental, and psychological variables. Kaplan (1990) stated there are
only two health outcomes that are of importance. These are life expectancy and quality of
life. In men, reduction of mortality from hip fractures due to osteoporosis is the behavioral
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health outcome.
Research completed by investigators Twiss, Gross, Waltman, Ott, & Lindsey
(2006) examined the outcomes of health behaviors in breast cancer survivors experiencing
bone loss. Analysis of their research supports the model proposed by Kaplan (1990). Twiss
et al. (2006) described baseline healthy lifestyle behaviors of postmenopausal breast cancer
survivors and then identified any relationship of healthy lifestyle behaviors with bone
mineral density. Their research involved 249 subjects who provided self-reported
responses to demographic and health status questionnaires, recorded a three day diet
history, and seven day physical activity questionnaire about lifestyle behaviors. The health
behaviors assessed included diet, calcium intake, vitamin D, alcohol intake, smoking
history, and physical activity. A baseline bone mineral density was obtained using a DEXA
scan. Height, weight and body mass index (BMI) were also measured.
They concluded that an imbalance between calorie intake and expenditurephysical activity, inadequate calcium and vitamin D intake affected bone mass. Alcohol
and tobacco use were already decreased in this population and demonstrated significant
negative relationships with bone mass. The relationship between weight, BMI and bone
mass was also significant. Clinical practice recommendations emphasize incorporation of
biological, environmental, and psychological variables as mediators for behavioral health
outcomes. The mediators described include health teaching strategies, intensive
counseling, coaching, and support mechanisms to enable Breast Cancer Survivors
understanding of the importance of healthy lifestyle practices performed daily to prevent of
osteoporosis.
Paffenberger et al. (1993) analyzed changes in physical activity, body weight,
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tobacco use, and blood pressure of men ages 45-84 and the relation of these factors to
mortality. They found that beginning moderate vigorous physical activity was associated
with a 23% lower risk of death than not taking up moderate vigorous sports. Quitting
tobacco use was associated with a 41% lower risk of mortality. Lean body mass was
associated with a lower mortality than long term or recent obesity. Finally, new diagnosis
of hypertension was associated with less risk than men with long term hypertension.
Application of Kaplan’s model to the study proposed by this investigator describes a
pathway to improve health outcomes for prostate cancer patients receiving ADT by
decreasing risk of osteoporosis with exercise. Prevention of osteoporosis by exercise is an
important health outcome (NIH, 2005). Exercise during ADT may reduce the risk of
osteoporosis, prevent fractures, and increase BMD resulting in improved health outcomes,
quality of life, and life expectancy for prostate cancer patients (Eastham, 2007; Greenspan,
2008).

C. Relationship of Exercise and Bone Density
Shipp (2006) wrote that the holy grail of inquiry regarding exercise and
osteoporosis has been identifying a type of exercise that builds bone. Animal models
provide insight about how bone responds to mechanical loading but application to patients
with osteoporosis is difficult. Shipp (2006) added that muscles respond to progressive
strength training through resistance exercises and, cardiopulmonary system responds to
endurance training. Shipp (2006) commented that if bone mass increases as a response to
increasing intensity and duration of mechanical strain it would eventually weigh so much
that it would not allow movement. He summarizes that more is not always better and that
we are not exactly sure what type of exercise and how much is enough. A normal rate of
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decline in bone mass is associated with aging. Men experience greatest bone loss when
testosterone levels are low (Colyar, 2004).
Measurement of BMD is quick simple and painless. The most accurate test is
DEXA due to the minimal exposure to radiation, rapid scanning, and precision of
measurement. Guidelines to interpret measurements for men have now been established by
the American college of Physicians (AGP). The purpose of BMD testing is to predict bone
strength, and to measure the effectiveness of treatment results for osteoporosis. DEXA has
also been used to assess effectiveness of exercise in relation to BMD (Coylar, 2004).
An important determinant of bone size, quality, and strength but not BMD in older
men was participation in long term regular sports and leisure activities (Daly & Bass,
2005). The researchers used data from a physical activity questionnaire to calculate an
osteogenic index score. The osteogenic index score used a formula that incorporated total
minutes per week for each low, moderate, high impact activity during each period it is
used, and the number of months per year multiplied by the number of years spent in each
activity. The formula: OI = Ground Reaction Force * [Ln (total minutes per week) +1) *
months/year * number of years participating in each activity. Ground Reaction Force
values are equated to 1 being a low value, 3 being moderate, and 5 being high impact
activity. DEXA scan scores were obtained for femoral neck, total hip and lumbar spine. A
CT scan was also used for comparison. This study demonstrated that long term
participation in sport and leisure activities was an important determinant of bone size
quality and strength, but not BMD. Their study indicated that different methods used to
estimate physical activity and effect on BMD in literature produced inconsistent findings
and that not all exercises are equally effective in producing an osteogenic response. They
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concluded that the most effective exercise for osteogenic response is, a weight bearing
exercise using intermittent force with increased weight. This supports the recommendation
to maintain regular weight bearing exercise to optimize bone health (Daly et al. 2005).
Rector, Rogers, Ruebel, & Hinton (2008) studied the effects of participation in
non weight bearing exercise to weight bearing exercise on bone health in adult male
athletes. They found that 63% of the non-weight bearing athletes had significantly lower
BMD of the body and spine as compared to 19% of the weight bearing athletes. Rector et al
(2008) defined bicyclists as non-weight bearing type of exercise and the runners as weight
bearing.
Gutin and Kasper (2002) reported that young women and men who exercise
regularly generally achieve greater peak bone mass (maximum bone density and strength)
than those who do not. Nieman (1999) pointed out that a relationship exists between
lifetime physical activity, bone mineral mass, and lowered risk of hip fracture in
post-menopausal women. For most people, bone mass peaks during the third decade of life
and after this peak, bone mineral density begins to decrease.
Fuchs et al. (2007) found combined treadmill running and medication,
biphosphonate, to be more beneficial in preventing declines in bone mass and strength then
of either treadmill running or medication alone in rats with removed ovaries. Schwab and
Klein (2008) examined the role of exercise to prevent osteoporosis. They noted that
exercise has a modest effect on increase in BMD and these gains can be lost quickly when
exercise is stopped. Their review of several studies indicated that future bone size and
strength in men is determined by participation in lifelong leisure activities and high impact
sports. They also note that a rapid loss in BMD and increased bone turnover occurs
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resulting in a negative calcium balance when weight bearing activities are decreased or
stopped.
National Health and Nutrition Examination Survey I (NHANES) found that 47%
of women who reported moderate to vigorous activity had lower risk of hip fracture than
women who reported no physical activity (Moayyeri, 2008; Farmer et ah, 1989). A review
of multiple studies by Moayyeri (2008) examined the protective effects of exercise: Some
of these studies are described below.
The Tromso study, from Norway, reported exercise had protective effects on hip
and ankles among men. A meta-analysis of eight prospective studies involving men
showed a positive association between exercise and hip fracture. The studies involving
men reported moderate to vigorous exercise and exercise from one to three hours per day.
Moayyeri (2008) concluded that several randomized controlled studies and meta-analysis
involving both men and women showed the positive effects of physical activity on BMD of
hip and spine.
Greenspan (2008) recommended treatment considerations for men receiving ADT
to prevent osteoporosis as weight bearing exercise for 30 minutes a session and three times
per week. Exercise provides overall increases in strength, flexibility, and balance and
increases BMD (Lin & Lane, 2008). Specific, weight bearing exercises for patients with
osteoporosis have demonstrated stimulation of the osteoblasts to form new bone.
Lin and Lane (2008) described walking, running, and impact exercises. ASCM
(2006) defined exercise goals for person with or at increased risk for osteoporosis. The
goals are to maintain and increase BDM. As described, there are multiple studies with
women and men that demonstrate exercise can increase bone mineral density or decrease
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further bone loss as compared to persons who do not exercise (ASCM, 2006).
A meta-analysis by Kelley et al. (2000) noted that in adult males exercise
increased and maintained BMD. Bone mineral density was improved and maintained at
specific sites: femur, lumbar, and os calcis.
D. Types of Exercise
Bone is living tissue that responds to exercise by becoming stronger. Nieman
(1999) stated that bone size and density increase when stress is applied. Bone builds in
areas of stress. This stress stimulates bone remodeling. Bone will continue to remodel until
it is able to adapt. Nieman (1999) summarized data demonstrating athletes, as compared to
sedentary persons, have greater bone density and weightlifters have the greatest bone
mineral masses. Muscular strength influences bone density.
Schwab et al. (2008) stated that aerobic, weight bearing, and resistance exercises
are beneficial for maintaining bone density in post-menopausal women. They emphasized
that bone responds to dynamic rather than static loading. Mechanical loading or repeated
stress can induce increases in bone strength. They referenced Turner (2006) who advised
prolonged loading desensitizes the bone cells whereas repeated loading stimulates bone
formation. As a result, Schwab et al. (2008) recommended frequent short session of
dynamic exercise. An example is walking for one hour, four times a week.
Reviews of literature by Spirduso (1995) and ACSM (2006) noted osteoclastic
activity increases in the sixth decade resulting in decreased bone mineral density. This is
attributed in part to decreases in hormone levels, calcium regulatory mechanisms and
lifestyle factors such nutrition and physical activity.
ACSM (2006) and Shepard (1997) stated that bone loss in men begins in the early
36

50’s at a rate of 0.4% a year and by age of 80 years old men have A 55% decrease in their
overall bone mineral density from their peak bone mineral density. There is also a loss of
muscle mass and strength noted earlier as sarcopenia that is in part attributed to decreased
stimulus second to sedentary lifestyle (Borst, 2005; ACSM, 2006). This loss of BMD can
be prevented with weight bearing exercise to increase muscle strength and endurance.
Borst (2005) stated that resistance training remains the most effective intervention for
increasing muscle mass and strength in older people. Ebling (2008) stated bone mineral
density is increased in healthy older men whose training is high intensity progressive
resistance or weight bearing exercise, or both. Progressive resistance or weight bearing
exercise is best for prevention of bone loss. This type of exercise forces a person to work
bones and muscles against gravity creating bone stress that stimulates calcium absorption
(NIH 2007). Regular regimen of weight-bearing exercises might include racquet sports,
lifting weights, and using resistance machines.
Both Fredrich (2003) and Berarducci (2004) commented that aerobic or endurance
and weight bearing or resistance exercise reduces risk of fracture. Marks (2002) stated that
osteoporosis can be treated with a graduated exercise program, which can stimulate bone
growth. Berarducci (2004) advocated for regular weight bearing activity because it is
associated with reduced fracture risk. Berarducci (2004) suggested weight bearing exercise
should be performed at least three times a week for 30-45 minutes.
Segal et al. (2002) studied resistance exercise in men receiving androgen
deprivation therapy for prostate cancer. A total of 155 men with prostate cancer who were
scheduled to receive androgen deprivation therapy for at least 3 months were randomly
assigned to a weight-lifting program three times a week for 12 weeks. Results noted that
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men assigned to weight lifting had less fatigue and higher quality of life scores as
compared to men in the control group. Men that lifted weights had higher levels of upper
body and lower body muscular fitness than men in the control group. The 12-week
weight-lifting intervention did not improve body weight, body mass index, or body fat
percentage but it did significantly improve symptoms of fatigue and quality of life.
Barry et al. (2008) summarized findings from other studies. They noted that
exercise benefits on bone measure associations between physical activity level, BMD, and
fracture incidence. Some studies evaluated changes in physical activity and response to
changes in BMD. They stated that BMD is highest in athletes who participate in sports
such as gymnastics or weight lifting that is high intensity loading forces. In contrast,
weight supported activity such as swimming or cycling have the lowest change in BMD.
Weingard (2006) identified examples of weight bearing exercise to include walking,
climbing stairs, and weight lifting or resistance training.
Bone formation is determined by mechanical loading force. Barry et al. (2008)
stated that the effects of bone building occur only when the mechanical loading force
generates stress greater than the stresses incurred by usual daily activities. They used
percentage of maximal heart rate to measure endurance exercise and percentage of one
repetition maximum (1RM) to measure resistance exercise. They added that as speed of
ambulation and heart rate increases ground reaction forces increases. Ground reaction
forces increase with running as compared to walking and high intensity resistance exercise
generate higher joint reaction forces. Weight lifting faster is more beneficial than slow and
sustained force without movement, as it provides no benefit to bone strengthening
exercise. For the purpose of this study, two categories of exercise are used;
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cardiorespiratory endurance and musculoskeletal resistance. Both categories have been
shown to increase BMD but the intensity and amount of progressive resistance varies and
this association may impact development of osteoporosis.
USDHHS (2008) physical activity guidelines for active older adults describe types
and amounts of physical activity in accordance with their abilities. These guidelines
consider not only fitness but limiting conditions. The guidelines focus on two types of
activities: aerobic or endurance and muscle strengthening or endurance. Endurance is
defined as, “moving large muscle in a rhythmic manner for a sustained period. (USDHHS,
2008)
Some examples provided in the guidelines include: walking, dancing, swimming,
water aerobics, jogging, bicycling, tennis, golf, and gardening that involve pushing a lawn
mower or raking. Resistance exercises strengthen major muscle groups, legs, hips, back,
chest, abdomen, shoulder, and arms by increasing the workload. USDHHS, 2008) defined
resistance exercises as working with resistance bands, weight lifting, push-ups, pull ups,
sit-ups, climbing stairs, carrying heavy loads, heavy gardening, gardening that involves
digging, lifting or carrying, carrying groceries, and yoga.
These two categories will be discussed in more detail to show differences and how
the exercises may directly or indirectly influence BMD and osteoporosis.
E. Cardiorespiratory Endurance
According to ACSM (2006) and Nieman (1999), cardiorespiratory endurance is
the ability of the large muscle dynamics to perform moderate to high intensity exercises for
prolonged periods of time and the ability of the circulatory and respiratory systems to
adjust and recover. There are three components of cardio- respiratory endurance. These
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are: exercise intensity, exercise duration, and exercise frequency. ACSM (1998) and the
Surgeon General’s Report (USDHHS, 1996) defined a minimum exercise program for
endurance as three days a week with a minimum of twenty minutes each session, at a
minimal intensity of 40-50%.
1. Exercise Intensity
Nieman (1999) defined exercise intensity as the level of exertion that
occurs during exercise. American College of Sports Medicine (2006) defined the intensity
of cardiorespiratory exercise as the percent of maximal capacity or V02 reserve. ACSM
(2006) used a percent of maximum heart rate (HR) to measure intensity. The target heart
rate or heart rate goal while exercising was calculated using the Karvonen formula.
ACSM (2006) provided a classification of exercise intensity for endurance
and this is summarized in Table 2.1. ACSM (2006) recommended cardiorespiratory
endurance intensity at minimum of 40% to have any measurable changes.
Table 2.1 Exercise Intensity for Cardiorespiratory Endurance
Percent of Maximal HR
35-54%
55-69%
70-89%
>90%
100%

Exercise Intensity
Light
Moderate
Hard
Very Hard
Maximal
ASCM 2006

USDHHS (2008) physical activity guidelines for active older adults recommended
150 minutes a week of moderate intensity, 75 minutes a week of vigorous activity, or a
combination of both moderate and vigorous. The guidelines defined moderate intensity as
a medium level of effort or 5 to 6 using a scale of 1-10. Zero was defined as sitting and 10
as the greatest effort possible. Moderate intensity causes a noticeable increase in breathing
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and heart rate. Vigorous intensity produces large increases in heart rate and breathing and
is defined as a 7 or 8 on the scale.
2.

Exercise Duration
Nieman (1999) defined duration as time spent in a single exercise session.

ACSM (2005) defined exercise duration for cardio respiratory endurance as 5-10 minutes
for lower exercise duration; 10-20 minutes moderate; and 20-60 minutes for improvement
of cardio-respiratory endurance. Barry et al. (2008) stated that duration of exercise is less
important than intensity for adaptive bone response. They quoted studies indicating that
bone after a few loading cycles becomes desensitized, confirming more is not better;
however optimal cycles are not clear.
3.

Frequency
The number of days per week that exercise occurs is called frequency.

Nieman (1999) defined frequency as how often a person repeats a complete exercise
session. ACSM (2005) defined frequency of exercise for cardio-respiratory endurance
improvement as a minimum of 3 days per week. USDHHS (2008) physical activity
guidelines for active older adults recommended the activity be performed at least 3 days a
week.
F. Musculoskeletal Resistance
Resistance exercises increase musculoskeletal fitness. Musculoskeletal fitness has
three components: muscle strength, endurance; and flexibility. For the purpose of this
study flexibility will not be included ACSM (1998) and the Surgeon General’s Report
(USDHHS, 1996) defined a minimum exercise program for resistance as two to three days
a week with a minimum of one set of eight to ten repetitions of eight different exercises to
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condition all the major muscle groups.
1. Muscle Strength
Nieman (1999) defined muscle strength as the maximal one effort force
that can be exerted against resistance. Golding, Myers, & Sinning (1989) defined muscular
strength as the ability to exert force through the recruitment of muscle fiber cells to
overcome resistance. The more the muscle fibers are stretched, the greater the strength.
USDHHS (2008) physical activity guidelines for active older adults recommended
muscle strengthening activities involving major muscle groups a minimum of 2 days a
week. Muscle strengthening involves a minimum of one set of 8 to 12 repetitions for each
exercise.
2. Muscle Endurance
Nieman (1999) defined muscle endurance as the ability of the muscles to
apply a submaximal force repeatedly or to sustain a muscular contraction for a certain
period of time. Golding et al. (1989) stated muscular endurance is the ability of a muscle to
exercise for an extended period of time without excessive fatigue. It is measured by
multiple submaximal contractions or number of repetitions. Barry et al. (2008) commented
that multiple brief sessions are more beneficial than one longer session due to
desensitization of bone after a few loading sessions. Weingard (2006), based on literature
review, recommended moderate to intense weight bearing exercise and resistance
exercises performed for at least 30 minutes a day once or twice a week to decrease cancer
treatment associated bone loss.
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G. Conclusion
Manini et al. (2006) studied measured free living activity energy expenditure
using a doubly-labeled water method to capture any form of physical activity from
fidgeting to purposeful exercise over a two week period. They found that an increase in
free living activity energy expenditure of 287 kcal/day was strongly associated with a
thirty-two percent lower risk of mortality.
McGlynn (1987) acknowledged evidence is lacking to support that regular
exercise prevents osteoporosis, but evidence does show a lack of exercise contributes to
bone loss. It is important to identify patients at increased risk of osteoporosis from
secondary causes (Ebling, 2008; Fitzpatrick, 2002) so effective treatment can reduce
potentially life-threatening complications. ACSM (2006) defines physical activity as any
body movement produced by skeletal muscles that result in energy expenditure. ACSM
(2006) defines exercise as planned structured and repetitive body movement done to
improve or maintain physical fitness. It is assumed that something useful or beneficial
occurs as a result of repetitive exercise. Exercise is recognized as a risk reduction factor for
osteoporosis. ACSM (2006) delineates minimum level of exercise to achieve improvement
in cardio-respiratory endurance and musculoskeletal resistance in healthy adults Table 2.2
notes the recommendations.
USDHHS (2008) physical activity guidelines for an active older adult provided
similar recommendations.
Further research is needed in the area of osteoporosis as related to men and how to
apply this research into everyday practice. Future research should focus on integrating
bone health into larger studies that evaluate behavioral issues associated with other
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diseases. Increasing knowledge about the most efficient and effective ways to apply risk
assessment, diagnostic, and therapeutic tools to promote bone health and reduce associated
risks (USDHHS, 2004).
Table 2.2 Minimum Levels of Recommended Exercise

Mode

Cardiorespiratory
Endurance Training
Uses large muscle groups

Musculoskeletal
Resistance Training
Multi-joint and involves large muscle

Frequency

3 or more days per week

Minimum of 2 times a week

Duration
Intensity

20 minutes a session
40% or higher

8 different exercises for 8 major muscles
8-10 repetitions

ASCM 2006 and Neiman 1999
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CHAPTER 3
METHODS

A. Design
This was an observational study. The association between bone mineral density in
subjects receiving ADT and the amount of self-reported exercise, classified according to
two types: cardiorespiratory endurance and musculoskeletal resistance was examined. The
contribution of potential confounders including age, body mass, cigarette smoking, alcohol
consumption, history of prior non traumatic fracture, use of medications, calcium intake
were taken into account.
Data was be obtained by asking subjects to provide information about exercise,
history of fractures, risk factors such as age, cigarette smoking, alcohol consumption using
a self reported questionnaire. The self reported questionnaire use sections on exercise from
the Canadian Fitness Survey .and sections on risk factors from the NHANES questionnaire
(Appendix B). After completion of the self reported questionnaire, the sample of blood by
finger stick was obtained for a 25 hydroxy vitamin D level. After the subject’s interview
their medical record was reviewed for past and current medical illnesses, medication use
— prescription and non prescription —, height and weight, and length of time on ADT.
Measurement of bone mineral density was completed by DEXA scan within four weeks of
the questionnaire if subject had received ADT for a minimum of 9 months. Subjects who
received ADT for 10 to 12 consecutive months the DEXA scan was completed within 8
weeks Subjects receiving ADT for greater than 12 consecutive months a DEXA was
completed within 3 months. Over 24 consecutive months a DEXA was completed within 6
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months.
B. Subjects
A convenience sample of 107 men with prostate cancer treated with ADT using
luteinizing hormone-releasing hormone (LH-RH) for 9 months or longer was recruited
from eight urology practices and one cancer center in Clark County, Nevada. Subjects are
seen by appointment with their physician every three to six months for LH-RH injections.
At the time of their visit, the physician or nurse will screen subjects for eligibility based on
inclusion criteria. Inclusion criteria are: 1) Diagnosis of prostate cancer in advanced stages
and 2) Treatment with LHRH for nine months or longer.
Subjects excluded: those who were receiving corticosteroid treatment, taking
medications affecting calcium metabolism or that contribute to osteoporosis, and anti
seizure medications. Also excluded are subjects who received a diagnosis of osteoporosis
prior to treatment for prostate cancer or history of non traumatic hip or spine fracture.
Subjects who were eligible were asked by their physician, if they were willing to
participate in the study.
C. Procedures
Physicians asked patients who met the eligibility based on the inclusion criteria if
they were willing to participate in the study. Subjects who agreed to participate were then
introduced to the Researcher or trained Collection Assistant. Patients who agreed to
participate were asked to review sign the consent to participate form. In addition, the
subject signed a release of information in accordance with HIPPA so the Research could
access the subject’s medical records. The subject was given a copy of the Subject Bill of
Rights in accordance with California requirements as the Research study was through
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Loma Linda University in California.
The researcher or collection assistant then provided the subject with the
questionnaire about self reported exercise, fracture history, and risk factors such as age,
cigarette smoking, and alcohol consumption. These questions were taken from the
National Health and Nutrition Examination Survey (NHANES 2006) and the Canadian
Fitness survey section was used for questions specific to exercise practices. A copy of this
questionnaire is available in Appendix B. Questions about medical history, medications,
height, and weight were obtained from the subject’s medical record. The investigator, Lori
Winchell, Advanced Nurse Practitioner, DrPH-C, or NIH certified and trained Collection
Assistant obtained a sample of blood by finger stick for a 25 hydroxy vitamin D level. The
sample of blood was obtained concurrent with the administration of the questionnaire. The
investigator is qualified to perform this procedure as a licensed health care professional and
is licensed to train collection assistants to perform the required fmgerstick (Appendix H).
The blood specimen was collected using a filter paper provided by ZRT Lab. ZRT lab is an
approved Clinical Laboratory Improvement Amendment (CLIA) facility. The sample was
placed in a sealed container and mailed through UPS to ZRT lab for analysis. Results
returned to the investigator and a copy provided to the subject’s physician and to subject
upon request.
At the appointment, the subject was given a provider’s order for and instructions
to complete a DEXA scan, if a DEXA scan was not already been completed within the
timeframe described above.
Permission for this study was obtained by the individual physician practices,
institutional review board at and Loma Linda University and by subject authorization for
47

release of medical information obtained from the subjects who agree to participate in the
study (Appendix E).
7.

Study Variables
The purpose of this study was to evaluate the relationship between self

reported type and duration of exercise and risk of osteoporosis, as measured by DEXA scan
and serum 25 hydroxy vitamin D in prostate cancer patients receiving ADT.
a. Independent Variable. The section of the questionnaire about a
subject’s exercise practices was taken from the Canadian Fitness Survey (CFS). The
survey was self-reported and obtained while the subject is at their physician appointment.
The survey questions assess types of exercise performed, cardiorespiratory endurance and
musculoskeletal resistance. The frequency, duration, and intensity of activity are
incorporated. This study assesses: 1) type of exercise; 2) frequency or the number of days
per week a person exercised for the past week, month, and 12 months; 3) intensity and 4)
duration or the minutes of each exercise session. For the purpose of this study, exercise as
defined in Table 2.1 (page 40) was used.
b. Dependent Variable. Osteoporosis is measured by BMD using a
DEXA scan and serum 25 Hydroxy vitamin D level. The DEXA measurement is called a
T-score and less than -2.5 at femoral neck or lumbar spine is considered a positive
diagnosis for osteoporosis. These standards are defined by Healthy People 2010
Osteoporosis and bone health objectives (Appendix A). Table 3.1 summarizes Healthy
People 2010 standards for osteoporosis.
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Table 3.1 Healthy People 2010 Standards for Osteoporosis

Normal

>-1.0 SD

Lumbar spine BMD
T-score
>-1.0 SD

Osteopenia
Osteoporosis
Serve
(established)

-1.0 to .-2.5 SD
>-2.5
w/fracture

-1.0 to -2.5 SD
>-2.5
w/fracture

Femoral neck BMD T-score

NIH 2004

c. Confounding Variables.

Confounding variables and how each was

measured are described. Items from the NHANES 2005-2006 questionnaire were used to
measure age, medications including calcium intake, medical diseases, history of fractures,
cigarette and alcohol use. A sample of blood by finger stick was obtained for a 25 hydroxy
vitamin D level. This capillary blood sample from the finger was dried on filter paper at the
interview and mailed directly to ZRT laboratory by mail without special processing or
precautions. This laboratory is CLIA approved and approved by Medicare.
BMI was calculated from height and weight obtained by review of medical records.
BMI is defined as the individual's body weight divided by the square of his height. Due to
its ease of measurement and calculation, it is the most widely used diagnostic tool to
identify obesity problems and fitness within a population (Appendix C). BMI can be
determined using a BMI nomogram, which displays BMI as a function of weight
(horizontal axis) and height (vertical axis) using contour lines for different values of BMI.
2.

Instruments
a. The Self-Report Questionnaires (Appendix B) The questions for this

study about exercise are quantified and incorporate frequency, duration, and intensity of
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self reported activity. The questions consist of sections from the Canadian Fitness Study
and the time frame of recall is daily, weekly, past month, and the past year. The Canadian
Fitness Study was the most comprehensive national population survey assessing exercise
ever carried out in Canada. There were over 17,000 respondents. This survey has followed
a longitudinal panel of participants and was administered in 1981, 1988, and 2002 (CFS
2005).
The questions for this study about health, medications and risk factors consist of
sections from the NHANES 2005-2006 questionnaire. It includes information about
current medical problems, age, ethnicity, height and weight, current medications both
prescription and non-prescription calcium, parathyroid disease, seizures, and use of
tobacco, alcohol. The questions obtained from review of the subject’s medical record were:
age, medical problems past and present; current medication both prescription and
nonprescription; and height and weight. The questions obtained during the self reported
questionnaire were: exercise practices, fracture history, alcohol, and tobacco use and
ethnicity.
The questions used in this study have been tested for reliability and validity through
use in past research studies; NHANES 2005-2006 and Canadian Fitness Survey 2005.
b. Body Mass Index (BMI). Reliability and validity is based on World
Health Organization standards (Appendix C).
c. Measurement ofBone Mineral Density by DEXA Scan-Reliability and
Validity ofInstrument Based on Routine Quality Control Measures. The checks include
calibration checks, maintenance and inspection of equipment and supplies. These checks
are in compliance with national and federal standards to ensure patient safety and accuracy
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of test data. Patients provided with DEXA scan orders were sent to Desert Radiology
which has four locations in the Las Vegas area: 7200 Cathedral Rock Drive; 2020
Palomino Lane; 3920 S. Eastern Ave; and 2811 West Horizon Ridge (Henderson).
Serum analysis for 25 hydroxy vitamin D to control for pre-existing or other contributing
factors to osteoporosis.
A sample of blood by finger stick was obtained for a 25 hydroxy vitamin D level.
Obtained immediately after completion of the self reported questionnaire completion, the
capillary blood sample from the finger was dried on filter paper and mailed by UPS directly
to ZRT laboratory without special processing or required precautions. ZRT lab is CLIA
approved and approved by Medicare. (Appendix G).
3.

Data Analysis
Exercise was quantified using the formula from the Canadian Fitness

Survey. The formula is provided below:
Total = (Occasions past 12 mos x hrs/occasion x METS) divided by 365 day/year.
The numerical values were added together for total exercise. The numerical values
obtained for endurance exercises were totaled and compared to resistance exercises in
relationship to DEXA T scores. The relationship between total and specific types of
exercise and bone density T-scores were studied using correlational analysis. Furthermore,
regression analysis controlling for confounders including age, body mass index, cigarette
smoking, alcohol consumption, calcium intake, and serum vitamin D concentrations were
conducted to understand the independent association between exercise and bone mineral
density.

51

4. Power Analysis
Power and precision analysis of 80% power for medium size effect with an
alpha of 0.05 required a minimum of 107 subjects for the independent variable, exercise
and confounding variables (Rosenthal, 1991).
D. Strengths and Limitations
The questionnaire was administered quickly, was inexpensive, and did not interfere
with the patient’s normal daily activity. However, the questionnaire did not provide
absolute measurement rather it was an estimate of exercise and may have recall bias.
Manini et al. (2006) noted in their research that previous self reported measurements of
exercise may have underestimated the benefits of higher levels of physical activity in older
adults. Durante and Ainsworth (1996) note that efforts to validate self-reports of physical
activity typically demonstrate moderate associations between recalled information both
direct and indirect measures of physical activity. They examined ways in which bias in
reporting physical activity could be diminished through application of cognitive methods.
This incorporates cognitive process involving recall and application to survey
questionnaires about physical activity. They identified 3 stages: comprehension; retrieval;
and decision making. Slattery and Jacobs (1995) research found accuracy of recall varied
contingent on how vigorous the exercise is. Blair and Burton (1985) also found the more
vigorous the exercise the more accurate the recall. Richardson et al. (1994) used the
Minnesota Leisure Time Physical Activity Questionnaire (MNLTPA) to identify physical
activity recall up to 10 years prior and found correlation for recall of activity was highest
for vigorous activity. To stimulate vigorous activity recall, a calendar for past 12 months
was used to stimulate recall of physical activities. The researchers found this technique
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showed the highest level of agreement between physical activity records kept for the past
year and the one year recall questionnaire of vigorous activities on the MNLTPA.
The patient may provide a socially desirable answer and overestimate exercise. A
patient may not accurately remember the physical activity performed over past year, but it
does provide a more complete physical activity profile. The limited ability of all
participants to accurately recall exercise activities introduces bias and may lead to
misclassification. There is some evidence that recall of more vigorous activity is more
accurate than recall of less intense or daily activities. Several studies have reported
reasonable reliability results for long term exercise recall (Kriska, Sandler, & Canley,
1995).
Men recruited for this study may not be representative of all men with prostate
cancer. This study did not include fracture evaluation so it is unknown whether beneficial
effects of lifetime loading on bone size, quality, and strength translate into a reduction in
fracture risk. Another limitation was the cost of DEXA scans and cost of the 25 hydroxy
vitamin D test as the budget for this study was limited and this in turn limited the sample
size.

Methods to increase power in this study included: use of homogenous participants,
prostate cancer patients receiving ADT by injection of LHRH. Homogeniety may
compromise external validity, or generalization, and limits results to this select group.
Threats to internal validity include:
1. Selection
Control over conditions in respondent characteristics that could also cause
the observed effect was included in the study questionnaire.
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2. Maturation
Naturally occurring changes over time could be confused with treatment
effect. As men age, bone density decreases.
3. Attrition
Loss of respondents to treatment by moving out of area, change or loss of
health insurance benefits, or death can produce artifactual effects.
4. Instrumentation
Study questionnaire tested for validity of content but the answers were
self-reported. As time factor increases accuracy of reporting due to memory may not be as
accurate.
Artifacts or confounding variables are specific threats to validity. Error variance
can occur due to limited control of artifacts such as variable subject characteristics.
Variables such as age, ethnicity, cigarette use, and alcohol consumption, calcium intake,
Vitamin D deficiency, medications, and medical conditions that predispose a subject for
osteoporosis risk factors were measured using the survey questionnaire developed and
standardized by the National Center for Statistics, Centers for Disease Control for the
2005-2006 National Health and Nutrition Questionnaire Survey and serum blood test for
25 OH vitamin D. These artifacts were included as part of the regression analysis.
E. Research Ethics
Ethical standards developed by the American Psychological Association (1992)
were applied to this study. Ethical acceptability of the research was described in existing
literature and defined as no reported instances of physical, emotional or other harm to
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subjects using these procedures.
Subjects were informed in writing about the research study. They were asked to
volunteer to participate and had the right to refuse or withdraw at anytime. Subjects who
agreed to participate were asked to sign an informed consent form (Appendix D).
Subjects were protected from physical harm, danger, or discomfort from research
procedures. This study did not use invasive procedures except for 25 hydroxy Vitamin D
blood sample.
Strict confidentiality of the completed questionnaire or of any information
collected about the subject during the research by the researcher was maintained in
accordance to the informed consent. Sharing of DEXA scan results required patient
permission for release of results in accordance with PHI authorization. Any undesirable
consequences to individual subjects that resulted from participation in this study were
corrected. For example, subjects were advised about abnormal DEXA scan or 25 OH
vitamin D results and advised to speak with their physician to discuss findings and
treatment options. Physician was provided with a letter summarizing test results and
nationally recognized treatment recommendations.
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ABSTRACT
Purpose: Men with prostate cancer receiving androgen deprivation therapy (ADT) are at
elevated risk for decreased bone mineral density. This study evaluates the relationship
between self-reported daily activity, endurance and resistance exercise, and bone mineral
density measured by dual-energy x-ray absorptiometry (DEXA) in prostate cancer patients
receiving ADT.
Data Sources: We recruited 96 men treated with ADT for 9 months from urology and
cancer practices. All completed the Canadian Fitness Survey to assess daily activity and
exercise. Data on demographic and lifestyle characteristics and calcium and vitamin D
supplementation were collected. Blood was collected for analysis of 25-OH vitamin D. A
DEXA scan was performed.
Conclusions: This study shows a positive association between endurance exercise and
DEXA T scores of the hip. Regression analysis showed that endurance exercise of medium
to heavy intensity (measured as energy expenditure in MET-hours/week) was associated
with T-scores of the hip (p-.048; 95% Cl .003, 0.112; p=.040) but not with spinal T-scores
after controlling for age, body mass index and alcohol use.
Implications for Practice: Findings are cross-sectional but if confirmed in prospective
studies suggest that increased endurance exercise is a practical measure Nurse Practitioners
can institute to prevent low bone density in the hip of men treated with ADT.
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INTRODUCTION
Prostate cancer is the second leading cause of cancer death in men (Strief, 2007;
American Cancer Society ([ACS], 2006). Prostate cancer grows in response to
testosterone. Androgen deprivation therapy (ADT) lowers testosterone level suppressing
prostate cancer cell production. Testosterone levels <300 ng/ml are associated with low
bone mineral density and increased risk for osteoporosis (Waxman, 2007). Hip fracture is
the most serious fracture in terms of mortality among men as 40% of hip fractures result in
death (Berarducci, 2004). After a hip fracture, the risk of mortality for men is two times
greater than for women (Waxman, 2007).
Men with prostate cancer receiving ADT are at increased risk for decreased bone
mineral density (BMD) resulting in osteoporosis and potential fracture. Identification of
patients at increased risk for osteoporosis from secondary causes is important so effective
treatment can be introduced to reduce potentially life-threatening complications (Ebling,
2008; Fitzpatrick, 2002). Exercise may reduce osteoporosis risk and prevent fractures.
Data is limited regarding the association of exercise and risk of low BMD and osteoporosis
in men treated with ADT. According to the American College of Sports Medicine (ACSM)
more knowledge is needed regarding exercise effects and associated treatment toxicities in
men with prostate cancer (Schmitz et al., 2010). The purpose of this study was to examine
the relationship between self reported daily activity, endurance and resistance exercise, and
BMD measured by DEXA scan in prostate cancer patients receiving ADT.
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LITERATURE REVIEW
ADT, also known as chemical castration is widely used as a treatment for all
prostate cancer stages (Ellsworth & Calamone, 2007). The goal of ADT is chemical
castration by decreasing testosterone levels below 50 ng/ml (Ellsworth et al., 2007). Lack
of testosterone impairs the cellular replication of new osteoblasts (Guyton, 1991; Guyton
& Hall, 1998). Lowering testosterone levels through ADT suppresses tumor growth and
decreases BMD increasing risk of osteoporosis and bone fracture (Fredrich, 2003; Smith,
2002; Strief, 2007).
Ryan et al. (2007) found that during the first year of receiving ADT for prostate
cancer, two thirds of men had osteopenia or osteoporosis of the hip or spine. Daniell et al.
(2000) attempted to quantify bone loss for men with prostate cancer following orchiectomy
or chemical castration. They found that BMD decreased 2.4 and7.6% during years 1 and 2
and continued to decrease with each additional year of treatment. The first year of ADT,
fracture risk is increased 1.5 times, occurring primarily in hip and spine (Holzbeierlein,
2006; Matthews, 2007). Over a 5 year period men receiving ADT for prostate cancer have
a 20% chance of fracture (Adler, 2010). Daniell et al. (2000) found greatly accelerated
bone loss following chemical castration in men with prostate cancer which may be
superimposed on depleted bone mass before initiation of hormonal therapy. After
correction for age BMD was greater in men who were obese, younger than 75 years old, or
participated in regular exercise.
Several studies demonstrated that BMD can be increased with exercise (Morrill,
Baio, & Marx, 2004; Nakata et al., 2006). Increased BMD decreases osteoporosis and risk
of fracture (Vincent & Braith, 2002). The National Health and Nutrition Examination
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Survey (NHANES) (Moayyeri, 2008; US Department of Health and Human Services,
1999) included exercise training as non-pharmacologic treatment for osteoporosis.
Exercise is physical exertion measured by the frequency, duration, and energy expenditure
(Canadian Fitness Survey, 2005). Energy expenditure during physical exertion is measured
as the metabolic equivalent of a task (MET). Generally, physical exertion may be divided
into cardiorespiratory endurance exercise and musculoskeletal resistance exercise. Some
examples of cardiorespiratory endurance exercises are walking, running, step-test
racquetball, rowing, tennis, and bicycling. Some examples of musculoskeletal resistance
exercises are weight lifting barbells, dumbbells, pulleys, or calisthenics. A meta-analysis
of eight prospective studies involving men showed an inverse association between
exercise, osteoporosis, and hip fracture. The meta-analysis defined exercise as moderate to
vigorous exercise from one to three hours per day (Kanis & Gluer, 2000; Pfeifer, Sinaki, &
Gesens, 2004). A study by Whiteford et al. (2010) examined the effects of one year
musculoskeletal resistance training on bone and lean muscle mass in men ages 55-80 years.
They found increased total hip BMD at 12 months comparable to walking 30 minutes three
times a week. Berarducci (2004) and Greenspan (2008) advocated regular weight bearing
activity performed at least three times a week for 30-45 minutes.
Physical activity or usual daily activities may be defined as what a person does at
home or in their leisure time (CFS, 2005; Pescatello et al., 2002). The type of usual daily
activity a person does most days of the week involves standing, walking, self-care
grooming, dressing, putting clothes away, and other home activities. A study by Pescatello
et al. (2002) reported lifestyle physical activities are associated with improved BMD.
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A meta-analysis by Liu et al. (2008) assessed screening tests for osteoporosis and
concluded that only dual energy x-ray absorptiometry (DEXA) was sufficiently sensitive
for measurement of BMD and diagnosis of osteoporosis. Central DEXA devices measure
BMD in the hip (femoral neck) and spine at lumbar vertebrae 1 through 4. T-scores
compare BMD with that of a young adult of the same gender. A score above -1 is
considered normal. A score between -1 and -2.5 is classified as osteopenia (low bone
mass). A score below -2.5 is defined as osteoporosis (WHO, 2004). This classification was
followed in this study.
METHODOLOGY
Subjects
A consecutive sample of 251 men with prostate cancer receiving ADT treatment
with luteinizing hormone releasing hormone (LH-RH) were identified and reviewed for
eligibility. At the subject’s scheduled appointment, the physician screened subjects for
eligibility based on following inclusion criteria: 1) Diagnosis of prostate cancer in
advanced stages, 2) Treatment with LH-RH for nine months or longer, 3) Age of subject 50
to 90 years. Subjects excluded were: those receiving corticosteroid treatment, taking
medications affecting calcium metabolism or that contribute to osteoporosis, and taking
anti- seizure medications. Subjects who received a diagnosis of osteoporosis prior to
treatment for prostate cancer or history of non traumatic hip or spine fracture were also
excluded
Of 251 men, 6 were deceased, 50 ineligible, 35 missed their scheduled
appointment, and 6 were duplicate medical records. A total of 154 men were asked by their
physician if they were willing to participate in the study and 42 declined. Out of those
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potentially eligible subjects, 112 recruited from eight urology practices and one cancer
center in Clark County, Nevada. Of the 112 men enrolled 96 completed the study. The
reasons 16 subjects did not complete the study were: moved out of area (1), illness
requiring hospitalization (2), immobility (2), lack of transportation to complete DEXA (3),
family emergency (2), travel out of state (2), withdrew for personal reasons (3), or
deceased (1).
Research Procedure
Permission for this study was provided by the individual health care provider
practices and the institutional review board at Loma Linda University. All subjects
provided authorization by written informed consent and agreement to release of medical
information in accordance with Health Insurance Portability and Accountability Act
(HIPPA).
Research Design
Subjects were recruited at scheduled office visits with their physician. Following
written informed consent, subjects were asked to provide information about their usual
daily activity and cardiorespiratory endurance and musculoskeletal resistance exercise as
well as factors related to risk of low BMD or osteoporosis including age, ethnicity,
cigarette smoking, alcohol consumption, and supplemental intakes of vitamin D and
calcium. Each subject’s medical records were reviewed to confirm eligibility and to obtain
data concerning their medical history and use of medications. The DEXA appointment was
scheduled at the same office visit and was performed within 3 months of questionnaire
completion.
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The subject completed the DEXA at the designated diagnostic centers available at
four different locations within the Las Vegas area. Height and weight are measured at the
DEXA scan appointment and were used to calculate body mass index in kg/m .
Instruments
The self-report questionnaire consisted of three parts. Part 1 was designed to collect
information about the health of people in the United States (UPHHS, 2006). This part
asked about risk factors relating to osteoporosis including age, ethnicity, cigarette
smoking, use of alcohol, and supplemental intakes of vitamin D and calcium. Parts 2 and 3
assessed daily activity and exercise using the Canadian Fitness Survey (CSF, 2005)
questions. Weller and Corey (1998) found the CFS questionnaire moderately reliable
(r=.48-.53) using an intra class correlation. There was overlap in activities measured in
parts 2 and 3, and the two parts are analyzed separately. To prompt participants to
remember all activities, a two page list of activities was read to them by research assistants.
Part 2 queried usual daily activities by the percentage of time the subject spent doing these
activities during an average day. Usual daily activities (housework or work) were
identified as sitting, standing, walking, walking upstairs, and lifting or carrying heavy
objects. This was measured as all of the time (100%), some of the time (25%, 50%, 75%),
or none of the time (0%). Part 3 queried usual cardiorespiratory endurance and muscular
resistance exercise over the past week, month, and 12 months and according to type of
activity, frequency of activity and amount of time spent for each activity. Energy
expenditure for medium (some perspiration and above normal breathing) to heavy (heavy
perspiration and breathing) activity (including housework, handiwork, garden work),
leisure activity (walking, jogging, running, bicycling, golf, swimming, skiing, etc.) and
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resistance exercise (weight training, calisthenics, etc) was classified according to the
metabolic equivalent of a task (MET). This value is determined by energy cost for different
activities. A list of activities and their MET values were defined by the CFS (2005) and
these values were used as part of the calculation for energy expenditure of each activity in
this study. MET values not identified on the list provided by the CFS (2005) study were
available in the Compendium of Physical Activities (Ainsworth et al., 2000). We
calculated the number of hours (or fractions) of each exercise/week x number of days/week
x METs specific to that activity resulting in MET-hours/week (MET/hrs/week). This was
done separately for cardiorespiratory endurance and resistance exercise.
Laboratory Analysis
A sample of blood by finger stick for a 25-OH vitamin D level was obtained
concurrent with the scheduled office visit and administration of the questionnaire. The
blood specimen was collected using a filter paper provided by ZRT Lab, an approved
Clinical Laboratory Improvement Amendment (CLIA) facility. The blood sample was
placed in a sealed container and mailed through UPS to ZRT lab for analysis. The current
recommendation for testing is by tandem mass spectrometry assay as other tests tend to
underestimate 25-OH vitamin D levels (Caplan, 2006). ZRT laboratory uses liquid
chromatography/tandem mass spectrometry (LC-MS/MS) and participates in DEQAS, the
25-OH vitamin D Quality Assessment Scheme, which provides control samples to ensure
assay accuracy. The sensitivity lower limit of detection of the 25-OH vitamin D assays is
0.5 ng/ml.
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Data Analysis
The study was planned to show a medium size effect, with a of 0.05 and 80%
power if 107 subjects were included. Actual data analysis was based on 96 subjects that
completed the study, thus the power was slightly less than planned. Descriptive statistics
were analyzed as means and standard deviations (SD) and medians and inter-quartile
ranges for continuous variables and number and percent for categorical variables. To
assess the relation between BMD categorized as normal, osteopenia or osteoporosis and
other variables, the Chi-square test for independence was used. Pearson’s correlation
coefficients were calculated between exercise and activity variables with risk factors (age,
ethnicity, body mass index, months of ADT, alcohol and cigarette use, and vitamin D and
calcium supplementation) and DEXA T-scores of the hip and spine. Skewed variables
were transformed to their square root, with results that were similar to those seen with the
non-transformed variables (data not shown). Partial correlation was used to explore the
relationship between exercise and activity variables and DEXA T-scores of the hip and
spine while controlling for body mass index and alcohol use (found to be independently
related to T-scores in the correlational analysis). Regression analysis was employed to
determine the predictive relationship between exercise and activity variables and DEXA
T-scores of the hip and spine controlling for age, body mass index and alcohol use.
Preliminary analysis was performed to ensure there was no violation of assumptions. A p
value of <0.05 was considered statistically significant. Data analysis was conducted by
SPSS software version 18 for Windows.
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RESULTS
Descriptive Analysis: Characteristics of the Sample
Sample characteristics are presented in Table 4.1.The mean age of the participants
was 75 years ranging from 56 to 90. The majority of participants were Caucasian (69.7%)
followed by African American (18.8%) and Hispanic (11.5%). The mean number of
months participants received ADT was 25. The majority of the participants were
overweight or obese, with a mean BMI of 28 kg/m2. Most participants did not take calcium
or vitamin D supplements. Over half of the participants used alcohol. Most participants did
not smoke or quit over 1 year previously. Tables 4.2 and Table 4.3 shows how exercise and
usual daily activity variables and risk factors were distributed among subjects with normal
T-scores, osteopenia, or osteoporosis of the hip and spine. There was a positive
relationship (p=.002) between alcohol intake and T-score category of the spine but no
relationship between alcohol intake and T-score category of the hip. No statistical
significance was found for ethnicity, cigarette use, calcium or vitamin D supplement for
BMD category of the spine or hip.
Correlation Analyses
Table 4.4 shows correlations between DEXA T-scores of the hip and spine,
exercise and usual daily activity variables, and risk factors. A positive association between
body mass index and T-score of the spine was found (r= .225, p=:=.028). There was a
positive association between endurance exercise measured as minutes/week and T-score of
the hip (r=296, p=.003) and between endurance exercise measured as MET-hrs/week and
T-score of the hip (r=.222, p=.030). There was no correlation between endurance exercise
and T-scores of the spine (r = .010, p =.920). Partial correlations controlling for body mass
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index and alcohol usage demonstrated very little change on strength of relationship
between endurance exercise and T-score of the hip. See Table 4.
Regression Analysis
Endurance exercise measured as minutes/week or as MET-hrs/week was predictive
for BMD of the hip but not predictive for BMD of the spine when controlling for age, body
mass index and alcohol. See Table 5.
DISCUSSION
The results of this study show that cardiorespiratory endurance exercise measured
as minutes/week or as energy expenditure in MET-hrs/week is associated with increased
BMD of the hip in men treated with ADT. There was no association with BMD of the
spine. Resistance exercise and usual daily activity (measured as percentage of the day
spent in various activities) were not associated with BMD of the hip or spine. To our
knowledge, no previous studies have examined the association between different types of
exercise and BMD in men receiving ADT (Schmitz et al.2010; Kelley, Kelley, Tran 2000).
Most of our subjects were elderly, and research is inconsistent as to long term
benefits of exercise and association with BMD in the elderly (Bleicher et al., 2010). We
found that endurance exercise was associated with improved BMD of the hip but not the
spine. Determinants of BMD at these two sites may vary. This notion is supported by a
study by Bleicher et al. (2010) who found that hip BMD and spine BMD have unique
determinants. While hip BMD was related to inability to stand from sitting, spinal BMD
was associated with BMI, dancing and alcohol. Other studies have found that spine BMD
increases while hip BMD declines with aging (Cauley et al., 2005; Bleicher et al., 2010).
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Our study suggests that exercise counteracts the effects of aging on BMD of the hip in men
receiving ADT, though prospective studies will be needed to confirm this.
There was no association between DEXA T-scores of the hip or spine and with
resistance exercise. In contrast to our findings, an interventional study by Vincent et al.
(2000) found that resistance exercise increased BMD. Likewise, the study by Whiteford et
al. (2010) examined the effects of one year of musculoskeletal resistance training on bone
and lean muscle mass in men ages 55-80. They found an increase in total hip BMD at 12
months comparable to walking 30 minutes three times a week. An interventional study by
Benbem and Benbem (2011) concluded that regardless of intensity or frequency resistance
exercise improved hip and spine BMD. In our study, only 28% of participants reported
performing resistance exercise (data not shown), thus, we may have lacked power to show
a relation between resistance exercise and BMD. In contrast more than half of our subjects
reported performing endurance exercise.
A study by Pescatello et al. (2002) reported usual daily activities are associated
with better BMD. The CHAMP study (Bleicher et al., 2010) found that for every standard
deviation increase in usual daily activity score, there was a 1-1.5% increase in BMD. We
likewise found that housework and handiwork activities when summed together with
leisure activities (together designated as endurance exercise) were associated with
improved BMD, however, when usual daily activity was measured as percentages of the
day spent in various activity, we found no relation with BMD. We suggest that a larger
sample size may be required to demonstrate this relation as such activities may have a
small effect due to their lower energy cost.
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We found that 15% of the participants had osteoporosis of the hip and 13% of the
spine .Campion and Maurice (2003) report a 4-6% prevalence of osteoporosis in men over
50 years old who are not receiving ADT for prostate cancer. Thus, our findings are
consistent with other research indicating that ADT use increases osteoporosis by 50% the
first year (Israeli, Ryan, and Jung 2008. Previous studies indicate that most of bone loss at
the lumbar spine and hip occurs during the first year of treatment. Studies by McLeod,
Huynh, and Rashid (2008) found that men receiving ADT had measurable changes of
BMD the first 9 months of use and an annual bone loss of 3-5% for the first 2-3 years with
ADT. Consistent with this, we included men who had received ADT for >9 months. An
intervention study by Ryan et al. (2007) examined duration of ADT in relation to BMD in
men with prostate cancer during the first year of therapy. They found that a T-score of less
than -1.0 was detected in two thirds of the subjects at lumbar spine and hip, findings that
our similar to ours where 64% of participants had a hip T-score of <-1.0 and 44% had
spinal T-scores of <-1.0.
In the present study, 25-OH vitamin D had no direct association with BMD. This
supports findings of other studies (Sakuma, Oinuma, & Endo, 2010; Lips et al., 2010;
Cranney et al., 2007). Studies indicate that 25-OH vitamin D has an indirect effect on BMD
by promoting calcium absorption. Also, our study did not find a relation between calcium
supplementation and BMD. Calcium has a direct effect on BMD (Tu & Lin, 2008). The
small sample size, inconsistent dosage, and use of doses lower then recommendations may
have contributed to the lack of an association.
In this study cigarette smoking had no association with BMD. In a study by Egger,
Duggleby, Hobbs, Fall, & Cooper (1996), an adverse association between smoking and
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T-score of the spine but not of the hip was found. The CHAMP study with 1,705 men
between the ages of 70-97 found no association between cigarette smoking and HMD
(Bleicher et ah, 2010). While in younger individuals smoking is clearly associated with
low BMD, this association may diminish with aging, both due to survival effects, and
because of the prevalence of smoking cessation in elderly survivors.
In this study, alcohol intake showed a U-shaped association with DEXA T-score of
the spine. Some previous research showed a positive association between BMD of the
spine and alcohol (Tucker et al., 2009; Bleicher et al., 2010). According to Bleicher et al.
(2010) research is inconsistent as to long term benefits of alcohol use and association with
BMD in the elderly.
Limitations
This study was cross sectional. Thus, we are not able to describe which variable is
the cause and effect. Other factors linked to exercise may lead to the association of exercise
with BMD of the hip.
Use of a convenience sample may have limited the generalizability of the results.
However, our sample was typical of other studies of men receiving ADT in regard to age
and body mass index. For example the mean age of men in a larger, representative study
was ~72 years (Malcolm et al., 2007), compared to ~75 years in the current study.
Scheduling of DEXA scan after completion of questionnaire rather than immediately
following resulted in dropout by some participants. As with most self-reports, exercise and
physical activity are subject to recall bias. A study of the reliability of the CFS
questionnaire by Weller (1998) found moderate reliability for most measures. Craig,
Russell, Cameron, and Baumann (2004) completed a validity and reliability study of the
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CFS, adapted from the Minnesota Leisure-Time Physical Activity (MLTPAQ)
questionnaire which was correlated with total energy expenditure (TEE) measured by
doubly labeled water for validity. The MLTPAQ underestimated the TEE. Other studies
have reported reasonable reliability results for long term exercise recall (Bowles,
FitzGerald, Morrow, Jackson, & Blair, 2004; Bonnefoy et al., 2001). Research indicates
that previous self reported measurements of exercise may have underestimated the benefits
of higher levels of exercise in older adults (Manini et al., 2006). There is some evidence
that recall accuracy increased with vigorous activity (Orsini et al., 2007; Bowles et al.,
2004; Winters-Hart, Brach, Storti, Trauth, & Krista, 2004). This is in line with our findings
that linked medium to heavy exercise to BMD.
BMD is built over a lifetime of exercise (Rogers & Hinton, 2010) and many other
factors than what we were able to measure in this study affect BMD. While lifetime
loading of bones contributes to BMD, the ability of subjects to remember and report
lifetime activity and exercise is obviously limited. We were only able to measure exercise
practices over the past 12 months however, the mean time of ADT use was over two years,
and the amount of exercise performed by the subjects during this period may change.
CONCLUSIONS
This study identifies the potential of exercise intervention for men with prostate
cancer receiving ADT to reduce risk of decreased BMD. Egerdie and Saad (2010)
recommend monitoring of BMD using DEXA and initiation of patient education and
prevention strategies to prevent treatment-induced bone loss. Options for supportive care
include calcium and vitamin D supplementation which have shown inconsistent or
negative results to prevent bone loss during use of ADT (Greenspan, 2008; Lattouf et al.,
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2011). This is due in part to varying and inconsistent dosages and poor compliance. The
recommendation of cardiorespiratory endurance exercise may be beneficial in preventing
bone loss of the hip. Findings suggest that increasing endurance exercise is a practical
measure that can be instituted (Ebling, 2008; Fitzpatrick, 2002). Adler (2010) notes that
exercise is available to the general public and that this provides an inexpensive,
nonpharmacologic approach for treatment of osteoporosis. Yee, White, Murata, Handanos,
& Hoffman (2007) found most men treated with ADT for prostate cancer did not receive
screening, prevention information, or treatment for osteoporosis. Nurse Practitioners
should encourage preventive and therapeutic treatment for bone mineral loss as a result of
ADT (Lattouf & Saad, 2007; Panju et al., 2009).Further research is needed in the area of
types of exercise as a preventive measure for osteoporosis and fracture risk and should
focus on integrating bone health into studies that evaluate behavioral and health issues
associated with exercise in aging populations. Increasing knowledge about the most
efficient and effective ways to apply risk assessment, diagnostic, and therapeutic tools to
promote bone health and reduce associated risks is important. (NIH, 2004)
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Table 4.1 Summary of Subject Characteristics (N=96)
Mean (SD)

Median

25%tile

75%tile

75 (7.6)

76

69

81

25.3 (18.4)

20

12

31

Body mass index, ke/m
25-OH Vitamin D, ng/ml*

28 f4.3)
25.3 (18.3)

27.5
20

25.1
12

31.3
31

DEXA T score, hip

- 1.3 (1.2)

-1.5

-2.1

-0.7

DEXA T score, spine **

-0.7 (1.6)

-0.8

-1.9

0.5

2.5 (1.8)

3

0

3

41.4 (44.8)

35

0

60

Frequency, x duration,
minutes/week

148.9
(218.2)

105

0

187.5

Energy expenditure,
MET-hours/week

4.6 (4.4)

3.5

1.3

6.4

Age, years
Androgen deprivation therapy, months
2

Self -reported cardiorespiratory endurance exercise
Frequency, days/week
Duration, minutes/week

Self-reported resistance exercise * * * *
Frequency, days/week

0.97 (1.7)

0

0

2

Duration, minutes/week

5.7(10.4)

0

0

10

Frequency x duration
minutes/week

20 (44.8)

0

0

30

Energy expenditure,
MET-hours/week

0.7 (1.6)

0

0

0.6

55.6(21.1)

50

50

75

Self reported daily activity, ^
% of hours/day

^

*n= 93 for 25-OH vitamin D
**One subject not able to complete DEXA spine due to implant device.
Cardiorespiratory endurance exercise activities include walking, bicycling, golf, skiing, fencing, karate,
wash or wax floors, handiwork, digging and others as defined by the Canadian Fitness Survey (2005).
****MuSCUlar resistance exercise activities include weights, barbells, dumbbells, pulleys push-ups, sit-ups,
squats and others as defined by the Canadian Fitness Survey (2005).
*****Daily activity -percent of activity time for one day is based on hours of activity over 12 hour period.
Physical activity include standing, walking, self-care grooming, dressing, putting clothes away, washing
dishes, gardening, watering, mowing, and other home activities as defined by the Canadian Fitness Survey
(2005).
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Table 4.2 Crosstabs for DEXA T-scores of the Hip (N=96)
DEXA
T-Score

DEXA
T-Score

DEXA
T-Score

>-1.0

-1.0 to -2.5

>-2.5

p =.925

Ethnicity
25 (37.3%)

33 (49.3%)

9 (13.4%)

African American

6 (33.3%)

8 (44.4%)

4 (22.2%)

Hispanic

4(36.4%)

5(45.5%)

2(18.2%)

Caucasian

p = 347

Alcohol use
Never/Quit>l year

18(41.9%)

18(41.9%)

7(16.3%)

1 to 4 drinks/month

11 (40.7%)

11 (40.7%)

5 (18.5%)

Over 5 drinks/month

6(23.1%)

17(65.4%)

3(11.5%)
p = 370

Cigarette use
Never

12(32.4%)

18(48.6%)

7(18.9%)

Quit > lyear

21 (43.8%)

20(41.7%)

7 (14.6%)

2(18.2%)

8(72.7%)

1 (9.1%)

Smoker

p = 628

Calcium supplementation
No

27 (38%)

32 (45.1%)

12(16.9%)

Yes

8 (32%)

14 (56.0%)

3 (12.0%)
p = 999

Vitamin D supplementation
No
Yes

X2

28 (36.4%)

37 (48.1%)

12(15.6%)

(36.8%)

9 (47.4%)

3 (15.8%)
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Table 4.3 Crosstabs for DEXA T-scores of the Spine (N:=96)

DEXA T-Score
>-1.0

DEXA T-Score
-1.0 to -2.5

DEXA T-Score
<-2.5

x2
p = 722

Ethnicity
38 (58.2%)

21 (31.3%)

7 (10.4%)

African American

9 (50.0%)

7 (38.9%)

2(11.1%)

Hispanic

6 (54.5%)

2(18.2%)

3 (27.3%)

Caucasian

p =.002

Alcohol use
Never/quit >1 year

31 (72.1%)

6 (14.0%)

6 (14.0%)

1 to 4 drinks/month

9(33.3%)

11 (40.7%)

6 (22.2%)

13 (50.0%)

13 (50.0%)

0 (00.0%)

>5 drinks/month

p =.132

Cigarette use
Never

17 (45.9%)

13(35.1%)

6(16.2%)

Quit > lyear

33 (68.8%)

11 (42.9%)

4 (08.3%)

3 (27.3%)

6 (54.5%)

2 ( 18.2%)

Current smoker

p =.196

Calcium supplementation
No

37 (52.1%)

25 (35.2%)

9 (12.7%)

Yes

16 (64.0%)

5 (20.0%)

3 (12.0%)

Vitamin D supplementation

p =.086

No

40 (51.9%)

26 (33.8%)

11 (14.3%)

Yes

13 (68.4%)

4(21.1%)

1 (05.3%)
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Table 4.4 Correlations between Subject Characteristics, Exercise and Daily Activity
Variables and DEXA T-scores of the Hip and Spine
DEXA T score hip
Age
.f
€.

Months of ADT
25-OH vitamin D
Body mass index
Self-reported cardiorespiratory endurance exercise
Frequency, days/week
Duration, minutes/week
Frequency x duration, minutes/week
Frequency x duration, minutes/week
controlled for BMI & alcohol
Energy expenditure, MET-hrs/week
Energy expenditure controlled for BMI &
alcohol
Self-reported resistance exercise
Frequency, days/week
Duration, minutes/week
Frequency x duration, minutes/week
Energy expenditure, MET-hrs/week
Daily Activity
Self-reported daily activity (% hours/day)
* Partial correlations
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r=-.250
p=.014
r= -.080
p= .437
r= -.053
p=.605
r=.168
p=. 102

DEXA T score
spine
r=.039
p=.706
r=-.095
p=.359
r= -098
p=.345
r=.225
p=.028

r=.188
p=.066
r=.240
p=.019
r=.296
p^.OOd
r=.282*

r =-.080
p =.442
r =-046
p=.657
r=.008
p=.938
r=-.013

p=.006
r=.222
p =.030
r= .212*

p=.903
r=-.047
p=.448
r=-.017

p=.Q40

p=.874

r=.061
p=.522
r=.080
p=.438
r=.078
p=.450
r= . 113
p=.272

r=-.006
p=.954
r =-055
p=.596
r=.080
r=.442
r=.084
p=.421

r=.049
p=.634

r=-.126
p=224

Table 4.5 Regression Analysis Showing Relationship between Endurance Exercise and
T-scores of the Hip and Spine Controlling for Age, BMI and Alcohol
p-coefflcient

95% confidence
interval

P-value

T-score hip

.048

.003, .112

.040

T-score spine

.000

-.002, .001

.956

T-score hip

.001

.013,0.072

.005

T-score spine

-.009

-.065, 0.083

.812

Endurance exercise (minutes/week)

Endurance exercise (MET-hrs/week
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ABSTRACT
Purpose: Several studies have found an association between decreased 25-OH vitamin D
blood level and prostate cancer progression. Vitamin D supplementation is controversial
and recommendations are inconsistent regarding frequency and dosage. This study sought
to identify determinants of 25-OH vitamin D levels in men with prostate cancer patients
receiving androgen deprivation therapy (ADT).
Data Sources: We recruited 108 men treated with ADT for >9 months from 8 urology and
cancer treatment practices. All completed parts of the NHANES 2005-2006 questionnaire
and Canadian Fitness Survey identifying age, ethnicity, length of use of ADT, calcium
supplementation > 1,000 mg/day, body mass index, exercise habits, alcohol and tobacco
use, and vitamin D supplementation > 800 HJ/day. Blood was collected for analysis of
25-OH vitamin D.
Conclusions: The majority of men (73%) had blood levels of 25-OH Vitamin D < 32
ng/ml (laboratory cut-off). Regression analysis showed that vitamin D supplementation
((3=6.556, Cl 1.463, 11.650; p=.012) and non-Black ethnicity (p=-7.816, Cl -12.996,
-2.635; p=.003) predicted 25-OH vitamin D level after controlling for age and tobacco use.
Implications for Practice: Supplementation was the only modifiable variable associated
with 25-OH vitamin D levels. These cross-sectional findings support current
recommendations by the Institute of Medicine for supplementation with > 800 IU vitamin
D/day for older men.
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INTRODUCTION
The National Cancer Institute (NCI, 2008) estimated that approximately 218,890
new cases of prostate cancer and 27,050 deaths caused by prostate cancer occurred in the
United States in 2007. Weiss, Kaplan, & Fair (2004) note that 70% of all prostate cancers
diagnosed are in men 65 years or older. Many factors have been identified that may
contribute to increased risk of prostate cancer. These factors include genetics, increased
dietary fat, increased levels of circulating testosterone, increased calcium blood level,
exposure to environmental toxins or metals, possible viral infection acting as an initiator,
and decreased 25-OH vitamin D blood levels (Weiss et al., 2004; Pienta & Esper, 1993;
Duyff, 1996).
A widely used treatment for all prostate cancer stages is androgen deprivation
therapy (ADT) (Ellsworth & Calamone, 2007). The goal of ADT is to decrease
testosterone levels below 50 ng/ml (Ellsworth et al., 2007) thereby suppressing tumor
growth.
Recently, vitamin D has been identified as having a role in the onset and
progression of prostate cancer. Ahonen et al. (2000) indicated that there is an inverse
association between 25-OH vitamin D blood levels and prostate cancer. They reported that
men with 25-OH vitamin D blood levels below median had an odds ratio (OR) of 1.7 (95%
Cl 1.2-2.6) of developing prostate cancer as compared to men with 25-OH vitamin D blood
levels above the median. According to Semmelweis and Belgyogyaszati (2010) and Gupta
and Lam (2009), low circulating levels of 25-OH vitamin D are associated with growth of
prostate cancer. Lambert, Young, Pertsons, & Ray (2007) and Stampfer et al. (2005)
suggested that vitamin D suppresses immune response by reducing cytokines and
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proliferation of lymphocytes. Improved prognosis may result because vitamin D receptor
cells modulate causal mechanisms of prostate cancer as reported in a meta-analysis of 67
independent studies by Raimondi, Johansson, Maisonneuve, & Gandini (2009) and Choo,
Mamedov, Chung, Kiss, & Danjoux (2011).
Several factors influence vitamin D blood levels of which some are modifiable,
such as sun exposure, diet and vitamin D supplementation, and some are not modifiable,
such as age and ethnicity. Currently, there is inconsistent information about appropriate
dosage of oral vitamin D supplementation to increase 25-OH vitamin D blood levels to a
sufficient level and also what the ideal level would be. Oral vitamin D supplementation at
dosages of 400-600 IU may be ineffective at increasing 25-OH vitamin D blood levels
(Caplan, 2006). A dosage of 1,000 lU/day or higher of vitamin D supplementation daily to
achieve therapeutic benefits is recommended by Caplan (2006). Another study found
commonly recommended dosages of less than 1000 IU of vitamin D supplementation to be
insufficient to achieve a relevant increase in 25-OH vitamin D blood levels, but higher
dosages were safe and effective (Leidig-Buckner et al., 2010). This study sought to identify
determinants of 25-OH vitamin D levels in men receiving ADT for prostate cancer, in
particular whether supplementation with 800 lU/day raised vitamin D blood levels in this
population.
LITERATURE REVIEW
Prevalence of Vitamin D Insufficiency
According to Holick (2006), vitamin D insufficiency is an epidemic in the U.S.
Risk factors that have been identified as contributing to vitamin D insufficiency are older
age and being of Black ethnicity (Holick, 2005). In the U.S., older adults ages 49-83 have
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been found to have a prevalence of vitamin D insufficiency ranging from 41% to 57%, and
Holick (2006) attributed this to decreased dietary intake and decreased ability of the skin to
synthesize vitamin D. The National Health and Nutrition Examination Survey (NHANES)
found that Blacks have the highest prevalence of vitamin D insufficiency (Looker, 2008).
This was also observed in a study by Moriakova et al. (2009) who found that the mean
25-OH vitamin D blood levels were about 25% lower in Blacks than in Caucasians. Also,
the prevalence of insufficiency differed between the two groups: 80% in Blacks versus
53% in Caucasians.
Role of Vitamin D and Prostate Cancer
Vitamin D is a fat soluble steroid. The active form is known as 1, 25 vitamin D and
the inactive form is 25-OH vitamin D. Vitamin D is produced in the skin after exposure to
ultraviolet B (UVB) light from a reaction between 7-dehydrocholesterol and UVB light at
wavelengths between 290 and 315 nm (Holick, 2006). The biologically inactive form of
vitamin D is produced in the skin and is then transported to the liver. The liver
hydroxylates or converts vitamin D to the pro-hormone 25-OH vitamin D, which is then
converted into the biologically active form in the kidneys and immune system (Holick,
2006).
Measurement of the inactive form, 25-OH vitamin D has been found to be a reliable
indicator of the active form (Cheng, Levine, Bell, Mangelsdorf, & Russell, 2004; Binkley,
Krueger, & Lensmeyer, 2009; Caplan, 2006). Current studies have shown an association
between plasma levels of 25-OH vitamin D and progression risk in men with prostate
cancer (Fang et ah, 2011). Trump et al. (2009) found the prevalence of 25-OH vitamin D
deficiency defined as < 20 ng/ml was 40% and insufficiency defined as 20-31 ng/ml was
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32% in men with recurrent prostate cancer. In men with localized prostate cancer,
deficiency was 18% and insufficiency was 50%. A study by Zheng et al. (2010) indicated a
higher 25-OH vitamin D blood level is associated with improved prognosis of prostate
cancer. In contrast, the findings from the Harvard Cohort studies, which consisted of the
Nurses’ Health Study, the Physicians’ Health Study and the Health Professionals
Follow-Up Study, did not demonstrate an association between vitamin D and the risk of
prostate cancer in middle-aged or elderly men. The Harvard Cohort studies used both
dietary intake and 25-OH vitamin D blood level as indicators of vitamin D status
(Giovannucci, 2009).
Normal Range of 25-OH Vitamin D
Guidelines to interpret the measurement of 25-OH vitamin D were defined by the
Institute of Medicine (Looker et al., 2011). The guidelines are: < 12 ng/ml (30 nmol/L)
indicates vitamin D deficiency; 12-19 ng/ml (30-49 nmol/L) indicates inadequacy; 20-50
ng/ml (50-125 nmol/L) indicates sufficiency; and 50 ng/ml (>125 nmol/L) may be harmful.
In contrast, Cavalier, Delanaye, Chapelle, & Souberbielle (2009) recommended the cut-off
for insufficient blood levels of vitamin D as < 30 ng/ml. Caplan (2006) and Henry (2004)
defined optimal levels as 32 ng/ml or higher.
In agreement with these authors, the current study used the laboratory cut-off point
of < 32 ng/ml to define insufficient 25-OH vitamin D levels.
Determinants of Vitamin D Insufficiency
Studies have identified determinants of 25-OH vitamin D levels. These include age,
ethnicity, calcium and vitamin D supplementation, obesity, exposure to sunlight, exercise,
alcohol intake and tobacco use (Moyad, 2008; Glass, Lens, Swaminathan, Spector, &
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Bataille, 2009). The relationship of vitamin D to each determinant is briefly described
below.
Age
Linnebur, Vondracek, VandeGriend, Ruscin, & McDermott (2007) described how
the aging process causes a decrease in cutaneous synthesis of vitamin D. Holick (2006)
stated that cutaneous production of vitamin D in a septuagenarian is one-fourth of that of a
20 year old. Likewise, findings by Orwoll et al. (2009) identified age as a common risk
factor for decreased vitamin D.
Ethnicity
Dark skin has been found to inhibit cutaneous synthesis of vitamin D (Holick,
2006; Mosekilde, 2005; Moriakova et al., 2009). Holick (2005) found that 84% of elderly
Blacks had 25-OH vitamin D blood levels under 20 ng/ml. Holick (2006) stated that that
increased skin pigmentation may lead to up to a 99% reduction in cutaneous vitamin D
production. The Institute of Medicine (IOM) found that Caucasians were less likely to be at
risk of vitamin D insufficiency or deficiency than Hispanics or Blacks. They also noted,
based on an article by Looker et al (2011), that thresholds for inadequacy are uncertain
because many non-Caucasian groups have better skeletal status then Caucasians despite
having lower serum 25-OH vitamin D.
Calcium Supplementation
A report by the National Nutrition Monitoring System found that increasing the use
of mineral dietary supplements was not associated with a corresponding increase in 25-OH
vitamin D (Yetley, 2008). Chung et al. (2009) in meta-analysis found that vitamin D
supplementation, calcium supplementation or a combination of both showed inconsistent
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results in determining cancer outcomes associated with 25-OH vitamin D blood levels.
Notably some of the studies reported that high calcium intakes were associated with an
increased risk of prostate cancer (Chung et ah, 2009)
Obesity
Obesity has been identified as a risk factor for lower levels of vitamin D. One study
found men with a body mass index of > 40 kg/m2 found that 1 out of 2 were deficient.
Orwoll et al. (2009) found a high prevalence (86%) of vitamin D deficiency in men who
had a body mass index >25 kg/m .
Exercise
While 25-OH vitamin D blood levels have not been directly associated with lack of
exercise, an indirect association has been shown. Deficiency of vitamin D has been
associated with muscle weakness in the elderly, which itself has an association with lack of
exercise (Caplan, 2006), thus, the relation between vitamin D and exercise may be
bidirectional.
Sun Exposure
Studies have found that people living in northern latitudes have low 25-OH vitamin
D blood level due to low sun exposure (Holick, 2006). Schwartz and Hanchette (2006)
evaluated the effect of geographic distribution of UV radiation, vitamin D insufficiency
and prostate cancer and found that the lowest levels were observed north of 40 degrees N
latitude. On the other hand, adults living in Arizona are commonly vitamin D deficient
despite increased sun exposure due to sun avoidance and use of sunscreen (Jacobs et al.,
2008). This is probably true of most southwestern states.
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Alcohol
Alcohol use has been identified as a possible risk factor for decreased 25-OH
vitamin D blood levels. This may be due in part to the association between excess alcohol
use and liver disease. The liver converts vitamin D to the pro-hormone vitamin D (Lips
2006). Therefore, liver disease caused by alcohol can be associated with decreased 25-OH
vitamin D blood levels. That proposition is supported by a study by Hepner, Roginsky, &
Moo (1976) that found that the degree of liver disease was related to the degree of 25-OH
vitamin D deficiency.
Tobacco Use
One study found that increased tobacco use predicted lower levels of 25-OH
vitamin D (Brot, 1999). Literature is sparse regarding a possible mechanism to explain this
association.
Vitamin D Supplementation
Vitamin D blood level is influenced by supplementation only at sufficiently high
dosage, particularly in the elderly. Peterlik, Boonen, Cross, & Lamberg-Allardt (2009) and
Tang, Eslick, Nowson, Smith, & Bensoussan (2007) completed a meta-analysis of 46
studies and found that supplementation with a minimum of 800 IU vitamin D/day was
required to sustain optimal level of 25-OH vitamin D vitamin D blood levels in elderly
population in the absence of adequate sun exposure.
METHODOLOGY
Subjects
A total of 154 men were screened for this study by their physician and then referred
to the researcher (LMW) for recruitment into the study. Subjects were recruited from eight
96

urology practices and one cancer center in Clark County, Nevada. At the patients’
scheduled appointments, the physicians screened the subjects for eligibility based on
following inclusion criteria: 1) diagnosis of prostate cancer in advanced stages, 2)
treatment with ADT for nine months or longer, and 3) age of subject 55 to 90 years.
Subjects excluded were those using corticosteroids, medications affecting calcium
metabolism, and anti- seizure medications. The researcher reviewed the informed consent
with each subject and 112 subjects were recruited. Of the 112 men enrolled, 108 completed
the study. The reasons four subjects did not complete the study were: time constraints, (1
subject); unwilling to undergo flngerstick, (1 subject); and inadequate specimen for lab
analysis, (2 subjects).
Research Procedure
Permission for this study was obtained by each of the participating health care
providers and the institutional review board at Loma Linda University. Subjects provided
authorization by written informed consent and agreement to release of medical information
in accordance with Health Insurance Portability and Accountability Act (HIPPA).
Research Design
This was a cross-sectional study. Subjects were recruited at scheduled office visits
with their health care provider. Following completion of informed consent, the subject was
asked to complete a questionnaire. Height and weight measurements were obtained from a
dual energy x-ray absorptiometry (DEXA) scan measurement completed within three
months of this study. If no DEXA scan report was available then height and weight
measurements were obtained from the subject’s medical record. The height and weight
•
were used to calculate body mass index (BMI) in
kg/m2 .
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The self-report questionnaire consisted of three parts. Part 1 of the questionnaire
was designed to collect information about the health of people in the United States
(UPHHS, 2006). This part asked about age, ethnicity, risk factors relating to medical
conditions, medication, supplemental intakes of vitamin D and calcium, tobacco use, and
alcohol use. Because of the low number of subjects, people of Caucasian, Asian, and
Hispanic ethnicity were grouped and coded as 1 while people of Black ethnicity were
coded as 2. Vitamin D supplementation was categorized as < 800 lU/day or > 800 lU/day;
calcium supplementation was categorized as < 1,000 mg/day or > 1,000 mg/day; alcohol
was categorized as never drank or quit > 1 year ago (coded as 0) and currently drinks
alcohol or quit < one year ago (coded as 1); tobacco use was categorized as 1 quit > 1 year
ago or never used tobacco (coded as 0) and current tobacco user of at least 1 cigarette, cigar
or pipe/day or quit < one year ago (coded as 0).
Parts 2 and 3 based questions about exercise and activity on the Canadian Fitness
Survey (CSF, 2005). Cardiorespiratory endurance exercise was measured over the past
week, month, and 12 months and according to type of activity, frequency of activity and
amount of time spent for each activity. Energy expenditure for medium (some perspiration
and above normal breathing) to heavy (heavy perspiration and breathing) activity
(including housework, handiwork, garden work), and leisure activity (walking jogging,
running, bicycling, golf, swimming, skiing, etc.) was classified according to the metabolic
equivalent of a task (MET). For the purpose of the current study, endurance exercise was
categorized as < 1.5 MET-hours/week or > 1.5 MET-hours/week. Sun exposure was
defined only by exercise and recreational activities performed outdoors. Activity
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performed in sunlight was empirically categorized using a cut-off of > 30 minutes 2
times/week or less.
Laboratory Analysis
Blood for 25-OH vitamin D samples was obtained during the subject’s scheduled
office visit. All visits were between the months of May through December, 2010. A sample
of blood by finger stick for 25-OH vitamin D level was obtained concurrent with the office
visit and administration of the questionnaire. The blood specimen was collected using a
filter paper provided by ZRT, an approved Clinical Laboratory Improvement Amendment
(CLIA) facility. The blood sample was placed in a sealed container and mailed through
UPS to ZRT for analysis. ZRT uses liquid chromatography/tandem mass spectrometry
(LC-MS/MS) and participates in DEQAS, the 25-OH vitamin D Quality Assessment
Scheme that provides control samples to ensure assay accuracy. The blood spot technical
bulletin (ZRT 2011) states the intra-assay precision was determined by choosing three
samples spanning the reference range and analyzing them seven times within the same run.
Inter-assay precision was determined by choosing three samples spanning the reference
range and analyzing them in 18 different runs. The sensitivity (lower limit of detection) of
the 25-OH vitamin D assay is 1.9 ng/ml.
Data Analysis
Data analysis was based on 108 subjects that completed the study. The Chi-square
test was used to assess the relation between 25-OH vitamin D, categorized as > 32 ng/ml
(sufficient) or <32 ng/ml (insufficient), and potential determinants of age, ethnicity, ADT,
vitamin D and calcium supplementation, BMI, exercise, exposure to sunlight, alcohol
intake and tobacco use. Spearman correlation coefficients were calculated between 25-OH
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vitamin D and the above determinants. Regression analysis was employed to determine the
predictive relationship between 25-OH vitamin D and statistically significant correlates.
Data analysis, conducted by SPSS software version 18 for Windows, included descriptive
and analytic statistics. A p value of < 0.05 was considered statistically significant.
RESULTS
Crosstabs summarized in Table 5.1 shows how age, ethnicity, calcium and vitamin
D supplementation, body mass index, exposure to sunlight, exercise, alcohol intake, and
cigarette use were distributed among subjects with sufficient or insufficient blood levels of
25-OH vitamin D. There was an inverse relationship between 25-OH vitamin D sufficiency
and Black ethnicity (p=.046), and smokers were more likely to be insufficient (p=.047). No
relationship was found for age, calcium or vitamin D supplementation, ADT use, body
mass index, exercise, sun exposure, or alcohol use.
Correlation
Table 5.2 shows correlations between 25-OH vitamin D blood level and each of the
possible determinants. 25-OH vitamin D was lower in men of Black ethnicity (r=-.356,
pO.OOl), was related to vitamin D supplementation (r=.243, p=.011), and was lower in
smokers (r=-.193, r=.045). There was no correlation between 25-OH vitamin D and age,
calcium supplementation, months of ADT treatment, BMI, exercise, sun exposure, or
alcohol use.
Regression Analysis
Vitamin D supplementation (p= 6.556, p=.012) and Black ethnicity (P =-7.816,
p=.003) remained predictive for 25-OH vitamin D blood levels after controlling for age
and tobacco use. See Table 5.3.
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DISCUSSION
The results of this study show that daily intake of vitamin D supplement of > 800
lU/day and Black and non-Black ethnicity were predictive of blood levels in men receiving
ADT for prostate cancer. There was no correlation between 25-OH vitamin D and age,
calcium supplementation, ADT, BMI, exercise, sun exposure, tobacco use, or alcohol use.
To our knowledge, no previous studies have examined the association between 25-OH
vitamin D and the above listed determinants in men receiving ADT.
Our subjects were mostly elderly, with a range of 56-90 years of age and 66% had
vitamin D blood levels <32 ng/ml. This finding is consistent with other studies such as
Linnebur et al. (2007) who identified vitamin D insufficiency, defined as in the current
study, in 74% of elderly male patients in an ambulatory care clinic. The optimal level may
be 50-80 ng/ml (ZRT, 2011); however, the implications of correcting lower levels in
patients with prostate cancer have not been demonstrated in interventional studies. A study
by Zheng et al. (2010) indicated that higher vitamin D blood levels are associated with
improved prognosis of prostate cancer providing justification for interventional studies to
be conducted.
Our study found vitamin D deficiency in 90% of the Black participants as
compared to 68% in the Caucasian, Asian and Hispanic group. This finding supports other
research indicating vitamin D insufficiency is higher in Black men (Looker et al., 2011;
Holick, 2006; Mosekilde, 2005; Moriakova et al, 2009). A cross-sectional study by Tseng,
Giri, Bruner, & Giovannucci (2009) found Black men with prostate cancer had
significantly lower blood levels of 25-OH vitamin D than their counterparts.
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Our study found that vitamin D supplementation > 800 lU/day was associated with
increased 25-OH vitamin D blood levels. This finding is supported by meta-analysis of 46
studies conducted by Peterlik, Boonen, & Cross and other authors, including
Lamberg-Allardt (2009) and Tang, Eslick, Nowson, Smith, & Bensoussan (2007). These
authors found that 800IU vitamin D supplementation/day was sufficient to sustain optimal
levels of 25-OH vitamin D blood levels in elderly populations in the absence of adequate
sun exposure. A study using 400-600 IU vitamin D/day found that this dose did not
significantly increase 25-OH vitamin D blood levels to a sufficient level (Lips 2006). Our
study is consistent with these findings, however, a limitation of our study is that we did not
record supplementation lower than 800 lU/day.
Our study found that calcium supplementation > 1000 mg/day was not associated
with 25-OH vitamin D blood level. This result agrees with a report by the U.S. National
Nutrition Monitoring System that found increasing the use of mineral dietary supplements
were not associated with a corresponding increase in 25-OH vitamin D (Yetley, 2008).
Furthermore, the EPIC study Gonzalez and Riboli (2010) and that by Chan et al. (2001)
found that increased calcium is associated with increased prostate cancer risk.
Our study found no association between BMI was associated and 25-OH vitamin D
blood level. Vitamin D is stored in the adipose tissue and persons with BMI > 30 have
lower 25-OH vitamin D blood levels than their counterparts (Wortsman, Matsuoka, Chen,
Lu, & Holick, 2000; Looker et ah, 2008). However, in a population of elderly survivors,
this association may change. Likewise, our study found no relation between exercise and
25-OH vitamin D blood level.
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We found no association between sun exposure and 25-OH vitamin D blood
level, however, a limitation of the study is that sun exposure other than during exercise was
not measured. Furthermore, over half (58%) of participants did not engage in outdoor
activities. The role of sun exposure may be limited in the Nevada location where sun
exposure is year round. We are unaware of specific recommendations for number of days
per week or length of time for sun exposure in patients with prostate cancer.
Our study found no relationship between alcohol use and 25-OH vitamin D blood
level. This is in agreement with a study by Hepner, Roginsky, & Moo (1976) that found no
direct association between 25-OH vitamin D and alcohol use but they did find the degree of
liver disease was related to the degree of 25-OH vitamin D deficiency. We did not measure
liver enzymes in the current study.
Our study found that smokers had lower 25-OH vitamin D levels than nonsmokers.
Our findings are consistent with a study by Brot (1999) who found that tobacco users have
significantly lower levels of 25-OH vitamin D than nonusers. Tobacco use was no longer a
statistically significant predictor of 25-OH vitamin D level in the regression equation
controlling for ethnicity and vitamin D supplementation.
We found no association between duration of ADT use and 25-OH vitamin D blood
level. Research is limited regarding the interaction of ADT, and vitamin D in relationship
to prostate cancer. Consistent with our findings, Chadha et al. (2009) found no statistically
significant association between ADT levels and 25-OH vitamin D levels.
Limitations
We measured 25-OH vitamin D only once and this may not reflect long term
circulating vitamin D status. Also, 25-OH vitamin D levels have been associated with
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seasonal changes that affect exposure to sunlight. Though most of the blood tests were
obtained during seasons associated with vitamin D repletion, we were unable to account
for total exposure to sun. However our study location in year-round sunny Las Vegas
should have minimized the affect of seasonal change.
CONCLUSIONS
Findings from this study indicate that men receiving ADT for prostate cancer have
a high prevalence of insufficient 25-OH vitamin D blood levels. Our study shows vitamin
D supplementation of > 800 lU/day may increase the 25-OH vitamin D blood levels for this
high-risk group. The association of higher 25-OH vitamin D blood levels with improved
prognosis of prostate cancer have been suggested by recent studies (Choo, Mamedov,
Chung, Kiss, & Danjoux, 2011; Zheng et ah, 2010). Interventional studies are needed to
further understand the effect of vitamin D supplementation on prognosis in prostate cancer.
Nurse Practitioners can play a key role in identifying and providing information
about putative benefits of vitamin D supplementation to patients who have prostate cancer
and are receiving ADT. Avoiding smoking should be emphasized as another important
determinant of bone health
ACKNOWLEDGEMENTS
We thank the participants, referring physicians: Joseph Candela MD, MPH; Oscar
Goodman MD Vijay Goli, MD; Lorene Jones, APN-C, Alex Lesani MD, Christopher
Minott, MD, William Wise, MD, Jeffrey Zapinski, MD and research assistants: Carmen
Vega, Ehraeda Rucker, Alejandra Chavez-Guillen, Esmeralda Barrios, Maritta Lord, Paul
Jucknath, ZRT laboratory staff, and Desert Radiology. Financial support was provided by
Paul Mennen, MD and Trudi Mennen.
104

References
Ahonen, M. H., Tenkanen, L., Ahonen, M., Lumme, S., Jellum, E., & Hallmans, G. (2000).
Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels. Cancer
Causes Control 11:847-852.
Ainsworth, B. E., Haskell, W. L., Whitt, M. C., Irwin, M. L., Swartz, A. M., Strath, S. J.,.
. . Leon, A. S. (2000). Compendium of Physical Activities: An update of activity
codes and MET intensities. Medicine and Science in Sports and Exercise32
(Suppl):S498-S516.
Ali MM, Vaidya V (2007). Vitamin D and cancer. J Cancer Rese Ther. Oct-Dec;3(4):
225-30.
Binkley, Krueger, and Lensmeyer (2009).25-hdyroxyvitamin D measurement, 2009: a
review for clinicians. Journal of Clinical Densitom.Oct-Dec;12(4):417-427.
Brot C, Jorgensen R, Sprensen H (1999) Influence of smoking on vitamin D status and
calcium metabolism. EJCN. 53(12):920-926.
Canadian Fitness and Lifestyles Institute (2005) Physical Activity Longitudinal Study
(PALS). 201-185 Sommerset Street West, Ottawa, Ontario. K2P 0J2 Canada. (613)
233-5528. wwwcflri.ca/eng/research/pals.php.
Caplan RH (2006) Vitamin D deficiency in the United States: A reassessment. Gundersen
Luthern Medical journal. Nov;4(l): 16-20
Cavalier E, Delanaye P, Chapelle JP, Souberbielle JC (2009).Vitamin D status and current
prospective.C/m Chem Lab Med. 47(2):120-7.

105

Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW (2004) Genetic evidence
that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc National
Acad Sci USA. 101(20): 7711-7715.
Chung M, Balk EM, Brendel M, Ip S, Lau J, Lee J (2009) Vitamin D and calcium: a
systematic review of health outcomes. Evid Technol Assess. Aug; 183:1-420.
Chadha, Tian, Mashtare, Kohli, Muindi, Trump (2009).Prostate cancer: early/localized
disease, locally advanced/reoccurrent/Advanced disease, and biology. 2009
Genitourinary Cancers Symposium. Amer Society of Clinical Oncology
(ASCO).ASCOconnection.org
Chan JM, Stampfer MJ, Ma J, Gann PH, Gaziano JM, Giovannucci EL (2001) Dairy
products, calcium, and prostate cancer risk in the physician’s health study.
American Journal of Clinical Nutrition. Oct;74(4):549-54.
Choo CS, Mamedov A, Chung M, Kiss A, Danjoux C (2011). Vitamin D insufficiency is
common in patients with non-metastatic prostate cancer. Nutrition R^.Jan;(l):21-6
Duyff, R. (1996). American dietetic association’s complete food and nutrition guide.
Publishing. Minn. 79 (81): 101-102.
Ellsworth, P., Caldamone, A. (2007). The little black book of urology. Jones and Artlett
pub. 2nd ed. pp 153-160.
Fang F, Kasperzck JL, Shui I, Henderickson W, Hollis BW, Fall K, Ma J, Gaziano JM,
Stempfer MJ, Mucci LA (2011). Prediagnostic plasma vitamin D metabolites and
mortality among patients with prostate cancer. PLoS One. Apr;6(4):el8625.
Giovannucci (2009) Vitamin D and cancer incidence in the Harvard cohorts. An
Epidemiology. Feb;19(2):84-8.
106

Gonzalez CA, Riboli E (2010).Diet and cancer prevention: contributions from
theEuropean prospective investigation into cancer and nutrition study. European
Journal of Cancer.Sep', 46(14):2555-62.
Gupta, D, Lamm D (2009) Vitamin D and prostate cancer risk: our view of the
epidemiological literature. Prostate Cancer Prostate Disease.\2(?>)\2\5-26.
Henry RP (2004) Functional indices of vitamin D status and ramifications of vitamin D
deficiency. American Journal of Clinical Nutrition. 80(Sup): 17069-17095.
Hepner, Roginsky, and Moo (1976) Abnormal vitamin D metabolism in patients with
cirrhosis. Digestive Diseases and Sciences. 21(7);527-532.
Holick MF (2006). High prevalence of vitamin D inadequacy and implications for health.
Mayo Clinic Proc. Mar;81(3):353-73.
Holick ME, Siris ES (2005). Prevalence of vitamin D inadequacy among postmenopausal
north American women receiving osteoporosis therapy. J din Endocrin Metab.
90:3215-3224.
Jacobs ET, Alberta DS, Foote JA, Green SB, Hollis BW, Yu Z, Martinez ME(
2008). Vitamin D insufficiency in southern Arizona. Amer J Clin Nutr.
Mar;87(3):608-13.
Krall EA and Dawson H B (1999). Smoking increases bone loss and decreases intestinal
calcium absorption. J bone Miner Res. Feb; 14(2):215-20.
Lambert JR, Young CD, Pertsons KS, Ray R (2007). Mechanistic and pharmacodynamic
studies of a 25-OH vitamin D derivative in prostate cancer cells. Viochem Biophys
Commun. Sep;361(l): 189-95

107

Leidig-Buckner, Roth, Bruckner, Lorenz, Raue, and Frank-Raue (2010)Are commonly
recommended dosages for vitamin d supplementation too low? Vitamin D status
and effects of supplementation on serum 25-OH vitamin D levels-an observational
study during clinical practice conditions. Osteoporosis Int. Jun;17 abstract ahead of
publication. PubMed.NIH.
Linnebur SA, Vondracek SF, VandeGriend JP, Ruscin JM, McDermott MX (2007)
Prevalence of vitamin D insufficiency in elderly ambulatory outpatients in Denver,
Colorado. Am Geriatric Pharmacotherapy. Mar;5(l)l-8.
Lips P (2006). Vitamin D physiology. Prog Biophys Molecular Biology. Sep;92(l):4-8
Looker AC, Johnson CL, Lacher DA, Pfeiffer CM, Schleicher RL, Sempos CT
(2011).Vitamin D status: U.S., 2001-2006. NCHS Data Brief. March. No. 54.US
dept. Health Human Services.CDC.
Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA (2008).
Serum 25 hydroxyvitamin D status of the US population: 1988-1994 compared with
2000-2004. AmJ Clin Nutr Dec; 88(6): 1519-27.
Moriakova, Akhter, N, Rao, Kukreja, Barengolts (2009). Determinants of
25-hydroxyvitamin D levels in African American and Caucasian male veterans.
Osteoporosis Int. Oct;20(10): 1795-803.
Mosekilde L (2005). Vitamin D and the elderly. Clinical Endocrinology (Oxf) Mar;62(3):265-81.
Moyad MA (2008) Vitamin D a rapid review. Urology Nurse. Oct;(5):343-9.
National Cancer Institute. (2008).Consensus development panel on prevention, diagnosis,
and therapy. Osteoporosis prevention, diagnosis, and therapy. NIH . JAMA 2001
285:785-795
108

Orwoll E, Neilson CM, Marshall LM, Lambert L, Holtton KF, Ho-22.
Peterlik M, Boonen S, Cross HS, Lamberg-Allardt C (2009) Vitamin D and calcium
insufficiency-related chronic diseases: an emerging worldwide public health
problem. Int JEnv Res Public Health. Oct; 6(10):2585-2607.
Pienta, K., Esper, P. (1993). Risk factors for prostate cancer. Ann. ofInternal
Me^/cme.l 18:793-803.
Pilz S, Dobnig H, Nijpels G, Heine RJ, Stehouwer CD, Snijder MB, van Dam RM, Dekker
JM (2009).Vitamin D and mortality in older men and women. Clin Endocrinology
(Oxf) Nov;71(5):666-72
Raimondi, Johansson, Maisonneuve, Gandini (2009). Review and meta-analysis on
vitamin D receptor polymorphisms and cancer risks. Carcinogenesis.
July;30(7): 1170-80.
Schwartz (2009). Vitamin D and intervention trials in prostate cancer: from theory to
therapy. Ann Epidemio. Feb;19(2):96-102.
Schwartz, GG (2005) Vitamin D and the epidemiology of prostate cancer. Semin Dial
Jul-Aug; 18(4):276-89.
Schwartz GG, Hanchette CL (2006) UV, latitude, and spatial trends in prostate cancer
mortality: all sunlight is not the same(united states). Cancer Causes Control.
Oct;17(8):1091-101.

109

Semmelweis E, Belgyogyaszati K (2010).The role of vitamin D in the prevention and
additional therapy of cancers. Magy Onkol.Dec, 54(4):303-14. A prospective study
of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate
cancer. PLoSMed. Mar;4(3):el03.
Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A (2007) Use of calcium or
calcium in combination with vitamin D supplementation to prevent fractures and
bone loss in people age 50 years and older: a meta analysis. Lancet
Aug;370(9588):657-66.
Trump, Chadha, Sunga, Fakih, Ashraf, Silliman (2009). Vitamin D deficiency and
insufficiency among patients with prostate cancer. BJU/«^.0ct;104(7):909-14
Tseng, Giri, Bruner, and Giovannucci (2009). Prevalence and correlates of vitamin D
status in African American men.5MC Public Health. Jun;18 (9): 191.
USPHHS (2006). National Health and Nutrition Examination Survey Data, Hyattsville,
MD: U.S. Department of Health and Human Services, Centers for Disease Control
and Prevention 2006 from http://www.cdc.gov/nchs.
Weiss, R., Kaplan, S., Fair, W. (2004). Management of prostate diseases. 4th edition,
Professional Communications, Inc.ppl09-138.
Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF (2000).Decreased bioavailability
of vitamin D in obesity. Am J Clin Nutr 72:690-3.
Yetley, EA (2008). Assessing the vitamin D status of the US population. AmerJ Clinical
Nutrition. Aug:88(2);558S-564S.

110

Zheng Y, Zhou H, Ooi LL, Snir AD, Dunstan CR, Seibel MJ (2010). Vitamin D deficiency
promotes prostate cancer growth in bone. Prostate. Dec;NIH.Pub Med
www.ncbi.nlm.nih.gov.catalog #21190224. Publisher Wiley-Liss, Inc.
ZRT laboratory (2011). 25-hydroxy vitamin D2/D3. Blood Spot Technical Bulletin. ZRT
Laboratory, 8605 SW Creekside Place, Beaverton, OR 97008 (866)600-1636.
info@zrtlab.com

111

Table 5.1 Crosstab for 25-OH Vitamin D Blood Level and Determinants (N=108)

25-OH Vitamin D
Ages in years
56-70 years old
71-80 years old
81-90 years old
Ethnicity
Caucasian/Asian/Hispanic
Black
Androgen deprivation therapy
< 24 months of treatment
> 24 months of treatment
Calcium supplementation
None or < 1000 mg/day
> 1000 mg/day
Body mass index
< 25 kg/m2
25-29.9 kg/m2
30 or higher kg/m2
Self reported exercise*
0-1.5 MET-hours/week
>1.5 MET-hours/week
Sun exposure during exercise ***
< 30minutes, 2 times/week
> SOminutes, 2 times/week
Alcohol Use
Never or quit > 1 year
Current use or quit< 1 yr
Tobacco Use
Never or quit > 1 year
Current use or quit< lyr
Vitamin D supplementation
None or < 800 lU/day

> 800lU/day

Sufficient
>32 ng/ml
N= 29

Insufficient
<32 ng/ml
N= 79

x2
p=.272

12(41.4%)
11 (37.9%)
6 (20.7%)

24 (30.4%)
26 (32.9%)
29 (36.7%)
p=.046

27 (93.1%)
2 (6.9%)

60 (75.9%)
19(24.1%)
p=.117

22 (75.9%)
7(24.1%)

47 (595.%)
32 (40.5%)
p=.508

21 (72.4%)
8 (27.6%)

62 (78.5%)
17(21.5%)
p=.144

4(13.8%)
18(62.1%)
7 (24.1%)

22 (27.8%)
33 (41.8%)
24 (30.4%)
p=.917

21 (72.4%)
8 (27.6%)

58-(73.4%)
21 (26.6%)
p=.359

19(65.5%)
10(34.5%)

44 (55.7%)
35 (44.3 %)
p=.868

13 (44.8%)
16(55.2%)

34 (43.0%)
45 (57.0%)
p=.047

26 (89.7%)
3 (10.3%)

58 (73.4%)
21 (26.6%)
p=.195

21 (72.4%)
8 (27.6%)
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66 (83.5%)
13 (16.5%)

Table 5.2 Spearman’s Correlation Coefficients between 25-OH Vitamin D Blood Level
and Determinants (N= 108)
Correlation
Coefficient
-.098
-.356
140
.150
.018
.009
.016
-.025
.13

P-Value

.313
Age in years
<.001
Ethnicity*
.150
ADT treatment in months
.120
Calcium supplementation
.856
Body mass index
.922
Endurance exercise
.872
Sun exposing during exercise
.793
Alcohol use**
.045
Tobacco use***
.011
.243
Vitamin D supplementation
*Ethnicity categories are Caucasian, Asian, and Ehspanic = 0 and Black = 1.
Alcohol use coded as non drinker or quit > one year prior = 0, and current drinker or quit
drinking < one year prior = 1.
Tobacco use was coded as nonsmoker=0 or quit > one year and current tobacco use or
quit tobacco < 1 year = 1.
**** Vitamin D supplementation was coded as <800 lU/day = 0 and > 800 lU/day = 1
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Table 5.3 Regression Model for the Relationship between 25-OH Vitamin D Blood Level
and Predictors, Controlling for Age and Tobacco Use (N = 108)
p coefficient
unstandardized

p coefficient
standardized

95% Cl

p-value

Age

-.197

144

-0.447, 0.052

.119

Ethnicity*

-7.816

-.275

-12.996, -2.635

.003

Vitamin D**
supplementation

6.556

.230

1.463, 11.650

.012

.170
-8.290, 1.477
126
-3.407
Tobacco use
*Ethnicity categories are Caucasian, Asian, and Hispanic - 0 and Black — 1
** Vitamin D supplementation was coded as <800 lU/day = 0 and > 800 lU/day = 1
Tobacco use was coded as nonsmoker = 0 or quit > one year and current tobacco use or
quit tobacco < 1 year = 1.
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CHAPTER 6
CONCLUSION

To our knowledge this study is the first to show endurance exercise is associated
with higher bone mineral density (BMD) of the hip though not the spine in men receiving
androgen deprivation therapy (ADT) for prostate cancer. Most of our subjects were
elderly. In general, published research is inconsistent as to long term benefits of BMD in
the elderly population. However, exercise may promote bone health in elderly men
receiving ADT. This study also found that daily intake of vitamin D supplement of >800
lU/day and non-Black ethnicity were predictive of 25-OH vitamin D blood levels in men
with prostate cancer receiving ADT. Vitamin D blood levels were not associated with
BMD of the hip or spine in our study. The only modifiable determinant of vitamin D blood
levels identified was supplementation with vitamin D >800 lU/day. This indicates that
more study is needed on the role of vitamin D on bone health.
A. Summary and Limitations
The study was cross-sectional and thus subject to limitations of cross sectional
studies. Causality cannot be assessed. Short of an interventional study, a follow-up
observational study could be performed, but not within the limited time of a doctoral
dissertation.
An observational study could be conducted by recruiting men before start of ADT
and following them up. A baseline BMD could be measured prior to starting ADT and
monitored with serial assessments throughout the first 1-2 years of treatment. Results
would be compared among participants according to reported amount of exercise.
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Additionally, having a control group of sedentary men matched for age and ethnicity who
were not receiving ADT therapy could further strengthen the research design.
Men receiving ADT for prostate cancer are not routinely screened in clinical
practice for low BMD. This study shows there is a high prevalence of low BMD in men
treated with BMD. Low BMD is clearly associated with future risk of osteoporosis and
fracture. The American Urology Association has no recommendations for screening men
for low BMD. The National Osteoporosis Foundation recommends screening for
osteoporosis in men aged >70 years old and in men at increased risk for low BMD at ages
50-69 years. After initial BMD screening by DEXA scan, the usefulness of interval
monitoring is controversial. The U.S. Preventive Services Task Force reports no current
studies have recommendations for repeated intervals of BMD testing with DEXA scan.
Some physicians recommend 1-2 year intervals to monitor BMD changes.
The current findings indicate that decreased BMD of the hip may be prevented with
increasing endurance exercise, which included activities of medium to high intensity, both
housework/handiwork related activities as well as recreational ones. The three most
commonly reported types of exercise in this study were walking outdoors, walking on a
treadmill, and bicycling. These activities may be recommended to men receiving ADT
wishing to potentially decrease their risk of low BMD. Our study sample size may have
been too small to determine the amount of resistance exercise needed to prevent low BMD.
The American College of Sports Medicine’s basic exercise recommendations for bone
health in adults over age 65 or adults 50-64 with chronic medical conditions are moderate
intense exercise 30 minutes a day, five days a week or vigorously intense endurance
exercise 20 minutes a day 3 days/week.
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We speculate that some of the side effects of ADT, including hot flashes,
irritability, decreased libido, and generalized joint pains, may interfere with ability to
exercise. Some subjects described these side effects as decreasing their ability to
participate in exercise and other usual daily activities at the same intensity as that engaged
in prior to starting ADT. However, we did not assess ADT side effects formally in this
study. Inclusion of a section in the questionnaire about exercise and usual daily activity
prior to initiating ADT as compared to current practices would have further strengthened
our research design, though the responses would be influenced by recall bias.
Current studies have shown an association between blood levels of 25-OH vitamin
D and progression risk in men with prostate cancer. This study also examined determinants
of 25-OH vitamin D blood levels. These determinants included age, ethnicity, calcium
supplementation, obesity, exercise habits, sun exposure, alcohol use, tobacco use, and
vitamin D supplementation. We found modifiable determinants were vitamin D
supplementation at >800 IU (positive relationship) and tobacco use (inverse relationship).
The determinant that was not modifiable was Black ethnicity.
A limitation of this study was that 25-OH vitamin D blood levels were not obtained
prior to start of supplementation so that any change could be identified. That information
would be useful to determine an adequate dosage of vitamin D supplementation to achieve
increased 25-OH vitamin D blood levels. In addition, adding a control group of men
receiving ADT for prostate cancer who were not taking supplementation would have
strengthened this study by establishing a baseline for both groups and then comparing to
see if the vitamin D blood level improved.
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The findings of this study suggest that future research of a prospective design to
determine the significance of exercise and change of BMD of the hip would further
confirm or refute this study’s findings. Further research is needed in the area of
cardiorespiratory exercise examining men who exercised while receiving ADT. This type
of study could include a group with a baseline measurement for BMD of the hip prior to
receiving ADT and then examine the changes in BMD in subgroups that exercise, those
that do not exercise, and a control group for men not receiving ADT controlling for age and
ethnicity.
Also, future studies in a prospective design are recommended to determine 25-OH
vitamin D blood level and adequate dosage of vitamin D supplementation for men with
prostate cancer receiving ADT. Obtaining baseline data for 25-OH vitamin D and specific
dosage for vitamin D supplementation and then conducting serial 25-OH vitamin D tests
would provide comparison data within and between the control group and the group
receiving vitamin D supplementation. The addition of a control group of men matched for
age and ethnicity who are receiving ADT but not taking vitamin D supplementation is
recommended to strengthen findings as it reduces confounder variables that were identified
in this study.
B. Conclusion and Implications for Preventive Care
Prostate cancer is a chronic disease with decreasing mortality rates due in part to
early recognition and treatment. Treatment with ADT increases risk of hip fracture. A hip
fracture in men increases the risk of mortality by 40%. This study identifies two modifiable
risk factors for men receiving ADT for prostate cancer. The first modifiable risk factor is
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cardiorespiratory endurance exercise. Cardiorespiratory endurance exercise may
potentially decrease risk of osteoporosis and fracture. The second modifiable risk factor is
vitamin D supplementation to improve 25-OH vitamin D blood level. In this study vitamin
D supplementation is associated with increased 25-OH vitamin D blood levels, and current
research indicates increased prostate cancer progression is associated with low 25-OH
vitamin D levels. It is hoped that this study will provide useful information to men with
prostate cancer who are receiving ADT. This study looked at modifiable risk factors that
can be decreased by changing lifestyle. The findings and limitations of this study as
discussed above indicate further opportunities for Preventive Care specialized to conduct
further research.

119

REFERENCES
Alpert, P. & Shaikh, U. (2007) Effects of vitamin D deficiency and insufficiency on
endocrine and paracrine systems. Biological Research for Nurses Oct. Vol 9(2).
American Cancer Society (2006). Prostate cancer riskfactors. Retrieved May 22, 2007
from http://www.webmd.com/prostatecancer/guide/prostate-cancer-risk-factors.
American Cancer Society (2008/ Overview: prostate cancer what is prostate cancer.
Cancer Reference Information. ACS Inc. 2009. last medical review 9/26/08.last
revised 11/12/08. Retrieved from http://www.cancer.org. Retrieved 12/23/08.
American College of Sports Medicine (1998). The recommended quantity and quality of
exercise for developing and maintaining cardiorespiratory and muscular fitness in
healthy adults. Medical Science Sports Exercise 30:975-991.
American College of Sports Medicine (2006). ACSM’s resource manual for guidelines for
exercise testing and prescription. (5th ed.). Lippincott Williams Wilkins.
American Joint Commission on Cancer (1997). Cancer staging manual. (5 til ed.).
Philadelphia, PA. Lippincott-Raven.
American Psychological Association. (1992).Ethical principles of psychologists and code
of conduct. American Psychologist 47, 597-1611.
Barry, D. & Kohrt, W. (2008). Exercise and the preservation of bone health. Journal of
Cardiopulmonary Rehabilitation and Prevention. 23:153-162. Retrieved from
www.j crpj oumal. com.

120

Berarducci, A. (2004). Osteoporosis: fracture prevention and therapeutic update.
Newsletter edited from CE Symposium held in conjunction with 2004 annual
meeting of the American Academy of Nurse Practitioners. Rockpointe. Suite # 600,
808 17th StNW, Washington, DC 20006.
Bilezikian, J., Marcus, R., & Levine, M., (Eds.). (2001). The parathyroids, (2nd ed.) San
Diego, CA: Academic Press.
Binkley, Krueger, & Lensmeyer (2009).25-hyroxyvitamin D measurement, 2009: A
review for clinicians. Journal of Clinical Densitom 7(4), 417-27.
Blair, E. & Burton, S. (1987).Cognitive processes used by survey respondents to answer
behavioral frequency questions. J. Consum Res 14:280-288.
Borst, (2005). Interventions for sarcopenia and muscle weakness in older people. Age
Aging, July 3. 4(4):414-415.
Canadian Fitness and Lifestyles Institute (2005) Physical Activity Longitudinal Study
(PALS). 201-185 Sommerset Street West, Ottawa, Ontario. K2P 0J2 Canada (613)
233-5528. Retrieved from wwwcflri.ca/eng/research/pals.php.
Caplan, R. H. (2006). Vitamin D deficiency in the United States: A reassessment
Gundersen Lutheran Medical Journal Nov 4(1), 16-20.
Choo, C. S., Mamedov, A., Chung, M., Kiss, A., & Danjoux, C. (2011). Vitamin D
insufficiency is common in patients with non-metastatic prostate cancer. Nutrition
Res. Jan;(l):21-6
Colyar, M. (2004). Bone density testing. Advance for Nurse Practitioners. July. 24-25.
Retrieved from www.advanceweb.com.

121

Conde, F., Sama, L., Oka, R., Vredevoe, D., Rettig, M., & Aronson, W. (2004j. Age,
body mass index, and prostate specific antigen correlate with bone loss in men
with prostate cancer not receiving androgen deprivation therapy. Urology, Aug:
64(2):335-40.
Cormack, D. (1993). Essential histology, (pp. 88, 179) Philadelphia, PA: JB Lippincott Co.
Daly, R. & Bass, S. (2006).Lifetime sport and leisure activity participation is associated
with greater bone size, quality and strength in older men. International
Osteoporosis Foundation and National Osteoporosis Foundation. 17:1258-67.
published online May 6. rmdaly@deakin.edu.au.
Daniell, H., Dunn, S., Ferguson, D., Lomas, G., Niazi, Z., & Stratte, P (2000). Progressive
osteoporosis during androgen deprivation therapy for prostate cancer. Journal of
Urology, Ja«;7di(l), 181-186.
Durante, R., & Ainsworth, B. (1996). The recall of physical activity: using a cognitive
model of the question answering process. Medicine and Science in Sports and
Exercise. Oct. 28(10): 1282-1291.
Duyff, R. (1996). American dietetic association’s complete food and nutrition guide.
Chronimed Publishing. Minn. 79 (81):101-102.
Eastham, J. (2007). Bone health in men receiving androgen deprivation therapy for
prostate cancer. Journal of Urology. Vol.177: 177-24.
Ebling, P. (2008). Osteoporosis in men. Clinical practice. New England Journal of
Medicine. Apr 3:358:14.
Ellsworth, P., & Caldamone, A. (2007). The little black book of urology. (2nd ed.)
(pp. 153-160) Jones and Bartlett.
122

Fang, F., Kasperzck, J. L., Shui, L, Henderickson, W., Hollis, B. W., Fall, K.,... Mucci, L.
A. (2011). Prediagnostic plasma vitamin D metabolites and mortality among
patients with prostate cancer. PLoS One. Apr;6(4): 18625.
Farmer, M., Harris, T., Madans, J., Wallace, R. H., Untley, J., & White, L. (1989).
Anthropometric indicators and hip fractures. NHANES I. Epidemiologic
follow-up study. loumaX American Geriatric Soc., 37:pp 9-16.
Favus, M. J., (Ed.). (2003).Primer on the metabolic bone diseases and disorders of
mineral metabolism. (5th Ed.). Washington, DC: American Society for Bone and
Mineral Research.
Ferrari, H., Hughes, B., Baron, J., Burckhardt, P., Li, R., Spiegelman, D.,. . .
Willett,W. (2007). Calcium intake and hip fracture risk in men and women: A
meta-analysis of prospective cohort studies and randomized controlled trials.
American Journal Clinical Nutrition. Dec. 86 (6): 1579-80.
Fitzpatrick, L. (2002). Secondary causes of osteoporosis. Mayo Clin. Proc. 77; 453-468.
Forsen, I., Sogaard, A., Myer, H., Edna, T., & Kopjar, B. (1999;. Survival after hip
fracture short and long term excess mortality according to age and gender.
Osteoporosis Int. 10:73-78.
Frayn, K. (1996). Metabolic regulation: a human prospective, (pp. 92-93). London,
. England:Portland Press, Ltd.
Friedrich, M. (2003;. Cancer source. Reviewer: Kerry Harwood, Clinical Nurse, Director,
Cancer Patient Education Program, Duke University Medical Center, Durham,
North Carolina. Publish Date: 02/05/2003. Retrieved from
http ://www.us .novartisoncology. com/guide/info/sitemap .j sp.
123

Fuchs, R. Shea, M., Durski, S., Stone, K., Widrick, J., & Snow, C. (2007). Individual and
combined effects of exercise and alendronate on bone mass and strength in
ovariectomized rats. BoneA\\290-96.
Gann, P., Hennekens, C., Ma, J., Longcope, C., & Stampfer, M. (1996/ Prospective study
of sex hormone levels and risk of prostate cancer. Journal National Cancer
Institute 88:1118-1126.
Giovannucci (2009) Vitamin D and cancer incidence in the Harvard cohorts. Ann
Epidemiology. Feb;19(2):84-8.
Golding, L., Myers, C., Sinning, W. (1989). Y’s way to physical fitness: complete guide
to fitness testing and instruction, (p. 142). YMCA of the USA, (3rd ed.).
Champaign, IL: Human Kinetics Publishers, Inc.
Greenspan, S. (2008). Approach to the prostate cancer patient with bone disease. Journal
ofEndocrinology Metabolism. 92:2-1.
Gutin, B. & Kasper, M. (1992). Can vigorous exercise play a role in osteoporosis
prevention? A Review. Osteoporosis Int. 282:1344-1352.
Guyton, A. (1991). Textbook ofMedical Physiology. (8th ed.) (pp. 885-8880. Philadelphia,
PA: W. B. Saunders.
Guyton, A. & Hall, J. (1998). Pocket Companion to Textbook ofMedical Physiology, (pp.
690). Philadelphia, PA: W. B. Saunders.
Holzbeierlein, J. (2006). Managing complications of androgen deprivation therapy for
prostate cancer. Urologic Clinics ofNorth America. 33(2). 181-190.

124

Kanis, J. & Gluer, C. (2000). An update on the diagnosis and assessment of osteoporosis
with densitometry. Committee of Scientific Advisors. International Osteoporosis
Foundation. OsteoporosisInt. 77:192-202.
Kaplan, R. (1990). Behavior as the central outcome in health care. American
Psychologist. Nov.45(11): 1211-1220.
Carlson, S., Larsson, J, Lund, D., Sugared, P., Manual, A., Holmstrom, K. O.,. . .
Larsson, D. (2010). Vitamin D and prostate cancer: the role of membrane initiated
signaling pathways in prostate cancer progression. Journal Steroid Biochemical
Mo/Bio. Jul;121(l-2):413-6.
Kelley, G., Kelley, K., & Tran, Z. (2000). Exercise and bone mineral density in men: a
meta-analysis. J. ApplPhysiol 88:1730-1736. Retrieved from www.jap.org.
Kriska, A., Sandler R Canley J. (1995). The assessment of historical physical activity and
its relation to adult bone parameters, American Journal ofEpidemiology.
127:1053-1063.
Lathrop, T. L. (1997). Stedman’s concise medical dictionary for the health profession (3rd
ed.). Dirckx, J. (Ed.), (p.37). Baltimore, MD: Williams and Wilkins.
Leibson, C., Tosteson, A., Gabriel, S., Ransom, J., & Melton, L. (2002). Mortality,
disability, and nursing home use for persons with and without hip fracture: A
population-based study. J Am Geriatr Soc. Oct. 50(10). 1644-50.
Lin, J. & Lane, J. (2008). Nonpharmacologic management of osteoporosis to minimize
fracture risk. Nature Clinical Practice-Rheumatology. Jan. vol. 4(1): pp 20-25.
Retrieved from www.nature.com/clinicalpractice.

125

Lips, P. (2006). Vitamin D physiology. Prog Biophys Molecular Biology. Sep;92(l):4-8.
Liu, H., Paige, N. M., Goldzweig, C. L., Wong, E., Zhou, A., Suttorp, M. J., Munias, B.,
... Shekelle, P. (2008). Screening for osteoporosis in men: a systematic review for
an American College of Physicians guideline. Ann Intern Med. May
6.148(9)685-701.
Looker A., Orwoll, E., Johnston C., Lindsay R., Wahner, H., Dunn, W.,. .. Heyse, S.
(1997). Prevalence of low femoral bone density in older U.S. adults from
NHANES III. J Bone Miner Res. Nov;12(l l):1761-8.
Malone, R. & Kessenich, C. (2008/ Fitamin D deficiency: implications across the
lifespan. Journal for Nurse Practitioners. 4(6):448-454. Retrieved from
www. npj oumal. org.
Manini, T. M., Everhart, J., Patel, V., Schoeller, D., Colbert, L., & Visser, M. (2006). Daily
activity energy expenditure and mortality among older adults. JAMA. July;296,
171-179.
Marcus, R., Feldman, D., & Kelsey, J., (Eds.). (2001). Osteoporosis Volume 2 (2nd
ed.)(pp. 207-27). San Diego, CA: Academic Press.
Marks, S. (2002). What is osteoporosis? Prostate and Cancer: A Family Guide to
Diagnosis, Treatment, and Survival, Fisher Books Perseus Publishing revised
edition 2002 pp 213 Cambridge, Mass, http://wwwperseuspublishing.com.
Matthews, P., (2007). Hormone ablation therapy: Lightening the load for today’s prostate
cancer patient. Urologic Nursing. Feb. Vol. 27 Supplement 3-9.
McGlynn, G. (1987). Dynamics offitness a practical approach (p. 176). University of
San Francisco: William C. Brown.
126

McLeod, N., Huynh, C., & Rashid, P. (2008). Osteoporosis from androgen deprivation
therapy in prostate cancer treatment. Australian Family Physician. April. Vol.
35(4):243-245.
Moayyeri, A. (2008).The association between physical activity and osteoporotic
fractures: a review of the evidence and implications for future research. AEP.Nov.
Vol. 18(11): 827-835.
National Cancer Institute (2008). Consensus development panel on prevention, diagnosis,
and therapy. Osteoporosis prevention, diagnosis, and therapy. National Institutes of
Health (NIH). JAMA 2001 285:785-195
National Osteoporosis Foundation (2002/ America’s bone health: the state of
osteoporosis and low bone mass in our nation. Washington (DC): National
Osteoporosis Foundation.
Nieman, D. (1999). Exercise testing and prescription: A health related approach. (4th ed).
(pp.211-248). CA: Mayfield Publishing Company.
NIH. (2000). Diagnosis and therapy. NIH consensus statement online. Osteoporosis
Prevention.. March 27-29; [cited 2004 Mar 26]; 17(1): 1-36.
NIH (2004). Bone health and osteoporosis: A report of the Surgeon General 2004. U.S.
Dept of Health and Human Services. 200 Independence Avenue, S.W.
Washington, D.C. 20201. Office of the Surgeon General, last revised Oct. 14.

127

NIH (2006). Osteoporosis in men,

U.S. Department of Health and Human Services.

National Institute of Arthritis, Musculoskeletal, and Skin Diseases. National
Institute of Health. November 2006. NIAMS Information Clearinghouse at (877)
22-NIAMS (226-4267). Retrieved Jan 5, 2008 from
http://www.niams.nih.gov/Health_Info/bone/Osteoporosis/men.asp.
NIH (2007). Osteoporosis overview, updated. NIH Osteoporosis and related Bone
diseases. National Area Source Center.2 AMS Circle, Bethesda, MD 20892-3676.
800.624.BONE. DPHHS. December 2007. Retrieved from
http://www.niams.nih.gov/Health_Info/Bone/Osteoporosis/default.asp.
NCI (2010). Fact Sheet: prostate-specific antigen test. National Cancer Institute. US
National Institutes of Health. Retrieved from www.cancer.gov.
Paffenberger, R., Hyde, R., Wing, A., Lee, I., Jung, D., & Kambert, J. (1993/
Association of changes in physical activity level and other lifestyle characteristics
with mortality among men., NEJM. Feb. Vol 32<3(8):538-45.
Parsons, J., Wright, E., & Partin, A. (2006). The Brady urology manual. Information. UK
Ltd. Bayer Healthcare Pharmaceuticals. 123-141 Retrieved from
www.tandf.co.uk/medicine.
Pfeifer, M., Sinaki, M., & Gesens, P. (2004). Musculoskeletal rehabilitation in
osteoporosis. Journal Bone Miner Res.

1208-1214.

Pienta, K. & Esper, P. (1993). Risk factors for prostate cancer. Ann. ofInternal Medicine.
//5:793-803.
Praemer, A., Fumer, S., & Rice, D. P. (1999). Musculoskeletal conditions in the United
States (p. 182). Rosemont, IL: American Academy of Orthopedic Surgeons.
128

Qaseem, A., Snow, V., Shekelle, P., et al (2008). Screening for osteoporosis in men: a
clinical practice guideline from the American college of physicians. Clinical
Efficacy Assessment Subcommittee of the American College of Physicians. Ann.
Intern. Med. 74#(9):680-684
Raimondi, Johansson, Maisonneuve, & Gandini (2009). Review and meta-analysis on
vitamin D receptor polymorphisms and cancer risks. Carcinogenesis.
July;30(7): 1170-80.
Rector, R., Rogers, R., Ruebel, M., & Hinton, S. (2008). Participation in road cycling vs.
running is associated with lower bone mineral density in men. Metabolism
Clinical and Experimental. 57:226-232 Retrieved from www.sciencedirect.com.
Richardson, M., Leon, D., Jacobs, D., Ainsworth, B., & Serfuss, R. (1994). Accuracy of
the Minnesota LTPA questionnaire. J. Clinical Epidemiol. 47:271-281.
Richmond, J., Aharonoff, G., Zuckerman, J., & Koval, K. (2003). Mortality risk after hip
fracture./. Orthopedic Trauma. Sept.17 (8 Suppl.). S2-5.
Rosenthal, R. and Rosenow, R. (1991). Essentials of behavioral research: Methods of
analysis (2nd ed.) (pp. 444-445). McGraw-Hill Series in Psychology.
Ross, R. & Small, E. (2002). Osteoporosis in Men Treated with Androgen Deprivation
Therapy for Prostate Cancer. Journal of Urology. Mqy. 7 67:1952-1956.
Rutecki, G. (2008). Osteoporosis-it’s not just for women anymore. Consultant. Nov.
48(12): 920. Retrieved from www.Consultant.com.
Ryan, C., Huo, D., Stallings, J., Davis, R., Beer, T., & McWhorter,L. T. (2007) Lifestyle
factors and duration of androgen deprivation affect bone mineral density of
patients with prostate cancer during first year of therapy. Urology 76(1): 122-126.
129

Schneider, E. & Guralnik, J. M.. (1990). The aging of America: Impact on health care
costs. JAMA. May 2, 263 (17): 2335-40.
Schwab, P. & Klein, R. (2008). Nonpharmacologic approaches to improve bone health
and reduce osteoporosis. Current Opinion Rheumatology. Lippincott Williams
and Wilkins. 20:213-217. schwabp@ohsu.edu
Seeman, E. (1995).The dilemma of osteoporosis in men.

American Journal Medicine

98(suppl. 2A): 76s-88s.
Segal, R., Reid, R., Coumeya, K., et al. (2003). Resistance exercise in men receiving
androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology
27:1653-1659.
Shahinian, V., Kuo, Y., Freeman, J., Orihuela, E., & Goodwin, J. (2005). Increasing use of
gonadotropin-releasing hormone agonists for the treatment of localized prostate
carcinoma. Cancer. 703:1615-24.
Shepard, R. {1991).Physical activity and health. Champaign, IL: Human Kinetics
Publishers, Inc.
Shipp, K. (2006). Exercise for people with osteoporosis: translating the science into
clinical practice. Current Osteoporosis Re^. Dec; 4(4).T29-33.
Sieber, P. (2002). Bone mineral density is maintained during Biclutamide (Casodex)
treatment, Presentation American Society Clinical Oncologists (ASCO) 38th
Annual Meeting May 18-21, Orlando, Florida 2002.
Sigurdsson, S., Thorlacus, S., & Tomasson, J. (1997). BRCA2 mutation in Icelandic
prostate cancer patients. Journal ofMolecular Medicine. 75:758-761.

130

Siroky, M., Edelstein, R., & Krane, R. (1999). Manual of urology: diagnosis and therapy
(2nd ed) (pp. 338-342). Philadelphia, PA: Lippincott, Williams, Wiggins.
Slattery, M. & Jacobs, D. (1995). Assessment of ability to recall physical activity several
years ago. Ann Epidemiology 5:292-296.
Smith, M. (2002). Osteoporosis during androgen deprivation therapy for prostate cancer.
Urology. 2002. 60:79-S6.
Spirduso, W. (1995). Physical dimensions of aging. Champaign, IL: Human Kinetics
Publishers, Inc.
Steinberg, G., Carter, B., Beaty T., Childs, B. & Walsh, P. (1990). Family history and
risk of prostate cancer. Prostate. 17\ 337-347.
Strief, D. (2007). Overview of prostate cancer: diagnosis and treatment. Urologic Nursing.
Dec. 27(6) 475-478.
Strueing, J. Hartge, P., & Watcholder, S. (1997). Risk of cancer associated with specific
mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New England Journal
ofMedicine: 335:1401-1408.
Tanvetyanon, T. (2005). Physician practices of bone density testing and drug prescribing to
prevent or treat osteoporosis during androgen deprivation therapy. Cancer 103:221
TAP. (2006). Lupron Depot, manufacturer medication information package insert. 2006.
TAP Pharmaceutical, Inc. Lake Forest, Illinois, 60045. Nov. website:
LupronOnY ourside.com.
Turner, C. (2006). Bone Strength: current concepts. Ann NY Academy Science
1068:429-46.

131

Twiss, J., Gross, G., Waltman, N., Ott, C., & Lindsey, A. (2006). Health behaviors in
breast cancer survivors experiencing bone loss. Journal of the American Academy
ofNurse Practitioners. 75(10) 471 -481.
USPHHS (2006). National Health and Nutrition Examination Survey Data, Hyattsville,
MD: U.S. Department of Health and Human Services, Centers for Disease Control
and Prevention 2006 Retrieved from http://www.cdc.gov/nchs.
USDHHS (2002).Report of the Surgeon General’s Workshop on Osteoporosis and Bone
Health. Dec 12-13; Washington (DC) [report on the Internet]: U.S. Department of
Health and Human Services; 2003 [cited 2004 June 28]. Available from:
http://www.surgeongeneral.gov/topics/bonehealth/
USDHHS (2008).Physical Activity Guidelines for Americans: Chapter 5: Active Older
Adults. Oct 16 Office of Disease Prevention & Health Promotion.
http://www.health.gov/paguidelines/guidelines/chapter5.aspx.
USDHHS (1999). Promoting physical activity: a guide for community action. Center for
Disease Control and Prevention. Division of Nutrition and Physical Activity.
USDHHS (1998). Put Prevention into practice (2nd ed.) (p. 413). Public Health Service and
Office of Disease Prevention and Health Promotion. Washington, DC: U.S.
Government Printing Office,. Chap. 57
USDHHS (1996). Physical Activity and Health: A Report of the Surgeon General. Atlanta,
GA: U.S. Department of Health and Human Services, Centers for Disease Control
and Prevention, National Center for Chronic Disease Prevention and Health
Promotion.

132

Venes, D. (Ed.) (2005). Taber’s cyclopedic dictionary. (20th ed.). FA Davis Co., CogniQ
handheld platform. 2000-2005 Unbound Medicine.
Waxman, J. (2007). Male osteoporosis. Clinical Advisor. Advisor Forum. June p. 90.
Waxman, J. (2007). Making the best use of osteoporosis agents, The Clinical Advisor: A
Forum for Nurse Practitioners 70(12) 23-31. Retrieved from
www.clinicaladvisor.com.
Weingard, K. (2006). Nursing implications of androgen deprivation therapy associated
bone loss. Urologic Nursing 26(4) pp261-269.
th

Weiss, R., Kaplan, S., & Fair, W. (2004). Management ofprostate diseases (4 ed.)
(pp. 109-138). Professional Communications, Inc.
Wilens, N. (2005).Osteoporosis in men. Advance forNP’s. April 13(4):pp31-34.
www.advanceweb.com
Woolf, S., Jonas, S., & Lawrence, R. (1996). Health promotion and disease prevention in
clinical practice. Baltimore, MD: Williams and Wilkins.
Zheng, Y., Zhou, H., Ooi, L. L., Snir, A. D., Dunstan, C. R., & Seibel M. J. (2010). Vitamin
D deficiency promotes prostate cancer growth in bone. Prostate. Dec; NIH. Pub
Med www.ncbi.nlm.nih.gov.catalog#21190224. Publisher Wiley-Liss, Inc.

133

APPENDIX A
HEALTHY PEOPLE 2010 OSTEOPOROSIS AND BONE HEALTH OBJECTIVES

Table 1-1. Healthy People 2010 Osteoporosis and
Bone Health Objectives
.HeahhyPeodeaOlO
Objective Number

thy People
Health
2010 Objective

3998 Baseline

2010 Target
. ■■-■■a&i&i T.&.

Objective 2.9

Reduce eases of
osteoporosis

1C percent of adults a geo 50
years and o’dor had osteoporosis
as measured by low tota! femur
bone mineral density (BMP) in
1988-9-1 (age adjusted to the
year 2000 standard population).

0 percent

Obj nctivn 2.10

Reduce
hosprtalizations
for vertebral
fracture

17.5 hofipitalizations por 10,000
adults aged 65 years and older
wore for vertebral fractures
associated with osteoporosis in
1998 (age adjusted to die year
2 00 0 s tan da rd po pu la ti on).

14.0
hosp tal zat.ons
per 10.000
adults aged 65
years and older

I

!Objective 15.28
?

Reduce hip
fractures

15-28a

Females aged 65
years and older

1,055.8 per 100,000

416 per 100,000

15-2 8 b

Males aged 65
years and older

592.7 per 100,000

474 pcr 109.000

Object we 19,11

Increase calc um
intake

46 percent of persons aged 2
yeans and older were at or
above approximated mean
calcium requirements (based
on consideration of calcium
from foods, dietary supplements,
and antacids) ;n 1988-94 {aye
adjusted to toe year 20CO
standard population).

75 ocreent

Ob ec lives
22.1-22.15

Increase physical
activity (there are
15 objectives for
increasing
physical activity)

:

.

Data
Data
Data
Data

Source
Source
Source
Source

2.9- National Health and Nutrition Examination Survey (NHANES), CDC. NCHS
2.10- National Hospital Discharge Survey (NHDS), CDC, NCHS
15.28 - National Hospital Discharge Survey (NHDS). CDC. NCHS
19.11 - National Health and Nutrition Examination Survey (NHANFS), CDC, NCHS
Source: USDHHS 2000.
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APPENDIX B
PATIENT SURVEY

PATIENT SURVEY
PART 1:
Date:

Name:

feet___inches

Height:

Ethnicity:.

Age:

Date of Birth:

Medical Condition

Weight:.

pounds

YES
age diagnosed

NO

H as this before or
after yoM were
diagnosed with
prostate cancer?

1. Osteoporosis
2. Thyroid
3. Parathyroid disease
4. Fracture/broken hip
5. Other types of fractures/broken
bones
6. Other types of calcium deficiency

NHANES QUESTIONNAIRE 2005
The 2005-2006 National Health and Nutrition Examination Survey (NHANES) by the
National Center for Health Statistics (NCHS), Center for Disease Control (CDC).
NHANES was designed to collect information about the health of people in the United
States. The 2005-2006 NHANES is the eighth in a series of national exam studies
conducted in the United Statesincel960. Specific modules have been selected for this
study. These modules include: Medical Conditions; Prescription Medication; Alcohol;
Tobacco; Osteoporosis. NHANES survey questionnaire, examination protocol, has been
produced by Federal agencies, which are in the public domain and may be reproduced in
part or full without permission.
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MEDICATION: PRESCRIPTION
Now I would like to talk about prescription medication you have used in the past year?
(These are products prescribed by your physician, health professional, dentist)
Medication
Name

How long have you
been using/taking this
medication?
Enter # days, weeks,
months, years

Main reason for which
you use this
medication?

Refused

Don’t
Know

MEDICATION: NON-PRESCRIPTION
What non-prescription medication you have used in the past year?
(These are products not prescribed by your physician, health professional, dentist)
Medication
Name

How long have you been
Main reason for
using/taking this medication? which you use this
Enter # days, weeks, months,
medication?
years
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Refused

Don’t Know

OSTEOPOROSIS
Yes

Question 1

No

Refused

Don’t know

Has a doctor ever told you that you had a broken or
fractured hip?
If yes, how old when you fractured/broke your hip?
Were you: Circle

Under 50
'No'
Yes

Over 50

Did that fracture occur as a result of fall from standing
height or less (tripped, slipped, fell out of bed)
Did that fracture occur as a result of a hard fall? (Off a
ladder, step stool, down stairs)
A car accident or other severe trauma.
Yes

Question 2

No

Refused

Don’t know

Has a doctor ever told you that you had a broken or
fractured hip forearm/wrist?
If yes, how old when you fractured/broke your
forearm/wrist?
Were you: Circle

Under 50
"No
Yes'

Over 50

Did that fracture occur as a result of fall from standing
height or less (tripped, slipped, fell out of bed)
Did that fracture occur as a result of a hard fall? (Off a
ladder, step stool, down stairs)
A car accident or other severe trauma.
Yes

Question 3

No

Refused

Has a doctor ever told you that you had a broken or
fractured spine?
How old when you fractured/broke your spine?
Were you: Circle
Did that fracture occur as a result of a hard fall? (Off a
ladder, step stool, down stairs)
A car accident or other severe trauma.
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Under 50
Yes
"No'

Over 50

Don’t know

Yes

No

Refused

Don’t know

Yes

No

Refused

Don’t know

Yes

No

Refused

Don’t know

Date
start

Date
end

Refused

Don’t know

Question 4
Has a doctor ever told you that you had osteoporosis,
sometimes called thin or brittle bones?
Question 5
Were you ever treated for osteoporosis?
Question 6
Have you ever taken any prednisone or cortisone pills
every day for a month or longer?
Question 7
Please think about your use of prednisone or cortisone
during your lifetime. For how long did you use
prednisone or cortisone nearly every day?

CIGARETTE USE
Question 1

Yes

No

Refused

Don’t know

Every
day

Some
days

Not at all

Don’t know
Refused

Years

Month

Days

Don’t know

# cigs

NO

Refused

Don’t know

Have you smoked at least 100 cigarettes in your
entire life? (5 packs of cigarettes)
Question 2
Do you now smoke cigarettes?
Question 3
How long has it been since you quit smoking
cigarettes?
Question 4
On the average, how many cigarettes do you now
smoke per day?
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ALCOHOL
The next questions are about alcoholic beverages. Included are liquors such as beer,
wine-coolers, whiskey, gin, vodka and any other type of alcoholic beverage._____
Question 1

Yes

No

Refused

Don’t know

Yes

No

Refused

Don’t know

Quantity

never
enter 0

Refused

Don’t know

Quantity

never
enter 0

Refused

Don’t know

Week

Month

Year

Don’t know

Yes

No

Refused

Don’t know

In any one year, have you had at least 12
drinks of alcohol beverage? By drink I mean
12 oz beer, 5 oz glass of wine, or 1 and half
oz of liquor.
Question 2
In your entire life have you had at least 12
drinks of any type of alcoholic beverage?
Question 3
In any one year, have you had at least 12
drinks of alcohol beverage? By drink I mean
12 oz beer, 5 oz glass of wine, or 1 and half
oz of liquor.
Question 4
In the past 12 months, on those days that you
drank alcoholic beverages, on the average
how many drinks did you have?
Question 5
In the past 12 months, how often did you
drink any type of alcoholic beverage?
{Probe: How many days per week? Month?
Year? Did you drink?)
Question 5
Was there ever a time or times in your life
when you drank 5 or more drinks of any
alcoholic beverage almost every day?
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PART 2: EXERCISE
What you do at home, work, or in your leisure time all contribute to your
current level of fitness. The following questions will provide a complete picture or
all your activities. To help describe your activities, we have designed four questions:
one for those activities you do daily; one for those activities you do each week; one for
those activities you have done in the past month; and the fourth for those activities
you have done in the past year.
1. DAILY ACTIVITIES
For those activities which you do most days of the week (such as housework,
or work), how much time do you spend:
SITTING
AH Day Va of the
time
□
□

STANDING
□

Y2 of the
time
□

Va of the
time

None of the
time
□

WALKING
□

□

□

□

□

WALKING UPSTAIRS
□

□

□

□

□

□

□

□

LIFTING OR CARRYING
□
HEAVY OBJECTS

□

Canadian Fitness Survey
The Canadian Fitness Study (CFS) was the most comprehensive national
population survey assessing exercise ever carried out in Canada. There were over 17,000
respondents. This survey has followed a longitudinal panel of participants and was
administered in 1981, 1988, and 2002 (CFS 2005).
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2. WEEKLY ACTIVITIES
Please refer to the reference card for a list of activities. Answer the following for
the physical activities you do each week.
Light housework, washing dishes, making bed, mowing lawn, etc.
Number of occasions each month
Jan

Feb

Mar

Apr

May

June

July

Aug

Sept

Oct

Nov

Dec

Intensity
LIGHT
Slight change
from normal

Average time actually
spent on each
occasion

MEDIUM
Some perspiration &
above normal
breathing

HEAVY
Heavy perspiration
& heavy breathing

Min

Hrs

Heavy housework and handiwork wash/wax floors, painting, etc.
Number of occasions each month
Jan

Feb

Mar

Apr

May

June

July

Aug

Sept

Oct

Nov

Dec

Intensity
Average time actually
spent on each
occasion

LIGHT
Slight change
from normal

MEDIUM
Some perspiration &
above normal
breathing

HEAVY
Heavy perspiration
& heavy breathing

Min

Hrs

Name of activity:
Code
Number of occasions each month
Jan

Feb

Mar

Apr

May

June

July

Aug

Sept

Oct

Nov

Dec

Intensity
Av. time actually
spent each occasion
Min
Hrs

LIGHT

MEDIUM
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HEAVY

Name of activity:
Code
Number of occasions each month
Jan

Feb

Mar

Apr

May

June

July

Aug

Sept

Oct

Nov

Dec

Intensity
HEAVY

MEDIUM

LIGHT

Av. time actually
spent each occasion
Min
Hrs

Name of activity:
Code
Number of occasions each month
Jan

Feb

Mar

Apr

May

June

July

Aug

Sept

Oct

Nov

Dec

Intensity
Av. time actually
spent each occasion
Min
Hrs

HEAVY

MEDIUM

LIGHT

Name of activity:
Code
Number of occasions each month
Jan

Feb

Apr

Mar

May

June

July

Aug

Sept

Oct

Nov

Dec

Intensity
HEAVY

MEDIUM

LIGHT

Av. time actually
spent each occasion
Min
Hrs

Name of activity:
Code
Number of occasions each month
Jan

Feb

Mar

Apr

May

June

July

Aug

Sept

Oct

Nov

Dec

Intensity
Av. time actually
spent each occasion
Min
Hrs

LIGHT

MEDIUM
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HEAVY

3. MONTHLY ACTIVITIES
Please refer to the reference card for a list of activities. Answer the following for the
physical activities you have done at least once in the last month. Do not include
activities already listed in Weekly Activities.
Name of activity:
Code
Intensity
Occasions in
the last month

Av. time actually
spent each
occasion
Hrs
Min

LIGHT

MEDIUM

LIGHT

MEDIUM

LIGHT

MEDIUM

LIGHT

MEDIUM

HEAVY

Name of activity:
Code
Intensity
Occasions in
the last month

Av. time actually
spent each
occasion
Hrs
Min

HEAVY

Name of activity:
Code
Intensity
Occasions in
the last month

Av. time actually
spent each
occasion
Min
Hrs

HEAVY

Name of activity:
Code
Intensity
Occasions in
the last month

Av. time actually
spent each
occasion
Min
Hrs
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HEAVY

Name of activity:
Code
Intensity
Occasions in
the last month

Av. time actually
spent each
occasion
Min
Hrs

LIGHT

MEDIUM

LIGHT

MEDIUM

LIGHT

MEDIUM

LIGHT

MEDIUM

HEAVY

Name of activity;
Code
Intensity
Occasions in
the last month

Av. time actually
spent each
occasion
Min
Hrs

HEAVY

Name of activity:
Code
Intensity
Occasions in
the last month

Av. time actually
spent each
occasion
Min
Hrs

HEAVY

Name of activity:
Code
Intensity
Occasions in
the last month

Av. time actually
spent each
occasion
Min
Hrs

HEAVY

Name of activity:
Code
Intensity
Occasions in
the last month

Av. time actually
spent each
occasion
Min
Hrs

MEDIUM

LIGHT
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HEAVY

4. ACTIVITIES IN THE PAST YEAR
Please refer to the reference card for a list of activities. Answer the following for the
physical activities you have done in the last 12 months. Do not include activities
already listed.
Walking for exercise

Name of activity:
Code

Months in which activity was done
Jan

Feb

Mar

Apr

May

June

July

Aug

____
Sept

Oct

Nov

Dec

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

15min or less

16-30 min

Jogging (short strides)

Name of activity:
Code

Months in which activity was done
Jan

Feb

Mar

Apr

61 min or
more

31-60 min

May

June

July

Aug

____
Sept

Oct

Nov

Dec

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

15min or less

16-30 min

Running Hong strides)

Name of activity:
Code

Months in which activity was done
Jan

Feb

Mar

Apr

61 min or
more

31-60 min

May

June

July

Aug

____
Sept

Oct

Nov

Dec

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

15min or less

16-30 min
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31-60 min

61 min or
more

Bicycling

Name of activity:
Code

Months in which activity was done
Jan

Feb

Mar

Apr

May

June

July

Aug

____
Sept

Oct

Nov

Dec

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

15min or less

61 min or
more

31-60 min

16-30 min

already listed.
Home Exercises (sit-uns/push-ups)

Name of activity:

Months in which activity was done
Jan

Feb

Mar

Apr

May

June

July

Aug

____
Sept

Oct

Nov

Dec

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

15min or less

Exercise classes

Name of activity:
Code

Months in which activity was done
Jan

Feb

Mar

Apr

61 min or
more

31-60 min

16-30 min

May

June

July

Aug

____
Sept

Oct

Nov

Dec

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

15min or less

16-30 min

Months in which activity was done
Feb

Mar

Apr

61 min or
more

Weight Training

Name of activity:
Code
Jan

31-60 min

May

June

July

Aug
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____ ,____
Sept

Oct

Nov

Dec

Code

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

16-30 min

ISmin or less

Yoga

Name of activity:
Code

Months in which activity was done
Jan

Feb

Mar

Apr

61 min or
more

31-60 min

May

June

July

Aug

____
Sept

Oct

Nov

Dec

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

ISmin or less

16-30 min

61 min or
more

31-60 min

Name of activity:
Code
Months in which activity was done
Jan

Feb

Mar

Apr "May 1 June~ July

Aug

____
Sept

Oct

Nov

Dec

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

ISmin or less

16-30 min

Months in which activity was done
Feb

Mar

Apr

61 min or
more

Racquetball / Squash / Tennis

Name of activity:
Code
Jan

31-60 min

May

June

July

Aug

____
Sept

Oct

Nov

Dec

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

ISmin or less

16-30 min
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31-60 min

61 min or
more

Baseball / Softball

Name of activity:
Code

Months in which activity was done
Jan

Feb

Mar

Apr

May

June

July

Aug

____
Sept

Oct

Nov

Dec

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

15min or less

16-30 min

61 min or
more

31-60 min

Swimming at a pool

Name of activity:
Code

Months in which activity was done
Jan

Feb

Mar

Apr

May

June

July

Aug

Sept

Oct

Nov

Dec

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

15min or less

16-30 min

Skiing: Water

Name of activity:
Code
Months in which activity was done
Jan

Feb

Mar

Apr

61 min or
more

31-60 min

May 1 June

July

Aug

____
Sept

Oct

Nov

Dec

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

15min or less

16-30 min

31-60 min

Skiing: Snow

Name of activity:
Code
Months in which activity was done
Jan

Feb

Mar

Apr

61 min or
more

May I June

July

Aug

____
Sept

Oct

Nov

Dec

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

15min or less

16-30 min

148

31-60 min

61 min or
more

Baseball / Softball

Name of activity:
Code

Months in which activity was done
Jan

Feb

Mar

Apr

May

June

July

Aug

Sept

Oct

Nov

Dec

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

15min or less

16-30 min

31-60 min

61 min or
more

Code

Name of activity:
Months in which activity was done
Jan

Feb

Mar

Apr

May 1 June~ July

Aug

____
Sept

Oct

Nov

Dec

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

15min or less

16-30 min

31-60 min

61 min or
more

Name of activity:
Code
Months in which activity was done
Jan

Feb

Mar

Apr

May I June

July

Aug

Sept

Oct

Nov

Dec

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

15min or less

16-30 min

31-60 min

61 min or
more

Name of activity:
Code
Months in which activity was done
Jan

Feb

Mar

Apr

May I June

July

Aug

____
Sept

Oct

Nov

Dec

Average Number of minutes spent on each occasion
Number of occasion
in last 12 months

15min or less

16-30 min
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31-60 min

61 min or
more

APPENDIX C
BODY MASS INDEX NOMOGRAM

Body mass index

From Wikipedia, the free encyclopedia
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A graph of body mass index is shown above. The dashed lines represent subdivisions
within a major class. For instance the underweight classification is further divided into
severe, moderate, and mild subclasses based on World Health Organization.
Body mass index is defined as the individual's body weight divided by the square of his
height.
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Body Mass Index Chart
Calculate vour body Mass Index
BMI

Height (in)
58 59 60 61 62 63 64 65 66 67 68 69

Wgt.
(lbs) 4'10" 4'11" 5'0" 5'1" 5'2" 5'3" 5'4" 5'5" 5'6"
21
100
20 20 19 18 18 17 17 16
22
21 21 20 19 19 18 18 17
105
23
22 22 21 20 20 19 18 18
110
24
115
23 23 22 21 20 20 19 19
25
24 23 23 22 21 21 20 19
120
125
26
25 24 24 23 22 22 21 20
27
130
26 25 25 24 23 22 22 21
135
28
27 26 26 25 24 23 23 22
28 27 27 26 25 24 23 23
140
29
145
30
29 28 27 27 26 25 24 23
150
31
30 29 28 27 27 26 25 24
32
155
31 30 29 28 28 27 26 25
34
32 31 30 29 28 28 27 26
160
35
33 32 31 30 29 28 28 27
165
36
170
34 33 32 31 30 29 28 27
37
35 34 33 32 31 30 29 28
175
38
36 35 34 33 32 31 30 29
180
37 36 35 34 33 32 31 30
185
39
190
40
38 37 36 35 34 33 32 31
41
195
39 38 37 36 35 34 33 32
200
42
40 39 38 37 36 34 33 32
41 40 39 38 36 35 34 33
205
43
210
44
43 41 40 38 37 36 35 34
215
45
44 42 41 39 38 37 36 35
45 43 42 40 39 38 37 36
220
46
47
225
46 44 43 41 40 39 38 36
48
47 45 44 42 41 40 38 37
230
235
49
48 46 44 43 42 40 39 38
50
240
49 47 45 44 43 41 40 39
51
50 48 46 45 43 42 41 40
245
250
52
51 49 47 46 44 43 42 40
53
52 50 48 47 45 44 43 41
255
260
53 51 49 48 46 45 43 42
54
54 52 50 49 47 46 44 43
265
56
57
55 53 51 49 48 46 45 44
270
275

58

56

54

52

50

49

151

57"
16
16
17
18
19
20
20
21
22
23
24
24
25
26
27
27
28
29
30
31
31
32
33
34
35
35
36
37
38
38
39
40
41
42
42

5'8"
15
16
17
18
18
19
20
21
21
22
23
24
24
25
26
27
27
28
29
30
30
31
32
33
34
34
35
36
37
37
38
39
40
40
41

70

71 72 73 74 75 76

5'9" 5'10" 5'11" 6'0" 6'1' 6'2" 6'3' 6'4'
14
14 14 13 13 13 12
15
15 14 14 14 13 13
16
15
16
15 15 15 14 14 13
16
16 16 15 15 14 14
17
17
18
17
17 16 16 15 15 15
18
18
17 17 17 16 16 15
19
19
18 18 17 17 16 16
19
19 18 18 17 17 16
20
21
20
20 19 19 18 18 17
21
21
20 20 19 19 18 18
22
22
21 20 20 19 19 18
22
22 21 20 20 19 19
23
24
23
22 22 21 21 20 20
24
24
23 22 22 21 21 20
24 23 22 22 21 21
24
25
24 24 23 23 22 21
25
26
27
26
25 24 24 23 23 22
27
27
26 25 24 24 23 23
27 26 25 24 24 23
27
28
28
27 27 26 25 24 24
29
28 27 26 26 25 24
30
29
29
29 28 27 26 26 25
30
30
29 29 28 27 26 26
31
30 29 28 28 27 26
32
31
32
33
31 30 29 28 28 27
32
31 31 30 29 28 27
33
32 31 30 30 29 28
34
33
34
33 32 31 30 29 29
35
34 33 32 31 30 29
36
35
34 33 32 32 31 30
35
36
37
36
35 34 33 32 31 30
36 35 34 33 32 31
37
38
37
36
35 34 33 33 32
38
37 36 35 34 33 32
39
38
38 37 36 35 34 33
40
39
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INFORMED CONSENT
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LOMA LINDA UNIVERSHY
School of Public Health

Self-Reported Exercise and Risk of Osteoporosis in Prostate Cancer Patients Receiving
Androgen Deprivation Therapy
Informed Consent
This is a research project by Lori Winchell, Registered Nurse, Nurse Practitioner and a doctoral student in
the School of Public Health at Loma Linda University. The information below will inform you about a
research study in which you may be interested in participating. Please take your time and read the
information carefully, before deciding whether or not you wish to participate in this study.
WHY IS THIS STUDY BEING DONE?
This study is being done to investigate the relationship between exercise and risk of bone loss in men who
receive injections of Lupron . You are invited to participate in this research study because you are
receiving injections of Lupron for one year or longer. Lupron slows prostate cancer growth but may also
decrease bone mineral density. Loss of bone minerals may cause weakening of the skeleton increasing
risk of fractures. Exercise is an important factor in the prevention and treatment of bone mineral loss.
This study is to investigate if there are differences in bone loss in men who exercise and men who do not.
A 107 men will be in enlisted the this study.
WHAT IS INVOL VED IN THIS STUDY?
Here are the procedures involved if you decide to participate in the study. The study will involve a visit to
your physician’s office. The visit can be scheduled at the same time as your next Lupron injection. At
this visit, you will be asked to complete a questionnaire about your risk factors and exercise practices.
The questionnaire will take 30 minutes. After completing the questionnaire, you will be asked to have a
blood test by finger stick. This blood test measures your vitamin D level which affects absorption of
calcium needed for bone strength. This is a standard medical test to screen for vitamin D deficiency.
Measurement of bone mineral loss is determined by a diagnostic test called, DEXA scan. This is a special
type of x-ray used routinely to identify bone mineral loss. Ifyour physician has not already ordered a
DEXA scan to screen for decreased bone mineral density, you may need second visit to your diagnostic
center as determined by your physician and health insurance. The DEXA is to be completed within thirty
days of the questionnaire. The test results will be provided to your physician for review at the next
routinely scheduled office visit. Once the blood lest, questionnaire, and if needed DEXA are completed,
your participation in this study will be over.
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Self-Reported Exereise and Risk of Osteoporosis in Prostate Cancer Patients Receiving
Androgen Deprivation Therapy
Informed Consent

WHAT ARE THE RISKS OF THIS STUD Y
This study exposes you to minimal risk. There will be some low dose exposure to radiation when
you get your bone mineral density tested. The amount of radiation exposure you receive from this
procedure is equivalent to a uniform whole body exposure of 1.0 mrem. This is equal to
approximately one day of natural environmental radiation the average person receives in the United
States (or the amount of radiation you would be exposed to during a cross country airplane flight).
The risk from radiation exposure of this magnitude is too small to be detected. There is also some
risk of bruising or pain from the blood test by finger stick.
All of the data collected during the study will be kept confidential. Your personal information will
be kept in a secured place including password protection in a computer database. Additionally, after
all data are collected your name will be deleted from data, and it will be replaced with a serial
number, called an identifier.
ARE THERE BENEFITS TO PARTICPATINGIN THE STUDY?
There may not be any direct benefit from participating in this study. Information obtained from this
study may help us to understand the way in which exercise affects our bone health and to develop
appropriate exercises for people with different levels of f itness. Understanding of the increased risks
of bone fractures in men receiving Lupron injections to suppress testosterone is important in
preventing a disease known as osteoporosis. All test results will be shared with your physician as
they are part of your medical care. Your physician will review test abnormalities (DEXA and
vitamin D level) and need for monitoring or treatment
HOW WILL MY PRIVACY BE PROTECTED?
Once you express an interest in participating in this study, you will remain in your exam room or be taken
to another private room to discuss the details in private. If you meet the criteria for the study, you will be
asked to complete the questionnaire and blood test You will also be asked to sign a release of information
for your DEXA scan results if already completed or given an physician’s order to complete your DEXA
scan. This must be done within 30 days of your visit. The data used from your medical information will
be kept confidential during collection. Once all your data is collected your name will be removed off the
document and just a number assigned.
WHAT ARE MY RIGHTS AS A PARTICIPANT?
Participation in this study is voluntary. Your decision whether or not to participate or terminate at
any time will not affect your present or future medical care. If you decide to stop, please inform the
study investigator.
WHAT ARE THE COSTS?
You and your insurance company are responsible for the costs related to routine medical treatment
including the DEXA scan. The serum vitamin D cost will be covered as part ol this study you and your
insurane company will not be responsible for this cost.
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date:

Self-Reported Exercise and Risk of Osteoporosis in Prostate Cancer Patients Receiving
Androgen Deprivation Therapy
Informed Consent

WHERE CAN I GET MORE INFORMA TION?
If you have questions you can contact Lori Winchell by e-mail, lwinchell@llu.edu or call (702) 458-6752
and leave a message with your name and phone number.
WHOM DO / CALL IF I HA VE QUESTIONS ABOUT MY RIGHTS AS A RESEARCH
PARTICIPANT?
If your wish to contact an impartial third party not associated with this study regarding any question
or complaint about the study, the Office of Patient Relations, Loma Linda University Medical Center,
Loma Linda, CA 92354, or call the Office of Patient Relations at (909) 559-4647 is available for
information and assistance.
INFORMED CONSENT STATEMENT
1 have read the comments of this consent form and have listened to a verbal explanation given to me
by the study investigator. My questions concerning this study have been answered to my
satisfaction. Signing this form dies not waive my rights nor does it release the responsibility of the
Principal Investigator, Dr. Serena Tonstad or Loma Linda University of their responsibility. I have
been given a copy of this consent form and the California Experimental Bill of Rights.
I hereby give voluntary consent to participate in this study.
Date:

Name:

INVESTIGA TOR’S STA TEMENT
I have reviewed the contents of the consent form with the person signing above. I have explained the
potential risks and benefits of the study.
Date:

Investigator
initial

Page 3 of 3

ILotna Linda Univtrslty
Adventist Health Sciences Cents?
Institutional Review Board
Approved _ey/zf)/10 Void after

§ChTir

f/ntteli

154

date:

APPENDIX E
RELEASE OF INFORMATION

StCVCIl Kurt/., M.D. DiploiiHiw.AiiH'iicwi Hoard of Urology
Joseph V. Candela, M.D., M.P.H. Diploniule, American HoanlUmlogy
Vijay Goli, M.D., F.A.C.S. Diplomair, American lloonlof Urology
O. Alex Lesani, M.D. Fellowship Trained in laiprosenpy & Roholic Surgery
Victor E Grigoriev, M.D. F.A.C.S. Di/ilnnwle, American lloanl of Urology

Patient Consent to the Use and Disclosure of Health Information for
Treatment, Payment, or Healthcare Operations
I, , undersuind that as pan of my health care. Las Vegas Urology originates and maintains paper and/or electronic records
describing my health history, symptoms, examination and test results, diagnoses, treatment and any plans for future care or
treatment. I understand that this information serves as:
• A basis for planning my care and treatment,
• A means of communication among the many health professionals who contribute to my care,
• A source of information for applying my diagnosis and surgical information to my bill
• A means by which a third-party payer can verify that services billed were actually provided, and
• A tool for routine healthcare operations such as assessing quality and reviewing the competence of health care
professionals
1 understand and have been provided with a Notice of Information Practices that provides a more complete description ol
information uses and disclosures. I understand that I have the following rights and privileges:
• The right to review the notice prior to signing this consent,
• The right to request restrictions as to how my health information may he used or disclosed to carry out
treatment, payment, or health care operations
I understand that Las Vegas Urology is not required to agree to the restrictions requested. I understand that I may revoke this
consent in writing, except to the extent that the organization has already taken action in reliance thereon. I also understand that
by refusing to sign this consent or revoking this consent, this organization may refuse to treat me as permitted by Section
164.506 of the Code of Federal Regulations.
I further understand that Las Vegas Urology reserves the right to change their notice and practices and prior to implementation,
in accordance with Section 164.520 of the Code of Federal Regulations.
I understand that as part of this organization's treatment, payment or health care operations, it may become necessary to
disclose my protected health information to another entity, and 1 consent to such disclosure for these permitted uses, including
disclosures via fax.
*Our practice may use and disclose your individually identifiable health information (IIHI) for research purposes in
limited circumstances.
Accept
Decline
I fully understand and accept

decline

the terms of-this consent.
Ditle

I’atient's Signature

7150 W. Sunset Kd:,#20l~ Las Vegas, NV 89113
7500 Smoke Ranch, #200, Las Vegas, NV 89128
(702) 233-0727 • Fax (702) 233-4799
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William R. WISH. MD. and JdT.VI. Xapmsky.MD., FA.C.S_
InsL-ph V. ('amIda. Ml) Mi’ll
Vi jay Cioli. Ml) KACS

Palieni Record of Disclosures

Vici.’r K Grigoriev. Ml) I'ACS
Slcvt'ii Klin/. MD
William Slcinknhl. Ml) FACS
William K. Wi»e. Ml)
<'A-

Jel l ivy /apinsky. Ml) FACS

Dililnvuilr*of thr Anu*ric.iu HootJ iif I rolov

|n iicneral. the HIPPA privacy rule cives individuals ihe riclu io ra|ucsi a rcsiriciiun on uses and disclosures of ihcir
proiccied licallh inronnaiion I PHI). The individual is also provided ihe riglu lo rccjtiesl confidcnlial comnuinicalion
or lhai a comnuinicalion of PHI may he by allernaiivc means, such as sendinu eorres|nmdcncc to ihe individual '5
olTice insiead ol'ilie individual's home.
1 Wish lo he conlacled in ihe following manner (Check all lhal apply);

Horne ti i

Work II (

)

)

_OK m mail lo my home
_OK 10 mail lo my Work Address__
__OK lo fas lot

__OK In leave message with detailed
Inl'urmaiimi.

_ Leave message will) call-haek number only
_Leave message whh

Wrilten Communiealion
(imisi insert name id'person)

Paliem Signaitire:__
I’atiem rCmardianl Signalure:
I’rimviiiik:
13: i i h Dare
Dale:

I.

'lire primes rale generally required hcalilieare providers m lake reasonable sleps lo limii ihe use nl disclosure ul and
requests tor I’l-A! to the miniimim necessary to accomplish die intended purpose. Tlv ' prm isions do n< o apply in uses oi
diselosiircs made |iursuam In an aiilhori/alion requesl by the imlhnlti.il.
I Iciii i heare em i ties imi-t keep records ni l’ll I disclosures. Iillormalion provided belmv. il'eompleled

'

properly. U l\ eonslinite an adequate record.
\l )TI-:: i • i
■lintdisclosures lor ITPlTreatment. I’ayinent. or Operations) may he permitted without prior c iiscnt

in hiemergenev,
.1. Record m dhc-ioMires ol I’roleclcd Health liiiormiitiim lAI I ACIIF.D)

NORTH WLST
7500 Sim»ke U.ineh Rtl.
So ite 2()0 • Las Vegas. NV S')I2K
702.211.-17
702.2.15.0727

7200 Ciilhedral Kock Drive .Suite
ISO • Los Vegas. NV SOI ’S
702.1-11 .‘KMX) • 702.1-11.5S<>4 FAX

156

J ^ '.upliei

U I V \

n.

vrriAjiuc jou jidu

n i MU 1.1, Iiu

K. UUJ/UU j

CHRISTOPHER A. MiNOTT. M.D.
Adult and Pediatric Urology
SOI S. Rsncho.Suit: C-4<, Ljj Vegas, rr./?9)06 • (702) 3f?<J-7239 •

(702) 389-3)50

ATTENTION:

f HEREBY AUTHORIZE AND REQUEST THAT MY COMPLETE MEDICAL RECORD
BE RELEASED TO:

CHRISTOPHER A. MINOTT, M.D.
ADULT & PEDIATRIC UROLOGY
501 S. RANCHO:STE C-AA
LAS l/EGAS, NV 39106 '
PHONE: (702) 3SA-7E3A
FAX:
(702) 384-3150
AT THE ADDRESS LISTED AB^YE, THE FdtLOWINC MEDICAL INFORMATION

I! COMPLETE RECORDS
I) RADIOLOCV REPORTS
I J ULTRASOUND REPORTS
I ! BIOPSY REPORTS

! 1 PATHOLOGICAL SLIDES
I I UROLOGICAL RELATED RECORDS
I I CAT S MRI SCANS
I I NUCLEAR SCANS

NOTE: SPECIAL OATES OF INTEREST____

TO

NAME:
SS//:

DOB_

ADDRESS:
CITY:

STATE:

ZIP:

SIGNATURE:

DATE:

Yi/ITN5SS:

DATE:
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Authorization for Use and Disclosure of
Protected Health Information

Nevada Cancer

Medical Record Number:
(NVC1 Use Only)

INSTITUTE
Research • Treatment • Education

Identity

V '

‘

V

Last four of Social

Date of Birth

Patient Name

■c

Prior Name(s) Used

CUlt'f^

Zip

State

City

Street Address

Tn

1 authorize the disclosure of medical information:
From (facility or individual to disclose records):

Disclose to (facility or individual to receive records):

Nevada Cancer Institute
Name of Facility or Individual

CAP Study - Lori Winchell. APN
Name of Facility or Individual

One Breakthrough Way
Street Address

P.O. Box 400591
Street Address

Las Veuas. NV 89135
City, State, Zip

Las Vettas. NV 89140
City, State, Zip

702-822-5433
Phone number

f702) 458-6752 / (800) 971 -7997 (fax)
Phone number

i.K*

Medical Information to Disclose V, \ * 'Ul t j
□

□

Radiology Reports

□

Emergency Reports

□

History & Physical

□
□
□
□
□
□
□

□

Progress Notes

o

□

Radiology Films

□

Operative Notes

□

Discharge Summary

□
□
□
□
□

□

Complete Health Record

□

Billing Records

□

Appointment Records

□

Laboratory Reports

□

Pathology Reports

□

Other:

X

Other:

X

Date Range

Of?

All Dates
□ Pertinent Health Records

/

/

to__ /__ /.

Consult report(s) (NVCI only), medication administration
record summary, patient drug list/medication list, patient history
form, DEXA report (not actual image - just report)

Page 1 of 2

158

I authorize the disclosure of information pertaining to:
A. The diagnosis or treatment of AIDS, including the results of HIV tests

□ Yes XNo

B. The diagnosis or treatment of drug and/or alcohol abuse

□ Yes XNo

C. Treatment and/or consultation for mental health or psychiatric disorders

□ Yes XNo

D. Psychotherapy notes only (no other medical information requested)

□ Yes XNo

Purpose of Use or Disclosure (Please indicatc/dcscfibe each authorized purpose of the use or disclosure);
□ At the request of the individual
□ Doctor Appointment:

______

L

l

at

a.m. / p.m.

Doctor’s Office Fax:

□ Transfer of medical care
□ Other: Ongoing Treatment or Care:____
X Other (please specify): Research study
I understand:
■ 1 may revoke this authorization at any time, in writing, except revocation will not apply to infonnation already
retained, used or disclosed in response to this authorization. I may revoke this document by presenting my written
revocation as provided in the Notice of Privacy Practices. Unless revoked, the automatic expiration date will be
one (1) year from the date of signature.
■ ! understand that information disclosed by this Authorization may be subject to re-disclosure by the recipient and
may no longer be protected by applicable privacy law. I further understand that the facility, its employees, officers
and agents are released from legal responsibility or liability for the use and disclosure of the above information to
the extent indicated and authorized
■
I have the right to inspect the health information to be released, unless prohibited by law, and I may refuse to sign
this authorization.
■ I understand that treatment, payment, enrollment in any health plan or eligibility for benefits is not conditioned on
signing this Authorization. I do not need to sign this form to assure treatment. I understand that failure to sign this
Authorization will not affect my health insurance benefits unless this Authorization is necessary to determine my
health insurance benefits. I understand that authorizing the disclosure of the above selected medical information is
voluntary. 1 can refuse to sign this authorization. 1 understand that I may inspect or have the information copied
to be used or disclosed. I understand that I have the right to receive a copy of this signed Authorization.
I HAVE READ AND UNDERSTAND THIS INFORMATION. I HAVE THE OPTION TO RECEIVE A COPY OF
THIS AUTHORIZATION AND I AM THE PATIENT OR AM AUTHORIZED TO ACT ON BEHALF OF THE
PATIENT TO SIGN THIS DOCUMENT VERIFYING AUTHORIZATION FOR THE USE OR DISCLOSURE OF
THE PROTECTED HEALTH INFORMATION UNDER THE ABOVE STATED TERMS.

Date

Signature of Patient

Signature of Legal Representative and Relationship to Patient
Legal Representative: State the legal capacity that you are
authorized to act on Patient’s behalf:

Please include with this Authorization the appropriate legal
document(s) granting authority to obtain information on behalf of
Patient. By law, no medical information will be disclosed to
Representative without the required legal documentation
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APPENDIX F
DEXA SCAN FACT SHEET
What is a bone density scan (DEXA)?
Bone density scanning, or dual-energy x-ray absorptiometry (DEXA), is an enhanced form
of x-ray that is used to measure bone loss. DEXA is today's established standard for measuring
bone mineral density. It is most often performed on the lower spine and hips to diagnose
osteoporosis. Osteoporosis involves a gradual loss of calcium, as well as structural changes,
causing the bones to become thinner, more fragile and more likely to break. DEXA is effective in
tracking the effects of treatment for osteoporosis and other conditions that cause bone loss. The
DXA test assesses an individual's risk for developing fractures.
These risk factors are considered when deciding if a patient needs therapy:
->A man with clinical conditions associated with bone loss;
->Medications that are known to cause bone loss;
->Diabetes, liver disease, kidney disease or a family history of osteoporosis;
-> Patient who experienced a fracture after only mild trauma;
X-ray evidence of vertebral fracture or other signs of osteoporosis.
DEXA may be recommended for older patients, especially if
->they have lost more than an inch of height; or
->have unexplained back pain.
How should I prepare?
On the day of the exam:
->You may eat normally.
->You should not take calcium supplements for 24 hours before your exam.
->You should wear loose, comfortable clothing, avoid garments that have zippers,
belts or buttons made of metal.
Objects such as keys or wallets that would be in the area being scanned should be
removed.
You may be asked to remove some or all of your clothes and to wear a gown during the
exam. You may also be asked to remove jewelry, eye glasses and any metal objects or clothing
that might interfere with the x-ray images
How does the procedure work?
Central DEXA devices measure bone density in the hip and spine. The DEXA machine
sends a thin, invisible beam of low-dose x-rays with two distinct energy peaks through the bones
being examined. One peak is absorbed mainly by soft tissue and the other by bone. The soft tissue
amount can be subtracted from the total and what remains is a patient's bone mineral density. The
DEXA test is usually completed within 10 to 30 minutes.
Inform your physician ifyou recently had an examination with barium injected with
contrast for computed tomography (CT) scan or radioisotope scan. You may have to wait 10 to
14 days before having the DEXA test.
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What will I experience during and after the procedure?
Bone density tests are a quick and painless procedure.
How is the procedure performed?
This examination is usually done on an outpatient basis.
The patient lies on a padded table. An x-ray generator is located below the patient and an
imaging device, or detector, is positioned above. To assess the spine, the patient's legs are
supported on a padded box to flatten the pelvis and lower (lumbar) spine. To assess the hip, the
patient's foot is placed in a brace that rotates the hip inward. In both cases, the detector is slowly
passed over the area, generating images on a computer monitor.
You must hold very still and may be asked to keep from breathing for a few seconds
while the x-ray picture is taken to reduce the possibility of a blurred image. The technologist will
walk behind a wall or into the next room to activate the x-ray machine.
Who interprets the results and how will 1 get them?
A radiologist, a physician specifically trained to supervise and interpret radiology examinations,
will analyze the images and send a signed report.
What are the benefits?
•
•
•
•
•
•

DEXA bone densitometry is a simple, quick noninvasive procedure.
Anesthesia is not required.
The amount of radiation used is extremely small—less than one-tenth the dose of a
standard chest x-ray, and less than a day's exposure to natural radiation.
DEXA bone density testing is the most accurate method available for the diagnosis of
osteoporosis and is also considered an accurate estimator of fracture risk.
DEXA equipment is widely available making DEXA bone densitometry testing convenient
for patients.
No radiation remains in a patient's body after an x-ray examination. X-rays have no side
effects in the diagnostic range.

Your test results will be in the form of two scores:
T score — This number shows the amount of bone you have compared with a young adult of the same
gender with peak bone mass. A score above -1 is considered normal. A score between -1 and
-2.5 is classified as osteopenia (low bone mass). A score below -2.5 is defined as osteoporosis.
The T score is used to estimate risk of developing a fracture.
Z score — This number reflects the amount of bone you have compared with other people in your age
group and of the same size and gender. If this score is unusually high or low, it may indicate a
need for further medical tests.
(http://www. radiologyinfo. org/en/info. cfm ?PG=dexa&bhcp=1)

161

APPENDIX G
ZRT LAB: BLOOD SPOT TESTING

Blood Spot Testing

Non-Hormone Users Guide to Collection
WOMkN

COUIter

Review i he ii User.> Guidcls) lo Col lee lion” on ihc back panel for collection limine.

Day N. 20. or2l of cycle

\Ve also stronely reeommeml you view our quick video on how to best collect a
blood spot sample at www.hlpod.spoividco comorw ww./rdah.com. laree type

Regular Pcrinils
(first das olldee<fing =dav II

Irreeular IVriod>

insinietions are available online at vvu w./nlah.eoin

Colleet when not bleed!lie
n tlavsbeK tieespeeiecl perioth

No Periods and/or women
only Cottisol or DHEA-S

MKN

Please read all insiruciioris prior to collection

:v

nine within M) minulcs of waking, and before eating

Collect your sample the

or drinking anything (except water).

Any day of the month
If you are testing blood lipitls or other CardioMetabolic Profile tests (e.e. insulin.
Any day of the month

I IhA I C. hsCRP) you will need to last |no food ordiink otherth.an water) 10-12
hours overnight before collecting your blood spots in the morning.

Hormone Users Guide to Collection

If you are testing FSH for fertility reasons, collect on day three of the menstrual

I’LliASi; Non-; You do NOT need to slop currml liormoiio llKTiipy prior lo

cycle.

t-ollLVlion. Oiiiiiiiue 10 use lioriiioncs as usual and follow chan

Test Results: Completion of the hormone tests typically takes about 3-5 days from

limiiii; of hlood collLVlinii.

the date ZRT receives your sample. Test results are returned to the health care

IIOUMONIi TYPE

IDI-iAL TIMi: TOaUJIxrSAMPU:

PiUs (Oral and Sllhliimual)

S-12 hours AI-TliK lusi iIusl'

provider who ordered them; you may obtain a copy there.

I’aidics

1-2 days ufior applying patch

InjcLlioiisIPcik-ls

Midpoiiu IvIwcl-ii injcclion/pcllcl inserts

ZRT laboratory
DISCI.AIMhK: ZRT l .ihuralory is a Icsiing I'acility only, and docs not diaunosc.

TopiraI fids. Creams. Sprays’"

I 2-2-1 hours Al l IK Iasi dose

nil. nullnvivii \| smaMii -i

mot limiicd u» liirth control, indaiotiin.

as iiokmom s

Heal, nr rcconmiead lie; urns'mi for inodical condilions.

If you collccl hhHHl spills outside ihc recommended time frame ahme. this may result in hommnclcvcl.s lower or Ilieher than ZK I referenee ranees for hormone users.
'Topical Hormone Users should follow ihe instructions helms to avoid direct contamination of the I'muers used for hlood eollc-elion.
- Do NOT use hare hands for topical hormone appliealion for at least two days prior lo hlood collection lapply lioiimuies usine laics cloves or other device Midi as
hormone-loaded syriiiec or applicator).
- Apply horiiinncs lo aivas of die hods that can he covered by clnihine so liiieers are less likely to inake eonlael vsiih horrmme-ireatesl skin.
- Wash hands u iih soap and water idler each applis'inioii of hormones. - Keep haihroom door knobs, laueel, lovve/s.eie. tree ol topical hoinmnes.

PLACE
DROPS

&

•T'“
UUACCCPTAOLE

UMACCrPTAD

PREPARECONTENTS
I. Lay outthe kit contents
2. Rriul name. dale, anil time on
hlood spot card.
1. Open the Hap of the hlood spot
card anil fold it hack, away from
the collection circles.
2. Tape the filter card Hat as shown
(below waist level) with flap
hanging down and away.
S. Open alcohol prep pail, sterile
gau/e: place on table.

NICK
FINGER
1. Pick up lancet, tw ist off cap.
and press small white section
ftrmlN against the side oflinger
tiji until lancet clicks.
2. Quickly wipe away the first
hlood drop with the sterile
gau/e pad.

1. Rush ion niekotl linger over eirele
of hloixl s.put card and gently
milk hlotvd from the linger.
2. As blood drop forms ;ind is rcudy
to fall, touch it to the center of the
circle (one drop per circle).
3. Move to the next empty eirele
mul continue collection until nil
circles have been filled.
-I. When finished, wash Imuds and
apply bandage to linger.

(t. Wash hands with soap and
warm water.
7. Dry hands with CLEAN towel.
K. Select linger lo draw blood
from (middle or ring linger of
non-dominant hand is best).
lJ. Wipe linger with alcohol prep
pad ft allow to dry for 13*30 see.
N< )TI\: To encourage blood flow,
before niCking linger rub hands
together ihul/or run hil
unnn water.

vrll.ib com I

TIPs: Collect so that your hand
is below your waist, allow ing
grilvity to assist with blood How .
If hlood stops llowing before
you are finished, use the sterile
gau/e pad to firmly wipe nick to
start hlood llow ing again or use a
second lancet.
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LABORATORY
TESTING
w./i llah.com

174

no xoT’
•touch filter paper with
finger
•smear blood onto filter

paper
•overlap hkxxl spots

MADE

I -S0<)-(MX)*\<>M)

SIMPLE

y;

■

k
TYPICAL SAMPLE
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r
•
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APPENDIX H
COLLECTION ASSISTANT TRAINING

CAP STUDY
COLLECTION ASSISTANT TRAINING

__________________________ Date:____

Name:.

Contact phone numbers:.
Date
Completed

Activity

C.A.

Initial

I have received and read
Official Visitor Policy
I have received and read
Dress Code Policy
I have received and read the
Patient Privacy Rights (HIPPA) policy
Completed the HIPPA certification
http://phrp.nihtraining.com/introduction
Viewed the ZRT lab blood spot testing
video
Bloodspotvideo.com
And completed practice session
Introduced to physicians/staff
Observation of Subject Interview

Collection Assistant
Signature:_______

Date:.

2010

Research Investigator
Signature:_________

Date:.

2010
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R.I.
Initial

Notes

APPENDIX I
IRB APPROVAL

INSTITUTIONAL REVIEW BOARD
Initial Approval Notice * Expedited Review

fRB# 5100047{

OFFICE OF SPONSORED RESEARCH *11185 Anderson Street • Lana Linda, CA 92350
(909) 550-4531 (vcice) • (909) SSMI3) (tan)

To:

Tonstad, Serena

Department:
Protocol:

Health Promotion & Education
Self-reported exercise and risk of osteoporosis in prostate cancer patients
receiving androgen deprivation therapy

This study was review and approved administratively on behalf of the IRB. This decision includes the
following determinations:
Risk to research subjects:
Approval period begins
Stipulations of approval:

Minimal
30-Apr-2010 and ends 29-Apr-2011

Consent Form
Unless IRB has given a specific waiver of informed consent (as documented in the approval stipulations
above) the IRB-approved and stamped consent form accompanies this letter. This now becomes the official
master consent form for making copies to provide to study participants.

Adverse Events / Protocol Changes
The IRB should be notified In writing of any modifications to the approved research protocol. Adverse
effects must be reported to the IRB in accordance with institutional policy. If sponsor or contractual adverse
event reporting requirements differ from requirements for reporting to IRB, ail reporting requirements must
still be met.

Protocol Review
Your protocol is tentatively scheduled for review and renewal at least two weeks prior to the approval enddate indicated above. To assure uninterrupted approval of this project, you will be sent a report form to
request renewal by completing and timely returning, to Office of Sponsored Research. Anticipate the
approval expiration so your study does not lapse: contact IRB for assistance if necessary. In addition to
reporting the requested renewal status information, you may also use the form to closeIhe study at that
time, if applicable.

Records
All records relating to this project, including signed consent forms, must be kept on file for three years
following completion of the study.Please note the Pi's name and the IRB number assigned to this IRB
protocol (as indicated above) on any future communications with the IRB. Direct all
communications to the IRB do the Office of Sponsored Research. Thank you for your cooperation in
LLU's shared responsibility for the ethical use of human subjects in research.
Signature of IRB Chair/Designee:.
Loma
Ihe IRB
Lome U nda Uraveratty Children's Hospiial, LLU Community Medical Center), Loma Linda University Behavioral Medicine, and alfllialed medical practices groups.
IRB Chair:
IRB Administrator:
IRB Specialist:
Rhodes L Rigsby, M.D.
Linda G. Halstead, MA, Director
Mart Testerman
Department ot Meddne
Olflce ot Sponsored Research
Oftfce ot Sponsored Research
(909) 558-2341, rrigsby@llu.edu
Ext 43570, Fax 80131, lhalstead@llu.edu
Ext 43042, Fax SOI31, mtesterman<§>llu.edu
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